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Sudden cardiac death (SCD) is defined as an unexpected circulatory arrest, mostly due to a 
cardiac arrhythmia, resulting into death.1-3 Especially patients with coronary heart disease 
are at risk for SCD, whereof approximately 50% dies unexpectedly shortly after symptoms. 
Previous studies demonstrated that the incidence of SCD is strongly correlated with the 
prevalence of coronary heart disease.4, 5 Consequently, the high number of patients with 
coronary heart disease in the United States of America, results in massive numbers of 
patients who die of SCD each year, with estimates ranging from 300 000 to 350 000.4, 6-9 
As numbers are comparable in Europe, more then 700 000 patients die yearly of SCD in 
the Western world.5 Of concern is that the majority of patient who died following sudden 
cardiac arrest, were unidentified to be affected by ischemic heart disease.2, 3, 8, 10 Although 
prodromal symptoms are often non-specific, they include chest pain (ischemia), palpitations 
(tachyarrhythmia), or dyspnea (congestive heart failure) and if present can be related to SCD. 
Major risk factors, increasing the risk of SCD include (risk factors for) coronary heart disease, 
prior coronary events, prior ventricular arrhythmia, poor left ventricular systolic function and 
symptoms of advanced heart failure.2 Unfortunately, an inverse relationship exists between 
the risk and total number of SCD in sub-groups of patients at increased risk (Figure 1).10
It is reported that 75-80% of SCD cases originate from ventricular fibrillation (VF) whereas 
in the remaining a bradyarrhythmia, including asystole and complete atrioventricular block 
is recorded.11 However, one should note that both causes of sudden death can intertwine: in 
other words, although the initial rhythm disorder can be VF, after some time VF extinguishes 
and asystole becomes the presenting rhythm when a first ECG is documented. Conversely, 
 
Figure 1. Absolute numbers of events rates of sudden cardiac death in the general population and in 
specific subpopulations over 1 year. Clinical trials that included specific subpopulations of patients are 
shown in the right side of the Figure. 
AVID = Antiarrhythmics Versus Implantable Defibrillator; CASH = Cardiac Arrest Study Hamburg; 
CIDS =  Canadian Implantable Defibrillator Study; EF = ejection fraction; HF = heart failure; 
MADIT = Multicenter Automatic Implantation Trial; MI = myocardial infarction; MUSTT = Multicenter 
































bradycardia or atrioventricular conduction delay can trigger VF, which makes a correct estimation 
of incidences difficult.6 Further research on the initial rhythm, causing SCD, conducted in 157 
patients experiencing SCD during ambulatory Holter monitoring demonstrated VF in 62.4% of 
patients, a bradyarrhythmia in 16.5% of patients, an episode of torsades de pointes in 12.7% 
of patients, and a ventricular tachycardia (VT) in 8.3% of patients.12  
Implantable cardioverter defibrillators
Since 40% of all cases of SCD are not witnessed, immediate and adequate treatment is 
difficult, resulting in high mortality rates.13 However, if witnessed, cardiac defibrillation can 
be life-saving. This experience dates back to 1947 when Dr. Claude Beck was correcting a 
pectus excavatum in a 14-year old boy. When during surgery VF occurred, Dr Beck initiated 
direct cardiac massage through the opened chest and, after more than a half hour of cardiac 
massage, used an animal cardiac defibrillator which he had developed while working in an 
animal laboratory many years earlier. The electrical defibrillation was successful and the 
rhythm restored to sinus rhythm.14
Although this success immediately led to the general acceptance of electrical defibrillation 
for life-threatening arrhythmias, the development of an implantable cardioverter defibrillator 
(ICD) took some time. It was Dr. Michel Mirowski, whose friend died due to several bouts 
of a ventricular tachycardia in 1967, influencing him to pursue the implantable defibrillator. 
In 1980, he and his team implanted the first implantable cardioverter defibrillator (ICD) in 
patients and successfully defibrillated VF.15 
Secondary prevention
The invention of the ICD raised the question if patients would benefit from ICD therapy 
and how to properly select them. Based on epidemiological studies, patients with life-
threatening ventricular arrhythmias were found to have a two-year recurrence rate of 30-
50%.16, 17 Accordingly, this population was the first in which the effect of ICD treatment was 
evaluated and eligibility for ICD treatment was based on the survival of at least one-life-
threatening ventricular arrhythmia such as VF or sustained VT (secondary prevention).15, 18-24 
Wever et al. ,working in Utrecht the Netherlands, performed the first study in which fifty 
patients who survived a cardiac arrest were randomized to be treated with antiarrhythmic 
drugs or an ICD.24 After a median follow-up of 24 months, it was demonstrated that the ICD 
treated group had lower rates of  major outcome events such as death, recurrent cardiac 
arrest or cardiac transplantation, underwent fewer invasive procedures, and were hospitalized 
less frequently.24 Thereafter, the effectiveness of ICD therapy was further assessed in three 
larger trials: the Antiarrhytmics Versus Implantable Defibrillator (AVID), the Canadian 
Implantable Defibrillator Study (CIDS), and the Cardiac Arrest Study Hamburg (CASH).18-20 
Patients included in these trials survived an episode of cardiac arrest or had a documented 
episode of sustained VT and were randomized to optimal pharmacological antiarrhythmic 
therapy or ICD treatment (Table 1). Although only AVID demonstrated a significant reduction 
in mortality, a meta-analysis of these three trials, demonstrated a significant 28% reduction 
in all-cause mortality in favor of ICD treatment and, with these results, the survival benefit 

































Although secondary prevention ICD therapy was proven to be beneficial, the most important 
limitation is that only 6% of patients survive an episode of cardiac arrest and therewith 
becomes eligible for ICD therapy.13 Accordingly, focus shifted to the identification of patients 
at high risk for life-threatening ventricular arrhythmias (primary prevention). Previous trials 
demonstrated that a left ventricular ejection fraction (LVEF) below 40% and frequent (runs 
of) premature ventricular beats were risk factors for SCD.26, 27  
Accordingly, patients included in the first small primary prevention trials were selected based 
on a reduced LVEF due to prior myocardial infarction and the presence of non sustained VT 
on 24-hour Holter monitoring in patients or inducible non-suppressible (by pharmacological 
treatment) sustained VT/VF on electrophysiological study.28, 29 Later on, multiple large randomized 
control trials were performed to assess if primary prevention ICD therapy was beneficial 
in selected populations (Table 2).30-37 30-32, 34-37 One of these was the Multicenter Automatic 
Defibrillator Implantation Trial (MADIT) which enrolled patients with a prior myocardial infarction, 
LVEF less than 35%, documented non sustained VT, and inducible/non-suppressible VT/VF 
during electrophysiological study.35 Subsequently, patients were randomized to either ICD 
treatment or optimal medical therapy. During a follow-up of 27 months and with the inclusion 
of only 196 patients, the study demonstrated a 54% mortality reduction in the ICD group. 
Important limitations of this trial were the relatively small cohort of patients and the significantly 
higher use of beta blockers in the ICD treatment group when compared with the optimal medical 
therapy group. Additional subgroup analysis of survival benefit demonstrated that the highest 
benefit was reached in patients with a LVEF less than 26%.38
Accordingly, this observation led to a simplified design, the MADIT II trial, randomizing 
patients post infarction with a LVEF less than 30% to either an ICD or no ICD without 
additional electrophysiological testing. The study required premature closure since the 
efficacy boundary had been reached. During an average follow-up of 20 months, a mortality 
reduction of 28% was observed in patients treated with an ICD.36 
With publication of the results of the MADIT trials, it became clear that patients with 
a poor left ventricular systolic function are at risk for sudden cardiac death due to a 
Table 1. Major secondary prevention implantable cardioverter defibrillator (ICD) Trials. 
aVID18 CIDs19 CasH20
sample size 1016 659 288
Design ICD vs. antiarrhythmic 
drugs
ICD vs. amiodarone ICD vs. amiodarone vs. 
metoprolol
Patients Resuscitated VF or 
postcardioversion from 
sustained VT
Resuscitated VF or VT with 
unmonitored syncope
Survivors of cardiac arrest 
secondary to documented 
ventricular arrhythmias
follow-up, months 18 36 57
Risk reduction with ICD 28% (p = 0.02) 20% (p = 0.14) 23% (p = 0.08)
































ventricular arrhythmia, which risk is high enough to warrant ICD treatment. And with this 
proven reduction in mortality, additional trials were designed in populations at high risk 
for life-threatening ventricular arrhythmias. Earlier studies and daily clinical practice had 
shown that patients are at very high risk for hemodynamically compromising ventricular 
arrhythmias in the period following acute myocardial infarction.10, 28, 39-41 Therefore, 
Hohnloser and coworkers started the Defibrillator in Acute Myocardial Infarction Trial 
(DINAMIT), including patients with a reduced left ventricular ejection fraction 6 to 
40 days after acute myocardial infarction and randomizing between ICD treatment and 
optimal medical therapy alone.33 During a mean follow-up period of 30 months, no 
over-all mortality difference was observed between the two treatment groups. Further 
classification by cause of death showed that ICD treated patients were 58% less likely 
to experience arrhythmic death but had a 75% higher risk for non-arrhythmic death. 
These results imply that ICD treatment following recent myocardial infarction does not 
improve patient outcome, but merely changes the mode of death in this vulnerable 
population. More recently, a similar trial (Immediate Risk Stratification Improves Survival 
(IRIS)) was conducted randomizing 898 patients 5 to 31 days after myocardial infarction.37 
Additional inclusion criteria were a left ventricular ejection fraction ≤40% and a heart 
rate of 90 or more beats per minute or nonsustained ventricular tachycardia. During 
a mean follow-up of 37 months, overall mortality was not reduced in the ICD treated 
group. However, risk of sudden cardiac death was 45% lower in the ICD group, but the 
risk of nonsudden cardiac death was 92% higher. These results confirmed the conclusions 
stated by DINAMIT that following recent myocardial infarction, patients do not benefit 
from ICD treatment. 
Based on all previously described primary prevention trials, Nanthakumar and co-
workers conducted a meta-analysis, which demonstrated a 25% mortality reduction in favor 
of ICD patients and, consequently, these findings led to the inclusion of primary prevention 
ICD treatment in the current guidelines.42, 43 
Table 2. Major primary prevention implantable cardioverter defibrillator (ICD) trials. 
MaDIT35 MUsTT32 MaDIT II36 COMPanIOn31 DefInITe34 sCD-HefT30 DInaMIT33 IRIs37
sample size 196 704 1232 1520 458 2521 674 898
Design ICD vs AAD EPS-guided: ICD vs 
AAD vs no AAD 
ICD vs AAD CRT-D vs CRT vs 
AAD
ICD vs AAD ICD vs AAD vs AAD 
+ amiodarone
ICD vs AAD ICD vs AAD
Patients Prior MI, EF ≤0.35, 
nsVT, EPS+
Prior MI, EF ≤0.40, 
EPS+
Prior MI, EF ≤0.30 I & NICM, EF ≤0.35, 
QRS >120ms
NICM, EF ≤0.35 I & NICM, EF ≤0.35 Prior MI, EF ≤0.35,
HR ≥80
Prior MI, EF ≤0.40,
HR ≥90
follow-up, months 27 39 20 14 29 46 30 37
Risk reduction with ICD vs aaD 54% (p = 0.01) 58% (p < 0.001) 31% (p = 0.02) 40% (p < 0.001) 35% (p = 0.08) 23% (p = 0.007) -8% (p = 0.66) -4% (p = 0.78)
AAD = antiarrhythmic drugs; CRT-D = cardiac resynchronization therapy-defibrillator; EF = ejection fraction; 
EPS = electrophysiological study;  HR = heart rate; ICD = implantable cardioverter defibrillator; I = ischemic; 


































Following the inclusion of primary prevention in the guidelines, a shift occurred in the 
population receiving an ICD device. Firstly, in 1996 only patients with a survived cardiac 
arrest received an ICD (secondary prevention), however in 2008 already 80% of ICD 
recipients had a primary prevention indication.44 As a result, an increasing part of ICD 
recipients suffered from a more advanced stage of heart disease with a reduced LVEF.45 
Importantly, left ventricular failure is associated with conduction disturbances causing 
mechanical dyssynchrony which further contributes to a reduction in the LVEF. 
Consequently, cardiac resynchronization therapy (CRT) devices were designed to 
improve LV performance by restoring the atrio-ventricular, interventricular en intraventricular 
synchronicity and therewith increase LV filling time, reduce MR, and correct septal 
dyskinesis.46 In numerous randomized and multicenter trials, CRT has shown to improve 
the systolic LV function and clinical prognosis of patients with end-stage, drug refractory 
heart failure (Table 3).31, 47-61  For instance, in the CARE-HF trial, patients with severe NYHA 
functional class ≥III heart failure due to a reduced LVEF (≤35%) and cardiac dyssynchrony 
(QRS ≥120msec) were randomly assigned to receive medical therapy alone or  in combination 
with CRT.53 During follow up, CRT demonstrated to be beneficial with a hazard ratio of 
0.63 (95% CI 0.51 – 0.77) for the primary endpoint (a composite of death from any cause 
or an unplanned hospitalization for a major cardiovascular event) in patients treated with 
CRT as compared with patients treated with medical therapy only. Almost simultaneously, 
the COMPANION trial reported results of advanced heart failure patients (NYHA III or 
IV) with a depressed LVEF (≤35%) and a wide QRS complex (≥120ms) who were randomly 
assigned to receive optimal medical therapy alone or in combination with CRT with either a 
pacemaker or a pacemaker defibrillator (CRT-D).31Again, the  risk of the combined endpoint 
of death from or hospitalization for heart failure was significantly reduced by 34% and 40% 
in the CRT and CRT-D respectively if compared with the conventionally treated group. In 
addition, CRT-D therapy also significantly reduced mortality with 36% when compared with 
the pharmacologic-therapy group. 
Table 2. Major primary prevention implantable cardioverter defibrillator (ICD) trials. 
MaDIT35 MUsTT32 MaDIT II36 COMPanIOn31 DefInITe34 sCD-HefT30 DInaMIT33 IRIs37
sample size 196 704 1232 1520 458 2521 674 898
Design ICD vs AAD EPS-guided: ICD vs 
AAD vs no AAD 
ICD vs AAD CRT-D vs CRT vs 
AAD
ICD vs AAD ICD vs AAD vs AAD 
+ amiodarone
ICD vs AAD ICD vs AAD
Patients Prior MI, EF ≤0.35, 
nsVT, EPS+
Prior MI, EF ≤0.40, 
EPS+
Prior MI, EF ≤0.30 I & NICM, EF ≤0.35, 
QRS >120ms
NICM, EF ≤0.35 I & NICM, EF ≤0.35 Prior MI, EF ≤0.35,
HR ≥80
Prior MI, EF ≤0.40,
HR ≥90
follow-up, months 27 39 20 14 29 46 30 37
Risk reduction with ICD vs aaD 54% (p = 0.01) 58% (p < 0.001) 31% (p = 0.02) 40% (p < 0.001) 35% (p = 0.08) 23% (p = 0.007) -8% (p = 0.66) -4% (p = 0.78)
AAD = antiarrhythmic drugs; CRT-D = cardiac resynchronization therapy-defibrillator; EF = ejection fraction; 
EPS = electrophysiological study;  HR = heart rate; ICD = implantable cardioverter defibrillator; I = ischemic; 

































Accordingly, these findings resulted in the American Heart Association/American 
College of Cardiology/Heart Rhythm Society guidelines to consider CRT a class I indication 
in patients with end-stage heart failure (NYHA III-IV) with an LVEF ≤35% and a QRS complex 
duration of ≥120ms.62 Similar recommendations were provided by the European Society of 
Cardiology in 2007.63 
Despite the widely proven beneficial effects of CRT therapy, 20-30% of CRT recipients 
do not show any clinical or echocardiographic improvement and are considered CRT non 
responder.46 Already several factors such as LV dyssynchrony, extent and location of scarred 
Table 3. Overview of inclusion criteria and main findings of randomized clinical trials evaluating cardiac 








(ms) ICD Main findings
MUsTIC-sR52 58 III ≤35 ≥150 No · Reduction in hospitalization
·  Improvement in 6 MWT, NYHA class, QoL, and 
Peak VO2
· Reduction in LV volumes and MR 
MIRaCle47 453 III, IV ≤35 ≥130 No · Improvement in 6 MWT, NYHA class, and QoL
· Reduction in LVEDD, MR, increase in LVEF
PaTH-CHf49 41 III, IV ≤35 ≥120 No · Reduction in hospitalization
· Improvement in 6 MWT, NYHA class, and QoL
MUsTIC-af57 59 III ≤35 ≥200 No · Reduction in hospitalization
·  Improvement in 6 MWT, NYHA class, QoL, and 
Peak VO2
MIRaCle-ICD61 369 III, IV ≤35 ≥130 Yes · Improvement in NYHA class, QoL, and Peak VO2
COnTaK-CD56 490 II-IV ≤35 ≥120 Yes · Improvement in 6 MWT, NYHA class, and QoL
· Reduction in LV volume, increase in LVEF
PaTH-CHf II50 86 III, IV ≤35 ≥120 Yes/No · Improvement in 6 MWT, QoL, and Peak VO2




186 II ≤35 ≥130 Yes · Improvement in NYHA class
· Reduction in LV volumes, increase in LVEF
CaRe-Hf53, 54 813 III, IV ≤35 ≥120 No ·  Reduction in all-cause mortality or 
hospitalization
· Improvement in NYHA class, QoL
ReTHInQ51 172 III ≤35 <130 Yes · Improvement in NYHA class
ReVeRse55, 58 610 I, II ≤40 ≥120 Yes/No · Reduction in hospitalization
· Reduction in LVESV
MaDIT-CRT59 1820 I, II ≤30 ≥130 Yes ·  Reduction in all-cause mortality or heart failure 
event
· Reduction in LVESV
RafT60 1798 II, III ≤30 ≥130 Yes ·  Reduction in all-cause mortality or heart failure 
hospitalization
6 MWT = 6 minutes walk test; ICD = implantable cardioverter defibrillator; LV = left ventricular; LVEDD = 
left ventricular end-diastolic diameter; LVESV = left ventricular end-systolic volume; LVEF = left ventricular 
































tissue and position of the LV pacing lead have demonstrated to determine the response 
to CRT.64-70 However, it is of interest if patients who respond to CRT, and therewith have a 
decreased myocardial wall tension, have less ventricular arrhythmias if compared to CRT 
non-responders. 
Complication of device treatment
With expending indications for ICD treatment, worldwide implantation rates increased to 
an estimated 275.000 units in 2008.62, 71 Although the beneficial effect on mortality has 
been thoroughly proven in a selected population, some serious drawbacks of ICD therapy 
should not be overseen. 
Firstly, device implantation is associated with a number of complications, such as 
pneumothorax and endovascular lead related complications such as right ventricular 
perforation and coronary vein dissection (Table 4).72-79 The first days following implantation 
can be accompanied by pocket hematoma and lead dislodgement. 
Secondly, during longer follow-up, other complications can occur, such as defibrillation 
lead failure,72-77, 80 pocket infections,79, 81-83 and inappropriate device discharge18, 30, 32-34, 36, 84. 
An important difficulty is the limited service life of the pulse generator, resulting in device 
replacement approximately every 4-5 years.85, 86 With increased survival of patients it is 
estimated that over 70% of implanted patients require an ICD replacement due to end-
of-life of the device and 40% even require a second replacement.86 These figures imply 
that the number of replacements can be expected to outnumber first implantations in the 
Table 4. Implantation related complications of implantable cardioverter defibrillators and cardiac 






















aVID18, 76 539 27 6 (1.1) NR 8 (1.5) 8 (1.5) NA
MaDIT II36 742 20 NR 0 (0.0) NR NR NA
DInaMIT33 312 30 NR 0 (0.0) NR NR NA
DefInITe34 229 29 2 (0.9) 0 (0.0) NR 6 (2.6) NA
sCD-HefT30 829 46 NR NR NR NR NA
IRIs37 445 37 NR 5 (0.8) NR NR NA
MaDIT-CRT59 1829 29 24 (1.3) 1 (0.1) 54 (3.0) 44 (4.4) 5 (0.5)
MIRaCle47, 79 571 6 1 (0.2) 2 (0.4) NR 31 (5.9) 35 (6.2)
MIRaCle ICD61, 
79
429 6 3 (0.7) 0 (0.0) NR 11 (2.9) 19 (4.5)
COMPanIOn31 1212 16 NR 8 (0.6) NR NR 22 (1.8)
CaRe-Hf53, 78 409 29 2 (0.5) 0 (0.0) NR 11 (2.8) 6 (1.5)
RethinQ51 250 6 2 (1.1) 0 (0.0) 2 (1.2) 13 (7.6) 1 (0.6)
































near future.87 Previous studies have demonstrated that surgical re-interventions, such as 
device replacements, are correlated to an increased occurrence of device infections.82, 83 
Additionally, Gould and Krahn reported that the consequences of an early re-intervention 
for a non-infectious cause can be considered more harmful than the underlying complication 
itself.88 However, the effect of replacement on non-infectious pocket related complications 
and the effect of additional replacements has not yet been assessed.
socio-economic implications
As already discussed, ICDs have shown to be an effective treatment modality in the 
prevention of sudden cardiac death in selected patients.18-20, 30, 32, 35, 36 However, it has been 
recognized that ICD recipients have an ongoing risk of sudden cardiac incapacitation that 
might cause harm to others when driving a car. Although numerous recommendations 
exist, thus far evidence is scarce to justify them and large variation exist between different 
countries concerning the legislation of driving restriction after ICD implantation (Table 5).89, 
90 Keeping in mind that driving restrictions are often being perceived as difficult for patients 
and their families, clear evidence on the necessity of these restrictions is vital.
Furthermore, with increased implantation rates, clinicians have expressed concern that 
the number-needed-to-treat with a primary prevention ICD might be too high and that the 
population eligible for primary prevention ICD treatment is of such magnitude that ICD 
therapy will strain financial resources and the pool of trained personnel.91, 92 Concomitantly, 
it is essential to assess the cost-effectiveness of ICD therapy in different subgroups in order 
to specify which patients would have a reasonable cost to benefit ratio if treated with an 
ICD. It is therewith important to realize that the accepted cost-effectiveness ratio per gained 
quality-adjusted life year vary widely per country. In the Netherlands a cost-effectiveness 
ratio below €40,000 per gained quality-adjusted life year is accepted whereas in the United 
States of America a threshold of $60.000 is accepted.93, 94 
Previously, several studies have assessed the cost-effectiveness of the prophylactic use 
of ICDs and showed a wide diversity in the cost and benefit ratio if the current guidelines are 
followed (Table 6).95-100 However, these dissimilarities in the beneficial effect of ICD therapy, 
Table 5. Overview of the recommendations by the American Heart Association (AHA) and the European 
Heart Rhythm Association (EHRA) for ICD patients with private driving habits.
aHa89 eHRa90
ICD for secondary prevention 6 months 3 months
ICD for primary prevention 1 week 4 weeks
following appropriate ICD therapy 6 months 3 months
following inappropriate ICD therapy None Until measures are taken
following ICD replacement None 1 week
following lead replacement None 4 weeks
































based on results from clinical trials, are difficult to extrapolate to routine clinical practice 
since these studies mainly used experts’ opinions for complication rates, device longevity, 
and costs. Furthermore, differences in study population and patient characteristics in 
previous analysis presumably had a large effect on the final cost-effectiveness of ICD 
therapy. Consequently, it is important to determine the cost-effectiveness of ICD therapy, 
based on clinical data and detailed costs derived from routine clinical practice.
Furthermore, the effect on the cost-effectiveness of ICD therapy should be calculated 
for various clinical circumstances as for instance an older age at implantation, higher rate of 
complications, and the obtained quality of life. Hence, based on these results one is able to 
allocate the limited financial resources and trained personnel in the most efficient manner 
for the health care system.
AIm AnD ouTlIne oF The TheSIS
In large clinical trials, ICD therapy and CRT-D have been proven to be an effective treatment 
in selected patients. However, the population assessed in these trials does not reflect the 
population receiving an ICD or CRT-D in the “real world”. Therefore the aim of the current 
thesis was to evaluate the clinical aspects and socio-economic implications of ICD and 
CRT-D treatment in the population presently receiving device therapy.
In Part I, the clinical characteristics and outcomes of the population indicated for 
defibrillator treatment in routine clinical practice were studied. Chapter 2 describes the 
mode of death and prognosis for different subgroups of device recipients outside the 
setting of a clinical trial. The increasing risk for pocket-related complications with recurrent 
device replacements is evaluated in chapter 3. Chapter 4 studied the effect of CRT on the 
occurrence of ventricular arrhythmias in patients who underwent upgrade from ICD to 
CRT-D. Finally, in chapter 5, the suitability and predictors of the unsuitability for an entirely 
subcutaneous ICD system were established. 
Table 6. Results of increased costs, increased life years, increased quality-adjusted life years, and 
incremental cost-effectiveness ratios for implantable cardioverter defibrillators compared with control 
therapy in different primary prevention ICD trials.
Increase in Cost ($) Increase in lY Increase in QalY ICeR ($/lY) ICeR ($/QalY)
MaDIT I35, 98   92,100 3.64 2.64 25,300 34,900
CabG Patch98, 101   55,700 (0.40) (0.29) Dominated Dominated
MUsTT32, 98 101,500 4.14 2.99 24,500 34,000
MaDIT II36, 98, 100   79,400 2.03 1.47 39,000 54,100
DefInITe34, 98 100,500 2.73 1.96 36,800 51,300
DInaMITe33, 98   58,800 (0.48) (0.34) Dominated Dominated
COMPanIOn31, 98   68,300 1.87 1.36 36,500 50,300
sCD-HefT30, 98   71,000 1.40 1.01 50,700 70,200
































In Part II, the social and economic implications of ICD and CRT-D therapy are examined. 
In chapter 6, lifetime cost and gained quality-adjusted life years were estimated for primary 
prevention ICD recipients. Device longevity and reasons for defibrillator replacement were 
studied in chapter 7. In chapter 8, an evidence based approach for driving restrictions in 
defibrillator patients was based on real-world incidences of appropriate and inappropriate 
device shocks. Finally, in chapter 9, strategies to identify those patients most likely to benefit 
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Although data on the mode of death of implantable cardioverter defibrillator (ICD) and 
cardiac resynchronization therapy- defibrillator (CRT-D) patients have been examined in 
randomized clinical trials, in routine clinical practice data is scarce. To provide reasonable 
expectations and prognosis for patients and physicians, this study assessed the mode of 
death in routine clinical practice.
Objective
To assess the mode of death in ICD/CRT-D recipients in routine clinical practice.
Methods
All patients who underwent an ICD or CRT-D implantation at the Leiden University Medical 
Center, the Netherlands between 1996 and 2010 were included. Patients were divided 
into primary prevention ICD, secondary prevention ICD, and CRT-D patients. For patients 
who died during follow-up, the mode of death was retrieved from hospital and general 
practitioner records and categorized according to a predetermined classification: heart 
failure death, other cardiac death, sudden death, non-cardiac death, and unknown death. 
Results
A total of 2859 patients were included in the analysis. During a median follow-up of 3.4 years 
(interquartile range, 1.7-5.7 years), 107 (14%) primary prevention ICD, 253 (28%) secondary 
prevention ICD, and 302 (25%) CRT-D recipients died. The 8-year cumulative incidence of 
all-cause mortality was 39.9% (95% CI 37.0–42.9%). Heart failure death and non-cardiac 
death were the most common modes of death for all groups. Sudden death accounted for 
approximately 7-8% of all deaths. 
Conclusion
For all patients, heart failure and non-cardiac death are the most common modes of death. 
The proportion of patients who died suddenly was low and comparable for primary and 


























Sudden cardiac death (SCD), mainly caused by life-threatening ventricular arrhythmias, 
is responsible for 50% of all cardiac mortality worldwide.1 As demonstrated by large 
randomized clinical trials, implantable cardioverter defibrillators (ICDs) are able to reduce 
the risk of SCD in survivors of life-threatening arrhythmias (i.e. secondary prevention), as well 
as in selected patients with ischemic and non-ischemic heart disease at high risk of sudden 
arrhythmic death (i.e. primary prevention).2-8 Nowadays, most defibrillators are implanted in 
combination with cardiac resynchronization therapy (CRT-D), which has a beneficial effect 
on mortality in heart failure patients with ventricular dyssynchrony (i.e.mechanical delay 
between septum and lateral wall contraction).9, 10 
As a result of the prevention of sudden death, it was hypothesized that most patients 
will ultimately die of causes other than sudden death and that this will lead to a shift in the 
mode of death in patients with an implanted defibrillator device. Interestingly, subgroup 
analyses of randomised controlled ICD trials failed to demonstrate such a shift.7, 11 
In routine clinical practice, data regarding the mode of death are rarely examined and 
extrapolating data from randomised controlled trials to routine clinical practice is difficult 
given the strict inclusion criteria of the trials. To provide reasonable expectations and 
prognosis for patients and physicians, it is necessary to assess the mode of death in a 
population with ICDs or CRT-Ds outside the setting of a clinical trial. 
Since 1996, all ICD and CRT-D recipients in the Leiden University Medical Center have 
been assessed and followed up. This cohort offers a unique opportunity to assess the mode 
of death in routine clinical practice. 
meThoDS
Patients
Since 1996, all patients who received an ICD or CRT-D at the Leiden University Medical 
Center, the Netherlands are registered in the departmental Cardiology Information 
System (EPD-vision®, Leiden University Medical Center) and prospectively recorded. For 
the current study, all patients who underwent ICD/CRT-D implantation for primary or 
secondary prevention of SCD between January 1996 and December 2010 were included. 
Patients with a congenital structural or monogenetic heart disease (e.g. tetralogy of 
Fallot, hypertrophic cardiomyopathy, long QT syndrome) were excluded. At baseline, 
patient characteristics and implantation data were collected and during follow-up, all 
visits were noted. 
Patients received a single-chamber or dual-chamber ICD after surviving life-threatening 
ventricular arrhythmias or in the presence of a depressed left ventricular function (left 
ventricular ejection fraction [LVEF] ≤35%) with or without non sustained ventricular 
tachycardia. CRT-D implantation occurred in patients with advanced heart failure (New York 
Hart Association [NYHA] class III or IV), depressed LVEF (i.e. ≤35%) and a wide QRS complex 
(>120ms). Eligibility for ICD implantation in this population was based on international 


























All defibrillator systems used were implanted transvenously without thoracotomy. Testing of 
sensing, pacing thresholds and defibrillator thresholds was performed during the implant 
procedure. Implanted systems were manufactured by Biotronik (Berlin, Germany), Boston 
Scientific (Natick, MA, United States, formerly CPI, Guidant [St. Paul, MN, United States]), 
Medtronic (Minneapolis, MN, United States), and St. Jude Medical/ Ventritex (St. Paul, MN, 
United States).
All devices were programmed with three consecutive zones with limits slightly varying per 
manufacturer: a monitor zone (lower limit between 150-155 beats per minute (b.p.m.); upper 
limit between 185-190 b.p.m.), an antitachycardia pacing (ATP) shock zone (lower limit between 
185-190 b.p.m.; upper limit between 205-210 b.p.m.) and an initial shock zone (≥205-210 b.p.m.). 
In the monitor zone, no therapy was programmed unless ventricular arrhythmia was detected 
during follow-up. In the ATP-shock zone, arrhythmias were initially attempted to be terminated 
by two bursts of ATP and, if arrhythmia continued, defibrillator shocks were used. In case of 
ventricular arrhythmia faster than the ATP shock zone, device shocks were the initial therapy. 
Furthermore, atrial arrhythmia detection was set to >170 b.p.m. with supraventricular tachycardia 
discriminators enabled. Therapy settings were adapted, only when clinically indicated. 
follow-up 
All patients were evaluated regularly at 3-6 month intervals for follow-up or more frequently 
when clinically indicated. Printouts of device interrogations were checked for delivered 
therapy, which was classified as appropriate when occurring in response to ventricular 
tachycardia or ventricular fibrillation and included ATP and shocks. The survival status 
of patients was retrieved from municipal civil registries, which are updated regularly. 
Subsequently, the cause of death was assessed in all deceased ICD/CRT-D patients. Only 
in a few cases the cause of death was assessed by a pathologist. In all other cases, the 
cause of death was either based on letters and follow-up reports from patients who died 
in the hospital without autopsy or by the expertise of the contacted general practitioners.
event subclassification and definitions
Causes of death were categorized according to a modified Hinkle Taler classification and 
categorized into 3 groups: cardiac, non-cardiac and sudden death.18 The cardiac group was 
further categorized in tachyarrhythmic, bradyarrhythmic, heart failure, non-arrhythmic non 
heart failure, and in cardiac but unable to classify further. The non-cardiac death group was 
further divided into a vascular and a non-vascular mode of death. Patients who died in their 
sleep or died unexpectedly without worsening of their clinical situation were categorized as 
sudden death. Patients who died suddenly but with a clear alternative mode of death were 
categorized as non-sudden (e.g. someone who died suddenly of acute myocardial infarction 
was categorized as “cardiac, non-arrhythmic non-heart failure” and not as sudden death). 
Heart failure was diagnosed when patients died of terminal heart failure, progressive failure 
of cardiac pump function, or cardiac asthma under maximum inotropic drug support. All 
other causes were categorized as cardiac but unable to classify further. In all cases, the 


























Continuous data are expressed as mean ± standard deviation; dichotomous data are 
presented as numbers and percentages. Device recipients were divided into 3 groups: 
primary prevention ICD patients, secondary prevention ICD patients and CRT-D patients.
One-way analysis of variance test was used to assess differences in continuous variables 
across different groups of patients; if the result of the analysis was significant, Bonferroni 
post hoc test was applied. Differences in categorical variables were analyzed using chi-
square tests or Fischer’s exact tests, as appropriate. Event rates over time were analyzed 
by method of Kaplan-Meier with corresponding log-rank test for differences in distribution 
between the curves. A competing-risk model was used to analyze the cause-specific 
mortality.19 The statistical software program SPSS 17.0 (Chicago, Illinois, United States) was 
used for statistical analysis. A p-value of < 0.05 was considered significant.
reSulTS
Patients
Since January 1996, 756 (26%) patients received an ICD for primary prevention of SCD, 914 
(32%) patients received an ICD for secondary prevention, and 1189 (42%) patients received 
a CRT-D. Median follow-up was 3.4 years (interquartile range, 1.7-5.7 years). Baseline 
characteristics are summarized in Table 1. 






































Figure 1. Kaplan Meier curve for all-cause mortality in primary prevention ICD recipients (bold line), in 

























Mode of death 
At the end of follow-up, 662 (23%) patients had died. For 548 (83%) patients the mode of 
death was obtained (Table 2). The cumulative incidence of all-cause mortality was 10.0% 
(95% CI 8.8-11.1%) after 2 years, 19.6% (95% CI 17.9-21.3%) after 4 years and 39.9% (95% CI 
37.0–42.9%) after 8 years. 
All-cause mortality was significantly different between the 3 groups and was highest for 
patients who received a CRT-D (Figure 1).
A total of 107 (14%) primary prevention ICD patients died during follow-up. In 85 (79%) of 
these patients, the mode of death was obtained. In absolute terms, most patients died from 
heart failure (n=37, 35%), followed by a non-cardiac cause (n=35, 33%). Seven patients (7%) 
died suddenly (Table 2, Figure 2). In the group with secondary prevention ICD recipients, 
253 (28%) patients died during follow-up and for 197 (78%) patients the mode of death was 
obtained. Further sub classification revealed that most patients died from a non-cardiac 
cause (n=95, 38%), but still a significant part died from heart failure (n=71, 28%). Twenty 
patients (8%) died suddenly. In the CRT-D group, 302 (25%) patients died during follow-
up. The mode of death was obtained in 266 (88%) of these patients. Not unexpectedly, 










Clinical characteristics        
     Age, mean (SD), years 60 ± 12 62 ± 14* 65 ± 10*† <0.001
     Male (%) 627 (83%) 733 (80%) 911 (77%)* <0.001
     Left ventricular ejection fraction (%) 32 ± 13 40 ± 15* 26 ± 9*† <0.001
     QRS, mean (SD), ms 109 ± 25 115 ± 29* 146 ± 33*† <0.001
     Renal clearance. mean (SD), mL/min 85 ± 36 82 ± 40 74 ± 40*† <0.001
     Ischemic heart disease (%) 584 (77%) 654 (72%)* 734 (62%)*† <0.001
     History of atrial fibrillation/flutter (%) 160 (21%) 197 (21%) 370 (31%)*† <0.001
Medication
     ACE-inhibitors/AT II antagonist (%) 626 (83%) 614 (67%)* 1038 (87%)*† <0.001
     Diuretics (%) 454 (60%) 412 (45%)* 1013 (85%)*† <0.001
     Statins (%) 540 (71%) 479 (52%)* 741 (62%)*† <0.001
Anti-arrhythmic medication
     Beta-blocker (%) 476 (63%) 385 (42%)* 769 (65%)† <0.001
     Amiodarone* (%) 78 (10%) 217 (24%)* 205 (17%)*† <0.001
     Sotalol* (%) 101 (13%) 177 (19%)* 106 (9%)*† <0.001
     Antiarrhytmic medication combined* (%) 617 (82%) 696 (76%)* 986 (83%)† <0.001
ACE = angiotensin-converting enzyme; AT = angiotensin;CRT-D = cardiac resynchronization therapy 
defibrillator; ICD = implantable cardioverter defibrillator; SD = standard deviation. * Patients could be taking 

























most patients died from heart failure (n=131, 43%), but still 30% (n=92) died from a non-
cardiac cause. 
morTAlITy rATeS Per moDe oF DeATh
Categorization by mode of death showed heart failure death and non-cardiac death as the 
main causes of death, which consequently had the highest 8-year cumulative incidence. 
For heart failure death, the 8-year cumulative incidence was 8.6% (95% CI 5.3-12.0%) in 
primary prevention ICD recipients, 9.6% (95% CI 7.1-12.0%) in secondary prevention ICD 
recipients, and 22.6% (95% CI 17.8-27.5%) in CRT-D recipients (log rank p<0.001). The 8-year 
cumulative incidence for non-cardiac death was 7.0% (95% CI 4.4-9.5%) in primary prevention 
ICD recipients, 13.8% (95% CI 10.9-16.7%) in secondary prevention ICD recipients, and 
18.7% (95% CI 13.7-23.7%)  in CRT-D recipients (log rank p<0.001). In Figure 3, cumulative 
incidences for heart failure death, sudden death, non-cardiac death, and other cardiac death 
are displayed according to the 3 device groups.
sudden death
Sudden death was the mode of death in 49 (7%) patients, of whom 17 (3%) patients died 
from a recorded sustained tachyarrhythmia (Table 2). ICD function was switched off in only 
2 cases by patient request; one in the tachyarrhythmic and one in the sudden death group. 
The 8-year cumulative incidence was 2.1% (95% CI 0.3 – 4.0 %) in primary prevention ICD 
patients, 3.2% (95% CI 1.6 – 4.8%) in secondary prevention ICD patients, and 3.6% (95% CI 
1.8 – 5.3%) in CRT-D recipients (log rank p=0.026).
DISCuSSIon 
The main findings of the present study can be summarized as follows: (1) large differences 
in the annual mortality rates between ICD and CRT-D patients were found during the first 
8 years of follow-up with CRT-D patients having the highest annual mortality; (2) heart failure 
and non-cardiac death were the most common causes of death in device recipients; (3) 
sudden death rates were low and comparable between primary and secondary prevention 
ICD patients and CRT-D patients. 
all-cause mortality in routine clinical practice
In the current study, the annual mortality rate for the total cohort was 5.0% during the 
first 8 year of follow-up. However, when subcategorized according to device type, large 
differences were found with an annual mortality of 2.9% in the primary prevention ICD 
patients, 4.5% in secondary prevention ICD patients, and 6.9% in the CRT-D patients. It is 
evident that these dissimilar mortality rates are due to the completely different composition 
of the groups, which is demonstrated by the significant differences in patient characteristics 
between those groups at baseline (Table 1).   
In comparison, in the ICD treated arms of major randomized trials, higher annual 
mortality rates were observed ranging from 5.8%-8.4% in primary prevention patients 


































Cardiac 44 91 159
     Tachyarrhythmic 1 9 7
     Bradyarrhythmic 0 0 0
     Heart failure 37 71 131
     Nonarrhythmic, non-heart failure 3 9 17
     Cardiac but unable to classify further 3 2 4
non-cardiac 35 95 92
     Stroke and other cerebrovascular disease 3 5 7
     Other vascular disease 2 4 10
     Vascular but unable to classify further 0 1 0
     Malignant neoplasm 15 35 32
     Infectious 8 28 29
     COPD 2 3 2
     Alzheimer and other dementias 0 2 1
     Other nonvascular disease 4 16 11
     Non-vascular but unable to classify further 1 1 0
sudden death: unable to classify further 6 11 15
Unknown 22 56 36
Total death 107 253 302
COPD = chronic obstructive pulmonary disease, ICD = implantable cardioverter defibrillator.





































































































































































































Figure 3. Kaplan Meier curve categorized in heart failure death, sudden cardiac death, non cardiac 
death, and other cardiac death. Cumulative mortality is presented for primary prevention ICD recipients 
(red line), secondary prevention ICD recipients (blue line) and CRT-D recipients (green line) separately. 
Modes of death other than the one described were censored.
be explained by either a healthier population at baseline, better (pharmacotherapeutic) 
treatment during follow-up, or a combination of both. Baseline mean left ventricular 
systolic function, for example, was higher in primary prevention patients in the current 
study (LVEF 32%) than in the major primary prevention ICD trials (LVEF 21%-30%).5, 8, 23, 23, 24 
Furthermore, inclusion of patients in the three major secondary prevention trials occurred 
between 1987 and 1998, while in the current study, patients received an ICD between 
1996 and 2010.4, 6, 20  
Also for CRT-D patients, the annual mortality rate was lower in the current analysis 
when compared with the outcomes of large clinical trials. For instance, in the CARE-HF 
and COMPANION, annual mortality rates of respectively 9% and 12% were reported.25, 26 
Again, these differences are mainly due to differences in the selection and composition 
of the patient population. The effect hereof is clearly illustrated in the MADIT-CRT Trial, 



























As one of the major causes of death, the high rate of heart failure death in ICD recipients 
is confirmed in the current study. For primary prevention ICD patients, one might expect 
an increased risk of heart failure mortality when compared with secondary prevention ICD 
patients because having a low LVEF is one of the main criteria to be selected for primary 
prevention ICD implantation.9 Interestingly, primary and secondary ICD patients have a 
similar annual heart failure mortality of approximately 1.1-1.2% within the first 8 years of 
follow-up (Figure 3A). There are several explanations for this similarity. First of all, the 
difference in baseline LVEF, albeit statistically significant, was only 8% between primary 
prevention ICD patients and secondary prevention ICD patients (mean LVEF 32% vs 40% 
respectively).  Secondly, Poole et al demonstrated that in ICD patients, the occurrence of an 
appropriate ICD shock was associated with a markedly increased risk of death.28 Furthermore, 
they demonstrated that the most common mode of death among patients who received an 
ICD shock was progressive heart failure. Since secondary prevention ICD patients receive 
more appropriate ICD shocks than primary prevention ICD patients, secondary prevention 
ICD patients exhibit in theory an increased risk of heart failure mortality.29
Finally, it has been demonstrated that in patients with heart failure, prolongation of QRS 
is associated with worse prognosis and higher cardiac mortality. 30 As can be seen in Table 
1, secondary prevention ICD patients had a significantly longer QRS duration than primary 
prevention ICD patients putting them at increased risk of heart failure mortality. 
Interestingly, in the major ICD trials, higher rates of heart failure mortality were observed: 
in  MADIT-2, Greenberg et al reported annual rates for non-sudden cardiac death of 2.5% 
and in the SCD-HeFT, the cumulative incidence of heart failure mortality after 5-years of 
follow-up was approximately 13% (value estimated from graph) resulting in an annual rate of 
approximately 2.6%.31 Even higher incidences were observed in the AVID trial: after 4 years 
of follow-up, cumulative incidence was approximately 13% (value estimated from graph), 
resulting in an annual incidence of 3.3%.7 Comparing the results of the current study with 
major randomized trials is difficult given the different time periods during which the studies 
were conducted as well as differences in patients’ characteristics. 
A remarkable outcome of the present analysis is the absence of any bradyarrhythmic 
death in all three subgroups of defibrillator recipients. Though, in other studies, were this 
mode of death was specified, bradyarrhythmic death also occurred in less than 1% of all 
deceased patients.11, 32, 33 A possible clarification for this finding could be the programmed 
backup pacing of defibrillator devices, avoiding serious deteriorating bradyarrhythmias and 
therewith bradyarrhythmic death. This explanation is supported by the results of Packer 
et al., in which only 1 out of 829 (1%) ICD treated heart failure patients deceases due to a 
bradyarrhythmic death versus 8 out of 1692 (5%) conventional treated heart failure patients.11 
SuDDen CArDIAC DeATh
In the current study, sudden death accounted for 7% of cases in all ICD recipients. These 

























clinical trials concerning ICD treatment. For instance, sudden death rates ranged from 30 to 
36% (AVID trial 30%, CIDS trial 36% and CASH trial 36%) in the secondary prevention trials and 
from 15 to 34% (MADIT I 20%, MADIT II 27%, SCD-Heft 20%, CABG patch 15% and MUSTT 
34%) in the primary prevention trials regarding ICD therapy.2, 6, 7, 11, 21, 23, 31, 34 Although the study 
populations included in the clinical trials were different than the one discussed currently, it 
could not clarify these significant differences in the proportion of patients who died suddenly. 
A more plausible explanation is the unknown cause of death in 17% of the patients in the 
present analysis, which probably contains a relatively high number of patients who died 
suddenly. In addition, variation in the definition for sudden death between the previously 
described trials and the current study could be the reason for these large dissimilarities.
Interestingly, comparable sudden death rates were found in primary prevention ICD 
recipients (7%), secondary prevention ICD recipients (8%), and CRT-D recipients (7%). This 
is remarkable since – by definition – all secondary prevention ICD recipients survived an 
episode of ventricular arrhythmia and consequently have an increased risk of ventricular 
arrhythmias during follow-up.29 In theory, this should lead to an increased risk of sudden 
death. However, this was not observed in the current study. Probably, the rate of persistent, 
shock refractory and thereby fatal ventricular arrhythmias between the three groups similar 
despite having different baseline characteristics. These results should be interpreted with 
caution since the low rates of sudden death lead to wide confidence intervals making 
accurate comparison difficult between the three groups. Further studies are needed to 
confirm these low sudden death rates.
lImITATIonS
There are limitations to this study. First of all, in 17% of all patients, the cause of death could 
not be identified and post-mortem  reports were unavailable. Secondly, since only a part 
of patients died in our hospital (i.e. cause of death identified), cooperation of the general 
practitioners for retrieving the cause of death was crucial. Furthermore, in the Netherlands, 
ICD/CRT-D implantations are performed in academic medical centers (n=7) and large 
community hospitals (n=18) and patients are referred to our hospital from smaller, regional 
hospitals. Consequently, the study population does represent routine clinical practice in the 
Netherlands. However, current study population could differ from routine clinical practice 
in other countries. 
ConCluSIon
In routine clinical practice, the annual mortality rate of ICD and CRT-D patients is 
approximately 5%. However, large differences in the annual mortality rates between 
primary prevention ICD patients, secondary prevention ICD patients, and CRT-D patients 
were found during the first 8 years of follow-up. The most common modes of death 
are heart failure death and non-cardiac death. Remarkably, sudden death rates were 
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Despite the positive effect on mortality of ICD therapy in selected patients, limited service 
life of the ICD results in a necessity of replacement in the majority of patients. Data on the 
effect of replacement procedures on the occurrence of pocket related adverse events are 
scarce.
Methods and Results
Since 1992, a total of 3161 ICDs were implanted in 2415 consecutive patients (80% men, mean 
age 62 (SD 13) years) ICDs were grouped by the consecutive number in which they were 
implanted, resulting into a group of first implanted ICDs and multiple groups of consecutive 
replacement ICDs. All pocket related complications requiring surgical re-intervention 
following ICD implantation or replacement were noted. In total, 145 surgical re-interventions 
were required in 122 (3.9%) patients, with a median time to first re-intervention of 75 days. 
The three years cumulative incidence of first re-intervention was 4.7% (95% CI 3.9-5.5%) 
and the incidence of re-intervention was 1.9 (95% CI 1.6-2.2) per 100 ICD-years. Event rate 
comparison of replacement ICDs versus first implanted ICDs showed a more than doubled 
need for re-interventions in replacement ICDs (rate ratio 2.2 [95% CI 1.5-3.0]). Further sub-
division by the consecutive number of ICD replacements, shows an increase in the annual 
need for surgical re-intervention, ranging from 1.5% (95% CI 1.2-1.9%) in the first implanted 
ICD, to 8.1% (95% CI 1.7-18.3%) in the fourth implanted ICD.
Conclusion
ICD replacement is associated with a doubled risk for pocket related surgical re-



























Implantable cardioverter-defibrillators (ICDs) have shown to be an effective treatment 
modality in the primary and secondary prevention of sudden cardiac death in selected 
patients.1-7 With expending indications for ICD therapy, worldwide implantation rates have 
increased to an estimated 275.000 units in 2008.8, 9 Although these major advances have a 
positive effect on mortality, some serious drawbacks of ICD therapy should not be overseen. 
The most important being the limited service life of the pulse generator, resulting in device 
replacement approximately every 4-5 years.10, 11 With increased survival of patients it is 
estimated that over 70% of implanted patients require an ICD replacement due to end-of-life 
of the device and 40% even require a second replacement.11 These figures imply that the 
number of can be expected to outnumber first implantations in the near future.12 Previous 
studies have demonstrated that surgical re-interventions, such as device replacements, are 
correlated to an increased occurrence of device infections.13, 14 Additionally, Gould and Krahn 
reported that the consequences of an early re-intervention for a non-infectious cause can 
be considered more harmful than the underlying complication itself.15 However, the effect 
of replacement on non-infectious, pocket related complications and the effect of additional 
replacements has not yet been assessed. 
This current increase in ICD replacements warrants clear mapping of the associated risks 
for complications, such as hematoma or infection. In this analysis a comparison is made to 
determine the requirement for pocket related surgical re-intervention in first implanted ICDs 
and replacement ICDs in a large number of implanted ICDs (n= 3161). 
meThoDS
Patients 
The study population consisted of consecutive patients who received an ICD system in the 
Leiden University Medical Center. Since 1992 all implant procedures were registered in 
the departmental Cardiology Information System (EPD-Vision®, Leiden University Medical 
Center). Data of the implant procedure and all follow-up visits were recorded prospectively. 
The data collected for the current registry ranged up to August 2008. Abdominal implanted 
ICDs were excluded from the current analysis. 
Indications for ICD treatment were made according to international guidelines at that 
time. Due to evolution of these guidelines, indications will have changed over time. 8, 16 
Majority of patients were indicated for ICD treatment in the presence of prior life-threatening 
ventricular arrhythmia or poor left ventricular ejection fraction [LVEF]. 
Device implantation and discharge
At implantation, patients were clinically assessed, as described previously.17-19 During the 
implant procedure testing of sensing and pacing thresholds and defibrillation threshold 
testing was performed. Before discharge all patients underwent pocket inspection to exclude 
hematoma or early signs of infection. If no abnormalities were found and temperature was 


























The primary end-point was the occurrence of a surgical re-intervention of the ICD pocket 
(not because of an elective device replacement, lead failure or device malfunction). Since 
the aim of the current study was to evaluate the differences in event-rates between first 
implanted ICDs and replacement ICDs, only pocket related causes were considered. If 
other causes, such as lead related complications or pulse generator malfunction were taken 
in account, comparison would be difficult, given the fact that commonly, leads are only 
implanted at the initial ICD implantation and can therefore not be compared to lead related 
complications at replacement. 
In the Dutch health care system, all patients are followed by the implanting center 
and periodical follow-up was performed every three to six months. This study included 
follow-ups performed up to September 2008. During periodical follow-up the pocket was 
inspected for abnormalities and ICDs were checked at their functionality and battery status.
Since periodical follow-up was performed every three to six months, patients with more 
than six months of missing data were considered as lost to follow-up.
statistical analysis
Continuous data are expressed as mean and standard deviation or range, median and 
first and third quartile where appropriate; nominal data are presented as numbers and 
percentages. ICDs were grouped by the consecutive number in which they were implanted 
in the patient. This classification divides the implanted ICDs into a group of first implanted 
ICDs and multiple groups of replacement ICDs. The number of required re-interventions 
and the sum of years the ICDs were followed-up (ICD-years) were calculated for each group. 
Event rates were calculated by dividing the number of surgical re-interventions by the 
number of ICD-years, expressed with a two-sided 95% confidence interval (95% CI). In the 
calculation of the 95% CI for event rates, a Poisson distribution of the observed number 
of events was presumed. Rate ratios were used to assess the differences in event rates 
between groups. Cumulative incidences were analyzed with the method of Kaplan-Meier. 
For all tests, a p-value <0.05 was considered significant.
reSulTS
Defibrillator implantations 
A total of 3328 ICDs were implanted in 2521 patients between 1992 and August 2008. For the 
current analysis, all abdominal (n= 102, 3%) placed ICDs were excluded. Sixty-five (2.0%) ICDs 
were lost to follow-up. The remaining 3161 devices, implanted in 2415 patients were included 
in the analysis. These consisted of 2415 (76%) first implanted and 746 (24%) replacement 
ICDs. Figure 1 shows the annual proportion of replacements out of all device implantations.
Patients and ICD characteristics
The majority of patients (80% men, mean age 62 (SD 13) years) had ischemic heart disease 
(62%) and a poor LVEF (33±15%) (Table 1). At implantation, QRS duration (124±37 ms) and 





























     Age, mean (SD), years 62 (13)
     Male sex (%) 1921 (80)
     Primary indication (%) 1504 (62)
     Ejection fraction (%) 33 (15)
     QRS, mean (SD), ms 124 (37)
     Renal clearance, mean (SD), ml/min 79 (38)
Device type
     Single chamber (%) 335 (14)
     Dual chamber (%) 1171 (48)
     CRT-D (%) 909 (38)
Medication
     Beta-blocker (%) 1291 (54)
     Sotalol (%) 333 (14)
     ACE inhibitors/AT II antagonist (%) 1806 (75)
     Calcium antagonist (%) 220 (9)
     Diuretics (%) 1506 (62)
     Statins (%) 1395 (58)
     Nitrates (%) 430 (18)
     Amiodarone (%) 454 (19)
     Aspirin (%) 961 (40)
     Oral anticoagulants (%) 1217 (50)
CRT-D = cardiac resynchronization device-defibrillator
blockers (54%), ACE inhibitors/AT II antagonists (75%), diuretics (62%), aspirin (40%) and oral 
anticoagulants (50%). Implanted first ICDs were single chamber devices (n=335, 14%), dual 
chamber devices (n=1171, 48%) or cardiac resynchronization therapy-defibrillators (CRT-Ds) 
(909, 38%). 
Incidence and causes of surgical re-intervention
During 7632.3 ICD-years of follow-up, 145 surgical re-interventions were required in 122 (3.9%) 
patients. Median time to first re-intervention was 75 days (interquartile range, 14 to 258 days). 
Cumulative incidence of first surgical re-intervention after the most recent ICD 
implantation was 3.5% (95% CI 2.9-4.1%) after one year, 4.3% (95% CI 3.5-5.1%) after two 
years and 4.7% (95% CI 3.9-5.5%) after three years. Over-all the event-rate of a surgical re-

























Ninety-five (66%) re-interventions were due to an infectious cause and the remaining 50 
(34%) were due to a non-infectious cause (Table 2). Infectious causes were pocket infections 
(57, 60%%) and decubic ulcers, requiring explantation (11, 12%) or relocation (27, 28%). 
Hematoma, requiring evacuation was the most common (31, 21%) non-infectious cause for 
surgical re-intervention. Calculated event rate for the occurrence of surgical re-intervention 
was 1.2 (95% CI 1.0-1.5) per 100 ICD-years for infectious cause and 0.7 (95% CI 0.5-0.9) per 
100 ICD-years for non-infectious cause.








    Pocket infection leading to explantation 57/57 38/38 19/19
    Decubic ulcer leading to explantation 11/11 7/7 4/4
    Decubic ulcer leading to relocation 27/22 11/9 16/13
non-infectious
    Hematoma requiring evacuation 31/29 24/24 7/5
    Device migration leading to relocation 10/10 3/3 7/7
    Pain complaints of the patient leading to relocation 9/7 7/6 2/1
Total infectious causes 95/81* 56/47* 39/34*
Total non-infectious causes 50/45* 34/32* 16/13*
Total 145/122* 90/77* 55/45*
*Since multiple re-interventions could have been required in a single ICD treatment, the number of different 
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first implanted ICD vs. replacement ICD
In the first implanted ICD group (2415, 76%), 90 surgical re-interventions were required in 77 
different ICDs during a summed follow-up of 5949 ICD-years. The 746 (34%) replacement 
ICDs required 55 surgical re-interventions in 45 patients during a summed follow-up of 1683 
ICD-years. 
As shown in Figure 2, three years cumulative incidence of first surgical re-intervention was 
3.9% (95% CI 3.1-4.7%) for first implanted ICDs and 7.5% (95% CI 5.3-9.7%) for replacement 
ICDs. The calculated event-rate per 100 ICD-years was 1.5 (95% CI 1.2-1.9) for the first 
implanted ICDs and 3.3 (95% CI 2.5-4.3) for replacement ICDs, corresponding to a more than 
doubled (rate ratio 2.2 [95% CI 1.5-3.0, p<0.001]) requirement for surgical re-intervention 
in replacement ICDs.
Further stratification demonstrated an event-rate of surgical re-intervention for an 
infectious cause of 0.9 (95% CI 0.7-1.2) per 100 ICD-years in first implanted ICDs and 2.3 
(95% CI 1.6-3.2) per 100 ICD-years in replacement ICDs. Per 100 ICD-years, the need for 
surgical re-intervention for non-infectious causes was 0.6 (95% CI 0.4-0.8) in first implanted 
ICDs and 1.0 (95% CI 0.5-1.5) in replacement ICDs. When comparing replacement ICDs with 
first implanted ICDs, the calculated rate ratios are 2.5 (95% CI 1.6-3.7, p<0.001) for infectious 
causes and 1.7 (95% CI 0.9-3.0, p=0.09) for non-infectious causes.
As is shown in Table 3, further sub-division in the consecutive number of ICD 
replacements, shows an increase in the need for surgical re-intervention with every 
consecutive ICD replacement. Event-rates per 100 ICD-years range from 1.5 (95% CI 1.2-1.9) 
in the first implanted ICD, to 8.1 (95% CI 1.7-18.3) in the fourth implanted ICD.

























































In this assessment of the requirement of pocket related surgical re-interventions after ICD 
treatment, the findings can be summarized as follows: 1) The three years cumulative incidence 
of first surgical re-intervention in all implanted ICDs was 4.7% (95% CI 3.9-5.5%) with an 
event-rate of 1.9 (95% CI 1.6-2.2) per 100 ICD-years; 2) Replacement ICDs demonstrate a 
doubled occurrence of surgical re-interventions (rate ratio 2.2 [95% CI 1.5-3.0]); 3) Infectious 
causes (rate ratio 2.5, 95% CI 1.6-3.7), as well as non-infectious causes (rate ratio 1.7 [95% 
CI 0.9-3.0, p=0.09) seem to be more frequent in replacement ICDs; 4) The occurrence of 
surgical re-interventions seem to increase with every consecutive replacement.
Replacements
Since large randomized trials have proven ICD treatment to improve survival in the primary 
and secondary prevention of sudden cardiac death, worldwide implantation rates have 
amplified substantially.8, 9, 20 With increased survival of patients and limited service life of the 
devices, Hauser estimated that over 70% of the currently implanted patients outlive their 
ICD and therefore requires replacement.11 which is in line with the results of this study. Due 
to the significant increase of ICD implantations the number of replacements is increasing 
rapidly. However, with the limited service life of the current devices, it can be expected that 
replacements will increase drastically and potentially even outnumber first implanted ICDs.12 
Previous studies have described the increasing risk for complications, associated with device 
replacements.11, 13, 21-24  The current study adds to prior literature in that it compares the 
Table 3. Requirement for re-intervention per consecutive implanted ICD.
Total 1st ICD 2nd ICD 3rd ICD 4th ICD 5th ICD
number of ICDs 3161 2415 609 107 24 6
events 145 90 46 5 3 1
Total years implanted 7632.3 5949 1406 236 37 4.3















Table 3. Requirement for re-intervention per consecutive implanted ICD. 
 Total 1st ICD 2nd ICD 3rd ICD 4th ICD 5th ICD 
Number of ICDs 3161 2415 609 107 24 6 
Events 145 90 46 5 3 1 
Total years implanted 7632.3 5949 1406 236 37 4.3 
Events per 100 ICD-years  
(95% CI) 
1.9  
(1.6 – 2.2) 
1.5  
(1.2 – 1.9) 
3.3  
(2.4 – 4.4) 
2.1  
(0.7 – 4.9) 
8.1  
(1.7 – 18.3) 
23.3  



























event rates in a large population and differentiates in the cause of intervention (infectious 
or non-infectious) and in the consecutive number of ICD replacements.
Re-interventions
The present study reports differences in the risk of surgical re-interventions between first 
implanted ICDs and replacement ICDs. In the comparison with previous trials, differences 
in defining end points should be taken into account. For a decent comparison between 
first implantation and replacement, the current analysis did not take causes in account that 
would distort comparison. Therefore, since leads are commonly only implanted at first 
implantation, lead related complications were not used in the analysis and only pocket 
related complications were noted.
The most frequent infectious cause for device explantation is cardiac device infection 
(CDI), a serious and potentially life threatening condition which is associated with significant 
morbidity and mortality. Additionally, CDI is associated with additional medical costs which 
have been estimated at an average of $50.000 per patient. 
With the expansion of evidence based indications for cardiac devices the number of 
device related procedures has rapidly increased over the past decade which also resulted 
in an increased number of CDI. Furthermore it has been reported that the increase in CDI 
has outpaced the increase in implantation rate.25 Recent reported rates of CDI vary between 
approximately 0.5% and approximately 5%.13, 14, 24, 26
It has been hypothesized that local perioperative wound contamination is a major 
mechanism predisposing to local or systemic pacemaker infection.27 Da Costa et al. 
evaluated the role of local bacterial flora on pacemaker-related infection and skin erosion 
and concluded that their results strongly support this hypothesis.26 Furthermore, it has been 
reported that device revision procedures (generator exchange / lead related procedure) are 
associated with CDI. Gould and Krahn reported that ICD generator replacement in patients 
with advisory devices is associated with a substantial rate of infectious complications (1.9% 
after a mean follow up of 2.7 months). Furthermore it should be taken in account that the 
consequences of an early re-intervention for a non-infectious cause can be considered more 
harmful than the underlying complication itself.15 In their recent paper Lekkerkerker et al. 
reported that device revisions are an important risk factor for CDI with an odds ratio of 3.67 
(95% CI 1.51 to 8.96, p<0.01) for any device related revision procedure, or an odds ratio of 
2.47 (95% CI 1.25 to 4.87, p<0.01) for a generator exchange and an odds ratio of 6.67 (95% 
CI .33 to 33.49, p=0.02) for a lead related intervention.14 Furthermore Klug and co-workers 
also described an odds ratio of 2.2 for generator replacements, after 12 months follow-up 
in 6319 implanted devices, of which 1854 being replacement devices.13 In the current study, 
during 7623.3 ICD-years of follow-up, per 100 ICD-years, the need for surgical intervention 
for infectious causes was 0.6 (95% CI 0.4-0.8) in first implanted ICDs and 1.0 (95% CI 0.5-1.5) 
in replacement ICDs. When comparing replacement ICDs with first implanted ICDs, the 
corresponding rate ratio was 2.5 (95% CI 1.6-3.7, p<0.001). 
Considering the above, the need for device replacement should be reduced to a 


























Replacement ICDs demonstrated a doubled occurrence of pocket related surgical re-
interventions when compared to first implanted ICDs. Furthermore, both the requirement 
for surgical re-intervention due to infectious cause and non-infectious cause seemed to 
be increased in replacement ICDs and the requirement for re-intervention increased with 
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To evaluate the impact of upgrading implantable cardioverter defibrillator (ICD) therapy 
to cardiac resynchronization therapy (CRT) combined with defibrillator (CRT-D) on the 
occurrence of ventricular arrhythmias (VAs) and appropriate ICD therapies.
background
CRT has shown to improve left ventricular (LV) systolic function and induce reverse LV 
remodeling. In addition, it has been hypothesized that CRT may reduce the incidence of VAs. 
Methods
Heart failure patients receiving an upgrade from ICD to CRT-D were evaluated. Patients were 
considered responders to CRT if LV end-systolic volume reduced ≥15% at 6 months follow-
up. Episodes of VA, triggering device therapy (anti-tachycardia pacing and shocks) were 
recorded before and after upgrade for the overall population. In addition, these outcomes 
were compared between CRT responders and non-responders during the follow-up period 
after CRT response was assessed.
Results
One-hundred-fifteen patients (93 (81%) male, 65±12 years) were evaluated during a 
mean follow-up of 54±34 months before and 37±27 months after CRT-D upgrade. In CRT 
responders (n=70), the frequency of VAs requiring appropriate device therapy demonstrated 
a trend toward a decrease from 0.51±0.79 to 0.30±0.59 per patient per year after CRT-D 
upgrade (p=0.052). In CRT non-responders (45), the frequency of VAs requiring appropriate 
device therapy significantly increased from 0.40±0.69 to 1.21±2.53 per patient per year after 
CRT-D upgrade (p=0.014).
Conclusion
After upgrade from ICD to CRT-D, non-responders to CRT showed a significant increase in 





















Cardiac resynchronization therapy (CRT) has demonstrated to be an effective treatment in 
patients with advanced heart failure. CRT improves clinical symptoms, reduces heart failure 
related hospitalization rates and improves long-term survival.1-4 These beneficial effects 
have been related to left ventricular (LV) reverse remodelling following CRT implantation. 
In addition, heart failure patients with a low ejection fraction (EF) are at risk of sudden 
arrhythmic death and prophylactic implantable cardioverter defibrillator (ICD) implant is 
indicated in many of these patients 5, 6. However, the effects after upgrade from ICD to CRT-
defibrillator (CRT-D) on the occurrence of ventricular arrhythmias (VAs) are controversial so 
far 7-10. While some studies have demonstrated a significant decrease in the burden of VA 
along with significant LV reverse remodelling 7, 9, other studies have shown no reduction or 
even an increase in the frequency of VAs or appropriate ICD therapies 8, 10. In addition, the 
association between LV reverse remodeling after CRT upgrade and changes in VA burden 
and frequency of appropriate ICD therapies is unclear.
Patients who received an ICD may develop heart failure symptoms at follow-up. 
Upgrading these patients to CRT has shown to improve clinical symptoms and LV function 11. 
Importantly, this subgroup of patients provides a unique opportunity to evaluate the effects 
of CRT upgrade on the burden of VAs. Accordingly, the present evaluation assessed the 
impact of CRT-D upgrade on the occurrence of VAs and appropriate therapies. In addition, 
the association between LV reverse remodeling and VA burden was evaluated. 
meThoDS
Patient population and data collection
Since 1996, data from all patients who received an ICD device at the Leiden University Medical 
Center were prospectively collected in the departmental Cardiology Information System 
(EPD-Vision®, Leiden University Medical Center, Leiden, the Netherlands). Characteristics 
at baseline, data of the implant procedure and of follow-up visits were recorded. For the 
current analysis, ICD patients who underwent an upgrade to CRT-D were selected.
The patient population included consecutive patients who underwent upgrade from 
single- or dual- chamber ICD to CRT-D due to progressive symptoms of heart failure. Before 
upgrading to CRT-D, all patients underwent complete clinical history, physical examination, 
12-lead electrocardiogram and transthoracic echocardiography. Clinical parameters 
included cardiovascular risk factors, renal function, New York Heart Association (NYHA) 
functional class, quality of life score as assessed with the Minnesota Living with Heart Failure 
questionnaire and the 6-minute walk distance 12, 13. Echocardiographic parameters included 
LV dimensions and LVEF. At 6 months follow-up after CRT-D upgrade, according to the current 
clinical protocol, clinical status was reassessed and a repeat transthoracic echocardiogram 
was performed to evaluate LV dimensions and systolic function. Patients were considered 
responder if a reduction in LV end-systolic volume (LVESV) ≥15% was documented.14 
All patients were followed-up from the ICD implantation date until September 2010 for 




















or ventricular fibrillation. Arrhythmia burden was calculated from the total number of episodes 
divided by the total number of years of ICD or CRT-D and presented in patient per year basis. 
These end points were prospectively recorded during two correlative follow-up periods: 
1. from the ICD implantation date to the CRT-D upgrade date and from the CRT-D upgrade 
date until the latest device interrogation follow-up. Changes in number of appropriate 
therapies and shocks after CRT-D upgrade were evaluated for the overall population. 
Therefore, each patient served as his or her own control for comparison of frequency of 
appropriate therapies and shocks prior and following CRT-D upgrade.
2. from the evaluation of response to CRT-D (at 6 months follow-up) until the last device 
interrogation follow-up. The incidence of appropriate therapies and shocks and 
arrhythmia burden after CRT-D upgrade were then compared between responders 
and non-responders to CRT-D. 
Device implantation and settings 
Eligibility for ICD implantation in this population was based on international guidelines 
for primary and secondary prevention 5, 6. Upgrade to CRT-D was performed according to 
current guidelines: advanced symptoms of heart failure despite optimized medical therapy, 
LVEF ≤35%, and a wide QRS complex (>120ms).15
Implantation of defibrillator systems were performed transvenously, with conventional 
right atrial and ventricular leads positioning. During CRT-D implantation, the LV lead was 
inserted via the subclavian vein followed by cannulation of the coronary sinus. Subsequently, 
the LV pacing lead was inserted through the coronary sinus with the help of an 8 Fr 
guiding catheter and positioned as far as possible in the venous system, preferably in a 
(postero-) lateral vein. Implanted systems were manufactured by Biotronik (Berlin, Germany), 
Boston Scientific [Natick, MA, USA, formerly CPI, Guidant (St Paul, MN, USA)], Medtronic 
(Minneapolis, MN, USA), and St Jude Medical/Ventritex (St Paul, MN, USA). 
Defibrillators were programmed as follows: a ventricular arrhythmia monitor zone was 
programmed in all patients (150-188 beats/min). No therapy was programmed in this zone 
until arrhythmias were detected during follow-up. VAs faster than 188 bpm were initially 
attempted to be terminated with two bursts of antitachycardia pacing and, after continuation 
of the arrhythmia, device shocks were the indicated therapy. VAs >210 beats/min were directly 
attempted to be terminated by device shocks. Furthermore, atrial arrhythmia detection was 
set to >170 beats/min with supraventricular arrhythmia discriminators enabled. Settings were 
adapted, only if clinically indicated (e.g. hemodynamic well-tolerated ventricular tachycardia 
at high rate; ventricular tachycardia in the monitor zone).
echocardiography
Transthoracic echocardiography was performed with the patients in left lateral decubitus 
position before CRT-D upgrade and at 6 months follow-up with commercially available 
ultrasound transducer and equipment (M4S probe, Vivid 7, GE-Vingmed, Horten, Norway). 
All images were digitally stored on hard disks for offline analysis (EchoPAC version 108.1.5, 
GE-Vingmed, Horten, Norway). LVESV, LV end-diastolic volume (LVEDV), and LVEF were 




















method 16. As previously described, response to CRT was defined by ≥15% reduction 
in LVESV at 6 months follow-up as compared with baseline echocardiogram (prior to 
CRT-D upgrade) 14.
follow-up and definition of end points 
Patients who were lost at follow-up or died before the 6-month echocardiography after 
CRT-D upgrade were excluded from the analyses. All remaining patients were followed 
in the ICD clinic at 3-6 monthly intervals. Occurrences of appropriate, successful ICD 
therapies were recorded as events. During device interrogation, episodes were assessed 
for appropriate ICD therapy (anti-tachycardia therapies or shocks) and verified by an 
electrophysiologist. Shocks were classified as appropriate when they occurred in response 
to ventricular tachycarrhythmia or ventricular fibrillation. Electrical storm was defined as 
three or more therapies for ventricular tachyarrhythmias within 24 hours 17. 
The burden of VAs requiring ICD therapy or shock was determined by calculating the 
number of episodes per patient per year. ICD therapies delivered within 24 hours following 
the previous therapy were not included for the analysis of the burden of VAs. Separate 
analyses for appropriate shocks only and for appropriate therapies (including appropriate 
shock and anti-tachycardia pacing) were performed.
statistical analysis
For reasons of uniformity, summary statistics for all continuous variables are expressed as 
mean and standard deviation. Dichotomous data are presented as numbers and percentages. 
Kolmogorov-Smirnov test was used to evaluate the distribution of continuous data. Student-t 
test was used to compare continuous data normally distributed whereas Mann-Whitney 
U-test was used to compare continuous data non-normally distributed. Categorical variables 
were compared with chi-squared test (when no cells had an expected frequency <5) and 
Fisher’s exact test (when 1 or more cells had an expected frequency <5). Comparisons of 
continuous data at baseline and at 6 months follow-up were performed with paired Student-t 
test (when data distribution was normal) or Wilcoxon Signed Rank test (for continuous data 
non-normally distributed). Specifically, changes in NYHA functional class between baseline 
and 6 months follow-up were evaluated with Wilcoxon Signed Rank test since this parameter 
followed a non-normal distribution whereas changes in other clinical parameters (quality of 
life and 6-minute walk test) and echocardiographic parameters of LV function and volumes 
were compared with paired Student-t test. Variables related to VAs burden and appropriate 
ICD therapies and shocks were not normally distributed and therefore, changes between 
baseline and 6 months were evaluated with Wilcoxon Signed Rank test.
Cumulative event rates from the date of CRT-D upgrade until the last follow-up were 
calculated using the Kaplan-Meier method. The log-rank tests for time-to-event data with 
respect to the end points (appropriate shocks and appropriate therapies) were used for 
statistical comparison between the 2 patients groups dichotomized based on response to 
CRT at 6 months follow-up. Univariate and multivariate Cox proportional-hazards models 
were constructed to identify independent determinants of the end points (appropriate 




















p-value<0.25 were retained in the multivariate model. In addition, VT-ablation was entered 
as a time-dependent covariate. A p-value of <0.05 was considered significant. All statistical 
analyses were performed with SPSS software (version 18.0, SPSS Inc., Chicago, Illinois).
reSulTS
Patient population
A total of 123 patients underwent a successful CRT-D upgrade because of worsening symptoms 
of heart failure. Eight patients who were lost at follow-up (n=2, 2%) or died (n=6, 5%) before 
the 6-month echocardiography following CRT-D upgrade were excluded from the analysis. 
Consequently, 115 patients were included in the analysis with a mean follow-up of 54±34 months 
after ICD implantation and an additional mean follow-up of 37±27 months following CRT-D 
upgrade. Demographic, clinical and echocardiographic characteristics before CRT-D upgrade 
are summarized in Table 1. Mean age was 65±12 years and 92 (80%) were male. Ischemic 
heart failure etiology was recorded in the majority of the patients (75%). Most patients had 
NYHA functional class III heart failure symptoms (93%) and a severely depressed LV function, 
with a mean LVEF of 26±8%. Mean QRS duration was 167±35 ms. Finally, medical therapy 
included angiotensin-converting enzyme inhibitors (90%), diuretics (85%), beta-blockers (77%) 
and amiodarone (40%). During the entire follow-up of the study (from ICD implantation to last 
follow-up after CRT-D upgrade), 21 (18%) patients underwent successful VT ablation and 11 
(10%) patients underwent successful atrioventricular junctional ablation. Seventeen (81%) and 
4 (19%) patients underwent VT ablation before and after CRT-D, respectively.
six months follow-up after CRT-D upgrade: clinical and echocardiographic 
parameters.
At 6 months follow-up after CRT-D upgrade, a significant improvement in clinical status 
and LV volumes and LVEF was observed in the overall population. NYHA functional class 
improved from 3.1±0.3 to 2.3±0.7 (p<0.001) and quality-of-life score decreased from 36±18 
to 29±17 (p<0.001). In addition, the 6-minute walk distance increased from 320±129 m to 
372±138 m (p<0.001). In the overall population, the LVESV and LVEDV reduced significantly 
(from 168±66 mL to 143±61 mL; p<0.001 and from 223±76 mL to 204±72 mL; p<0.001, 
respectively) with a significant increase in LVEF (from 26±8% to 31±9%, p<0.001).
appropriate device therapy burden before and after CRT-D upgrade in the 
overall population
During the time elapsed between ICD implantation and CRT-D upgrade (54±34 months), 59 
(51%) patients received appropriate therapies. The total number of appropriate therapies 
was 11±50 per patient and the burden of VAs was 0.46±0.75 per patient per year. The 
appropriate ICD shock burden was 0.36±0.77 per patient per year. A total of 8 (7%) patients 
experienced an electrical storm before CRT-D upgrade. Of the 59 patients receiving 
appropriate device therapy before CRT-D upgrade, 9 (15%) patients underwent VT-ablation. 
Cumulative incidence of device therapy was 29% (95% CI 21-37%) after one year, 36% (95% 




















49 (43%) patients experienced appropriate therapies during an additional mean follow-up 
of 37±27 months. The total number of appropriate therapies reduced to 5±17 per patient, 
although this change was not statistically significant (p=0.119). In addition, the frequency 
of VAs (0.66±1.70 per patient per year; p=0.775) and appropriate ICD shocks (0.52±3.01 
per patient per year, p=0.218) remained unchanged. A total of 8 (7%) patients experienced 
an electrical storm after CRT-D upgrade. Of the 49 patients receiving appropriate device 
therapy after CRT-D upgrade, 11 (22%) patients underwent VT-ablation. Cumulative 
incidence of device therapy was 25% (95% CI 17-34%) after one year, 34% (95% CI 25-44%) 
after two years, and 62% (95% CI 49-75%) after 5 years. Finally, a total of 34 (30%) patients 
died after CRT-D upgrade. 
Table 1. Patient characteristics at CRT-D upgrade.
Variable n= 115
age, years 65 ± 12
Male sex, n (%) 93 (81%)
Primary indication (%) 35 (30%)
QRs duration, ms 167 ± 35
History of atrial fibrillation (%) 24 (21%)
Renal clearance, ml/min 63 ± 34
Ischemic heart disease, n (%) 86 (75%)
nYHa functional class, n (%)
     III 107 (93%)
     IV 8 (7%)
6-Minute walk test, m 312 ± 130
Quality-of-life score 37 ± 18
left ventricular end-diastolic volume, ml 225 ± 79
left ventricular end-systolic volume, ml 169 ± 67
left ventricular ejection fraction, % 26 ± 8
Device type
     Single-chamber (%) 36 (31%)
     Dual-chamber (%) 79 (69%)
Medication  
     Amiodarone, n (%) 46 (40%)
     Anticoagulants, n (%) 100 (87%)
     Diuretics, n (%) 98 (85%)
     Ace-inhibitors/AT II antagonist, n (%) 104 (90%)
     Beta-blocker, n (%) 89 (77%)
     Spironolactone, n (%) 54 (47%)
Continuous variables are expressed as mean ± SD. ACE = angiotensin-converting enzyme; AT = angiotensin; 




















Changes in appropriate device therapy burden after CRT-D upgrade 
according to the echocardiographic response
Based on a reduction of LV end-systolic volume ≥15% at 6 months follow-up after CRT-D 
upgrade, 70 (61%) patients were responders. Table 2 summarizes the changes in clinical 
status and echocardiographic parameters at 6 months follow-up after CRT-D upgrade for 
both groups of patients, responders and non-responders. 
In the group of responders, the percentage of patients who received appropriate 
device therapies decreased from 54% to 33% after CRT-D upgrade. In addition, the total 
number of appropriate device therapies also decreased from 12±62 to 2±4 per patient 
after CRT-D upgrade. Furthermore, the frequency of VAs requiring appropriate device 
therapy demonstrated a trend toward a decrease from 0.51±0.79 to 0.30±0.59 per 
patient per year after CRT-D upgrade (p=0.052) (Figure 1). Interestingly, the frequency of 
appropriate device shocks reduced significantly from 0.21±0.32 to 0.11±0.33 per patient per 
year (p=0.009) (Figure 1). Furthermore, in the group of responder patients to CRT, 3 (4%) 
patients experienced an electrical storm and 12 (17%) patients underwent VT-ablation. 
In the group of patients who did not show response to CRT, the percentage of patients 
who received appropriate device therapies was 47% before CRT-D upgrade and 58% after 
CRT-D upgrade. In these patients, the total number of appropriate device therapies per 
patient was 8±22 prior to CRT-D upgrade and 10±25 after CRT-D upgrade. In addition, the 
frequency of appropriate device shocks remained unchanged after CRT-D upgrade (from 
0.24±0.52 to 0.46±1.23 per patient per year, p=0.333) (Figure 1). In contrast, the frequency 
of VAs significantly increased from 0.40±0.69 per patient per year before CRT-D upgrade 
to 1.21±2.53 per patient per year after CRT-D upgrade (p=0.014) (Figure 1). In the non-
Table 2. Clinical and echocardiographic parameters at 6 months follow-up in responders and non-
responders to CRT-D.
Responder non-responder
  baseline 6 month P-value baseline 6 month P-value
nYHa functional class, n (%) <0.001* 0.211*
     I 0 10 (13) 0 4 (9)
     II 0 39 (52) 0 22 (49)
     III 71 (95) 25 (33) 41 (91) 17 (38)
     IV 4 (5) 1 (1) 4 (9) 2 (4)
6 MWT, m 339±137 382±146 0.009 291±113 357±124 0.001
Qol score 36±18 29±17 0.001 36±17 27±17 0.005
lVeDV, ml 227±72 190±65 <0.001 216±82 223±77 0.113
lVesV, ml 172±62 128±51 <0.001 163±72 164±67 0.879
lVef, % 25±9 33±9 <0.001 26±7 27±8 0.140
Continuous variables are expressed as mean ± SD. 6 MWT = 6 min walk test; QoL = Quality-of-life; LVEDV 
= left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-




















































Figure 1. Changes in the number of episodes of appropriate ICD therapy and appropriate ICD shocks 
per patient per year in responders and non-responders to CRT.
responder patients group, 5 (11%) patients experienced an electrical storm and 9 (20%) 
patients underwent VT-ablation.
Predictors of combined end point after CRT-D upgrade
Figure 2 shows the Kaplan-Meier estimates of the combined end point (appropriate ICD 
therapies) for responder and non-responder patients after CRT-D upgrade. The cumulative 
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CI 9-29%) after one year, 29% (95% CI 17-41%) after two years, and 51% (95% CI 33-69%) 
after 5 years. In contrast, in the group of non-responders a significantly higher cumulative 
incidence of 34% (95% CI 20-48%) after one year, 42% (95% CI 27-57%) after two years, and 
76% (95% CI 59-93%) after 5 years was observed (log rank p=0.017). 
Regarding appropriate ICD shocks, cumulative incidences in responder patients at one, 
two and 5 years of follow up were 9% (95% CI 1-16%), 13% (95% CI 4-23%), and 26% (95% CI 
12-40%), respectively. In contrast, the group of non-responders showed significantly higher 
cumulative incidences of ICD shocks: 23% (95% CI 11-36%) after one year, 32% (95% CI 
17-47%) after 2 years, and 66% (95% CI 45-88%) after 5 years (log rank p=0.001) (Figure 3).
On multivariate Cox regression analysis, response to CRT defined as reduction in 
LVESV≥15% was independently associated with lower risk of appropriate ICD therapies 
(hazard ratio: 0.439 [95% CI: 0.245-0.786], p<0.001) (Table 3) and ICD shocks (hazard ratio: 
0.354 [95% CI: 0.167-0.750], p=0.007) (Table 4). 
DISCuSSIon
The findings of the present study can be summarized as follows: 1) “upgrade” of ICD to 
CRT-D did not result in a significant change in the frequency of appropriate ICD therapies 
and shocks in the overall population; 2) responder patients to CRT-D (with a significant 
reduction in LVESV at 6 months follow-up) demonstrated a trend towards a reduction in the 
frequency of appropriate device therapies and a significant reduction in the frequency of 
appropriate device shocks; 3) in contrast, patients who did not show response to CRT had 
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effect of CRT upgrading on the occurrence of Vas
In the present study, the overall population showed significant clinical and echocardiographic 
improvements at 6 months follow-up after CRT. These findings are in line with previous 
studies in which CRT is associated with an improved clinical and echocardiographic 
outcome in heart failure patients (12). Interestingly, these improvements in clinical status 
and LV systolic performance was not accompanied by a significant change in the number 
of appropriate ICD therapies or the burden of ICD shocks. 
The effects of CRT upgrade on VAs have remained controversial, so far. In a study 
by Ermis et al., in which 18 consecutive ICD patients underwent an “upgrade” to CRT-D, 
the frequency of arrhythmias and number of appropriate device therapies were reduced 
following CRT-D implantation (8). The appropriate shock burden in these 18 patients 
was 0.58±1.02 per patient per year prior to CRT and declined significantly (p=0.05) to 
Table 3. Cox proportional hazard ratio model to predict appropriate ICD therapies.
Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value
Gender, male 1.011 0.472-2.163 0.978
nYHa functional class 1.451 0.443-4.757 0.539
Ischemic cardiomyopathy 0.675 0.362-1.257 0.215* 0.522 0.273-0.999 0.049
Creatinine clearance (ml/min) 1.001 0.993-1.010 0.740
amiodarone 0.632 0.347-1.153 0.135* 0.598 0.323-1.110 0.107
Response to CRT 0.509 0.290-0.893 0.019* 0.439 0.245-0.786 <0.001
Interim successful VT ablation 1.375 0.487-3.885 0.548
CI = confidence interval; CRT = cardiac resynchronization therapy; HR = hazard ratio; NYHA = New York Heart 
Association; VT = ventricular tachycardia. *variable was included in multivariate analysis.
Table 4. Cox proportional hazard ratio model to predict appropriate ICD shocks.
Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value
Gender, male 1.066 0.437-2.599 0.889
nYHa functional class 2.004 0.604-6.651 0.256
Ischemic cardiomyopathy 0.977 0.437-2.188 0.956
Creatinine clearance (ml/min) 0.991 0.977-1.004 0.174* 0.993 0.980-1.007 0.326
amiodarone 0.874 0.424-1.803 0.715
Response to CRT 0.319 0.153-0.668 0.002* 0.354 0.167-0.750 0.007
Interim successful VT ablation 2.038 0.702-5.915 0.190* 1.987 0.683-5.783 0.208
CI = confidence interval; CRT = cardiac resynchronization therapy; HR = hazard ratio; NYHA = New York Heart 




















0.04±0.19 per patient per year following CRT. Similar results were found in the study by 
Kiès et al., in which 17 consecutive ICD patients underwent an “upgrade” to CRT-D (9). In 
that study, the number of VAs was significantly (P < 0.01) reduced from 0.92±2.2 episodes 
per patient per month to 0.12±0.2 episodes per patient per month after CRT-D upgrading. 
Permanent biventricular pacing has been proposed as one of the mechanisms to reduce 
the frequency of VAs requiring ICD therapy. During permanent biventricular pacing, the 
ventricular conduction delay is reduced leading to a decrease in the occurrence of re-entry, 
avoidance of pause-dependent tachyarrhythmias and reduction in the circulating levels 
of norepinephrine, all known mechanisms that may trigger VAs 18, 19. However, on the 
other hand, both basic science and clinical studies have shown a proarrhythmic effect of 
biventricular pacing due to a reversed direction of activation of the left ventricular wall. 
This reversal of the normal activation sequence may prolong the QT interval and increase 
the existing transmural dispersion of repolarization, creating the substrate and trigger for 
re-entrant arrhythmias 20.
Interestingly, in the Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-
ICD) trial, the occurrence of appropriate ICD therapies or shocks in the group of patients 
who received CRT-D did not show a significant reduction 21. In this trial, a total of 369 patients 
with moderate to severe heart failure symptoms and wide QRS complex were randomized to 
biventricular ICD (CRT on group) or to  ICD only (CRT off group). There were no significant 
differences between both groups with respect to the occurrence of appropriate therapies 
and/or appropriate shocks, despite improved quality of life, functional status and exercise 
capacity in the CRT group 21. In addition, in the REsynchronization reVErses Remodeling in 
Systolic left vEntricular dysfunction (REVERSE) study, in which 508 mild heart failure patients 
were randomized to activated CRT (CRT ON) and activated ICD (CRT OFF), the estimated 
event rate for a first treated VA episode was not significantly different between the two 
groups after 2 years follow-up period (18.7% in the CRT ON group vs. 21.9% in the CRT 
OFF group, p=0.84) 22. The event rates observed in the REVERSE study are significantly 
lower as compared to the results of the present study. However, it must be noted that in 
the REVERSE study only subjects with mild heart failure were included and therefore the 
reported outcomes may not necessarily apply to patients with more severe symptoms of 
heart failure as those included in the current analysis. The presence of more advanced heart 
failure status with dilated LVs may be associated with an increased likelihood of VAs requiring 
device therapy 10. Based on this assumption, it can be hypothesized that patients with LV 
reverse remodeling following CRT may show a significant reduction in the incidence of VAs 
when compared with the patients who do not show LV reverse remodeling following CRT.  
Device therapy in responders and non-responders
Gold et al., showed that the antiarrhythmic effect of CRT could be explained by induction 
of a favourable LV reverse remodelling and decreased myocardial wall tension and electrical 
stabilization of the myocyte membranes 22. In the present study, the group of responders 
to CRT showed a trend toward a reduction in the number of appropriate device shocks 
after CRT upgrading. In the REVERSE study, in which the patients from the CRT ON group 




















those without such a favourable reverse remodelling (5.6% vs 16.3%, Hazard Ratio=0.31, 
p=0.001) 22. These findings may confirm the hypothesis of Gold and co-workers in that the 
improvement in LV dimensions and function, accompanied by a reduction in wall tension, 
results in a decreased arrhythmogenicity of the myocardium and reducing  ICD therapy in 
responders to CRT-D (after upgrade). Additional studies are warranted in order to elucidate 
how much LV reverse remodelling is needed to minimize the number of appropriate ICD 
therapies in patients who were upgraded to CRT. 
study limitations
A number of limitations should be acknowledged. This was a retrospective observational 
analysis of prospectively assessed data evaluating the occurrence of VAs requiring 
appropriate device therapy in a cohort of patients before and after CRT-D upgrade. Since 
patients received ICDs in a single center over a long period of time, evolving guidelines 
may resulted in a heterogeneous population. Furthermore, few patients had multiple device 
therapies within 24 hours following the previous therapy. These episodes were not counted 
for analysis of the burden of ventricular arrhythmias. In addition, since all CRT-D devices had 
antitachycardia treatment function and the oldest implanted ICD devices did not have this 
function, the number of appropriate shocks in the ICD group might be overestimated when 
compared with the CRT-D group. To date, definition of response to CRT is still a debated 
issue. In the present evaluation, a cut-off value of 15% reduction in LVESV was used to divide 
the patient population in responders and non-responders to CRT. Using the median value 
of LVESV reduction at 6 months follow-up would be a valuable option to dichotomize the 
population. However, in the present evaluation this value was 17% and the analysis based 
on the median reduction in LVESV yielded similar results. In addition, further studies are 
needed in order to evaluate if LV reverse remodeling occurs beyond 6 months follow-up 
after CRT-D upgrade and if this may result or not in further reduction in VA burden. 
ConCluSIon
In this large single-centre study, the frequency of VAs requiring appropriate device therapy did 
not significantly change in the overall population following “upgrade” of ICD to CRT-D. Most 
important however, in the subgroup of patients who showed echocardiographic response 
to CRT at 6 months follow-up (reduction in LV end-systolic volume ≥15%), a trend toward a 
reduction in the frequency of appropriate device therapies and a significant reduction in 
the frequency of appropriate device shocks was observed. Moreover, echocardiographic 
non-responders following CRT-D had a significant increase in the frequency of VAs requiring 
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Currently, Implantable Cardioverter Defibrillators (ICDs) rely on transvenously implanted 
leads for cardiac sensing, pacing, and defibrillation. Recently, an ICD with a subcutaneous 
lead (S-ICD) was developed which may be easier to implant and has fewer device related-
complications. Since the S-ICD is incapable of cardiac pacing, it is of interest what proportion 
of ICD recipients is suitable for an S-ICD and what the characteristics of these patients are.
Methods and Results
The study cohort consisted of all patients who received a single or dual-chamber ICD in our 
center between 1996 and 2011. Patients without a preexistent indication for pacing  were 
defined suitable for an S-ICD if they did not reach one of the following endpoints during 
follow-up: 1) an atrial and/or right ventricular pacing indication, 2) successful antitachycardia 
pacing without a subsequent shock, 3) an upgrade to a CRT-D device. A total of 1,742 patients 
were included in the analysis. During a median follow-up of 3.3 years (interquartile range, 
1.8 – 5.6 years), 627 (36%) patients reached an endpoint. The cumulative incidence of ICD 
recipients, suitable for an initial S-ICD implantation was 60.2% (95% CI 57.4%-62.9%) after 
5 years. Significant predictors for the unsuitability of an S-ICD were: older age, secondary 
prevention, severe heart failure, atrial fibrillation, and a wide QRS. 
Conclusion
After 5 years of follow-up, approximately 60% of the patients would have been suitable for 
an S-ICD implantation. Several baseline clinical characteristics were demonstrated to be 





























In the past decades implantable cardioverter-defibrillators (ICDs) have become an 
established therapy for the prevention of sudden cardiac death.1-4 Since the first 
implantation in 1980, ICDs have undergone many improvements and have evolved from 
large abdominally placed devices into substantially smaller devices placed pectorally.5 
Currently, ICDs rely on transvenously implanted leads for cardiac sensing, defibrillation, and 
if necessary also for cardiac pacing. Recently however, a new, entirely subcutaneous, ICD 
system avoiding the need for the placement of sensing and therapy electrodes within or 
on the heart has been developed. Initial results demonstrated that this device adequately 
detected and treated episodes of sustained ventricular tachyarrhythmia.6 It is suggested 
that the subcutaneous ICD might be easier to implant and will result in a lower proportion 
of device related complications when compared with a transvenously implanted ICD.6 
However, despite the supposed advantages, an important drawback of the subcutaneous 
ICD is the incapability of cardiac pacing.7 Therefore, patients that have a cardiac (atrial and 
or ventricular) pacing indication at implantation are unsuitable for such a device. Moreover 
patients that develop such an indication during follow-up would preferably also not receive 
a subcutaneous ICD. Furthermore, the latter device is also not capable of antitachycardia 
pacing (ATP), resulting in a diminished suitability for the subcutaneous ICD in patients 
receiving successful ATP for ventricular arrhythmias. Finally, for patients requiring an 
upgrade to a cardiac resynchronization therapy defibrillator (CRT-D) due to worsening 
heart failure, an initial transvenously implanted ICD is preferred over a subcutaneous 
implanted ICD. 
The objective of this study was to establish, in a large clinical cohort of ICD recipients, 
the suitability for an entirely subcutaneous ICD system. Furthermore, among baseline 




This retrospective analysis comprised all consecutive patients who received an ICD system at 
Leiden University Medical Center. Implant procedures were registered in the departmental 
Cardiology Information System (EPD-Vision®, Leiden University Medical Center). Characteristics 
at baseline, data of the implant procedure and all follow-up visits were recorded. The data for 
the current registry were collected between January 1996 and April 2011. 
Eligibility for ICD implantation in this population was based on international guidelines 
for primary and secondary prevention. Due to evolving guidelines, indications will have 
changed over time.8, 9 
Device implantation and programming
All defibrillator system implantations were performed transvenously, without thoracotomy. 




























defibrillation test was performed. Used systems were manufactured by Biotronik (Berlin, 
Germany), Boston Scientific [Natick, MA, USA, formerly CPI, Guidant (St Paul, MN, USA)], 
Medtronic (Minneapolis, MN, USA), and St Jude Medical/Ventritex (St Paul, MN, USA). 
Devices were programmed according to a strict protocol to guarantee uniformity. In 
single-chamber ICD recipients, cardiac stimulation parameters were set to VVI 40. In dual-
chamber ICDs, a non-tracking backup mode of DDI 40 was programmed with sufficiently 
long AV delay to secure intrinsic conduction at the lower rate. If applicable, algorithms such 
as managed ventricular pacing (MVP) or remote mode switching (RMS) were also used to 
avoid unnecessary right ventricular pacing.10 
The antitachycardia modes in all devices were programmed with three consecutive 
zones with limits slightly varying per manufacturer: a monitor zone (lower limit between 
150-155 bpm; upper limit between 185-190 bpm), an antitachycardia pacing (ATP) shock 
zone (lower limit between 185-190 bpm; upper limit between 205-210 bpm), and an initial 
shock zone (≥205-210 bpm). In the monitor zone, no therapy was programmed unless a 
ventricular arrhythmia was detected during follow-up. In the ATP-shock zone, arrhythmias 
were initially attempted to be terminated by two bursts of ATP and, if the arrhythmia 
persisted, defibrillator shocks were used. In case of a ventricular arrhythmia faster than the 
ATP shock zone, device shocks were the initial therapy. Detection times or number of intervals 
for ATP treatment were programmed as follows: 26 intervals for Biotronik, 1.5 seconds for 
Boston Scientific/Guidant, 18 out of 24 intervals for Medtronic and 12 intervals for St Jude 
Medical/Ventritex devices. Furthermore, atrial arrhythmia detection was set to >170 bpm 
with supraventricular tachycardia discriminators enabled. Therapy settings were adapted, 
only when clinically indicated. 
Device interrogation was scheduled every 3-6 months after implantation. Delivered 
therapies were then adjudicated by a trained electrophysiologist. Data of these ICDs were 
included until the last date of ICD check-up. 
endpoints
Patients who received a CRT-D device were not included in the current analysis. Furthermore, 
all patients who were pacemaker-dependent or had another clear indications for pacing 
directly following implantation (i.e. settings other than VVI 40 or DDI 40) were excluded from 
the study population.8, 9 (Figure 1) For the remaining patients (i.e. the study population) the 
combined primary endpoint of this analysis was the unsuitability for an S-ICD, which was 
defined as the occurrence of one of the following individual endpoints:
1. The development of an atrial and/or right ventricular pacing indication:
In the event that patients during follow-up required atrial and/or right ventricular pacing, 
this was considered as the development of a pacing indication.8, 9 Also, if the pacing 
settings of the ICD required adaptation by the treating physician (e.g. due to a reduced 
heart rate on heart rate histogram in combination with fatigue), this was considered as 
the development of a pacing indication. Furthermore, when the pace burden significantly 
increased between 2 routine follow-up visits (pace burden became >20%), it was also 
considered as an indication for pacing. The date at which the development of a pacing 




























2. ATP delivery: the first date of successful appropriate ATP (i.e. without subsequent 
appropriate shock) was considered the endpoint.
3. Device upgrade: if a patient required upgrade to a CRT-D device (NYHA III/IV despite 
optimal medical therapy, LVEF ≤35% and QRS ≥120ms or NYHA II despite optimal 
medical therapy, LVEF ≤35%, QRS ≥150ms, and sinusrhythm), the date of the upgrade 
was considered as the endpoint.11, 12
For all patients, the first date at which a patient reached one of the above endpoints 
was considered the date for reaching the primary endpoint. If the patient did not develop 
one of the above mentioned endpoints, the patient was censored at the date of last ICD 
follow-up. 
If a patient deceased during follow-up, censoring at the date of death occurred.
statistical analysis
Continuous data are expressed as mean and standard deviation (SD) or median with 25th 
and 75th percentile where appropriate; dichotomous data are presented as numbers and 
percentages. 
Event-free rates from all three individual endpoints, indicating the suitability for an 
S-ICD (i.e. patients without pacing dependence, ATP delivery or device upgrade during 
Study population 
n = 1742 (54%) 
Initial population 
n = 3201 
CRT-D implantation 
n = 1230 (38%) 
Pacing indication at 
implantation 
n = 229 (7%) 




























follow-up), were analyzed separately using the method of Kaplan-Meier and the log-rank 
test. Consequently, also the combined endpoint was analyzed using the same statistical 
tests. In patients with more than one endpoint, the date of the first endpoint was used 
for analysis with the method of Kaplan-Meier and the log-rank test. In order to correct 
for competing risk of the S-ICD unsuitability (i.e. death), a competing-risk model was 
used.13, 14 Univariate and multivariate Fine-Gray regression models were constructed 
to identify independent determinants of the combined endpoint.15 All variables with a 
p-value<0.20 in univariate analysis were retained in the multivariate model. A p-value 
< 0.05 was considered statistically significant. Statistical analyses were performed with 




During the study period, a total of 3,201 patients received a ventricular antitachycardia 
device. Of these, 38% (n=1230) received a CRT-D  and 7% (n=229)were pacing dependent 
directly following implantation . Consequently, these patients were excluded from the 
current analysis. (Figure 1) The remaining 1,742 (54%) patients were considered the study 
population and had a median follow-up of 3.3 years (interquartile range, 1.8 – 5.6 years). 
Of these patients (80% men, average age 59 ± 14 years), 47% received an ICD for primary 
prevention. (Table 1)
follow-up
In primary prevention patients, the 5 year cumulative incidence for an appropriate shock 
was 15.2% (95% CI 11.9 – 18.5%) and the 5-year cumulative incidence for an inappropriate 
shock was 24.3% (95% CI 20.4 – 28.2%). At the end of follow-up, 94 (12%) patients were 
deceased, which resulted in a cumulative incidence for all-cause mortality of 14.0% (95% 
CI 10.9% – 17.1%) at 5 years following device implantation.
In secondary prevention patients, 5-year cumulative incidences for appropriate and 
inappropriate shock were 35.2% (95% CI 31.5 – 38.9%) and 24.3% (95% CI 21.0 – 27.6%) 
respectively. A total of 241 (26%) of these patients died, resulting in a 5-year cumulative 
incidence for all-cause mortality of 18.6% (95% CI 15.7% – 21.5%) following ICD implantation. 
Incidence of the individual endpoints:
During follow-up, 215 (12%) patients developed an indication for atrial and/or ventricular 
pacing. The cumulative incidence for the necessity of cardiac pacing was 4.2% (95% CI 
3.2% to 5.3%) at 1 year follow-up and increased to 13.0% (95% CI 11.1% to 15.0%) at 5 years 
follow-up. (Figure 2a)
With respect to ATP, a total of 472 patients (27%) experienced at least one successful 
appropriate ATP delivery during follow-up. Consequently, the cumulative event rate for a 
first successful appropriate ATP was 11.3% (95% CI 9.8% to 12.9%) at 1 year follow-up and 




































     Age, mean (SD), years 59 ± 14 58 ± 13 60 ± 15
     Male (%) 1394 (80) 656 (80) 738 (80)
     Ischemic heart disease (%)







     Structural congenital heart disease (%) 30 (2) 13 (2) 17 (2)
     LVEF (%) 39 ± 16 36 ± 15† 41 ± 16
     QRS duration, mean (SD), ms 111 ± 27 108 ± 24 114 ± 29
     NYHA functional class III/IV (%) 207 (12) 114 (14) 93 (10)
     Renal clearance, mean (SD), mL/min 86 ± 40 89 ± 36 85 ± 42
     History of atrial fibrillation (%) 318 (18) 141 (17) 177 (19)
Device type
     Single-chamber (%) 388 (22) 92 (11) 296 (32)
     Dual-chamber (%) 1354 (78) 725 (89) 629 (68)
Medication
     Statins (%) 977 (56) 529 (65) 448 (48)
     Diuretics (%) 830 (48) 436 (53) 394 (43)
     ACE inhibitors/AT II antagonist (%) 1195 (69) 624 (76) 571 (62)
     Calcium antagonist (%) 177 (10) 89 (11) 88 (10)
antiarrhythmic medication
     Beta-blockers* (%) 863 (50) 491 (60) 372 (40)
     Sotalol* (%) 301 (17) 107 (13) 194 (21)
     Amiodarone* (%) 275 (16) 68 (8) 207 (22)
     Antiarrhythmic medication combined* (%) 1329 (76) 631 (77) 698 (75)
ACE = angiotensin-converting enzyme; AT = angiotensin; LVEF = left ventricular ejection fraction; NYHA 
= New York Heart Association; SD = standard deviation. * Patients could be taking >1 antiarrhythmic 
drug. † The mean is above 35% due to substantial proportion of patients with a congenital heart disease 
(e.g. hypertrophic cardiomyopathy).
CRT-D upgrades were performed, according to the then current guidelines, in 121 (7%) 
of the patients. Consequently, the cumulative incidence for the requirement of a CRT-D 
upgrade was 0.3 (95% CI 0.1% to 0.7%) at 1 year follow-up and increased to 5.9% (95% CI 
4.6% to 7.3%) at 5 years follow-up. (Figure 2c)
Incidence of the combined endpoint:
The combined endpoint (the necessity for cardiac pacing, appropriate ATP without 
subsequent shock or device upgrade) was reached in 627 patients (36%). At 1 year follow-up 
the cumulative incidence of the combined endpoint was 14.8% (95% CI 13.1% to 16.6%) 





























































     
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Figure 2. Kaplan-Meier curve showing the cumulative event-free survival of A) the occurrence of atrial 




























suitability 60.2%) at 5 years follow-up. (Figure 3) Appropriate ATP and the necessity of 
cardiac pacing resulted in the unsuitability for an S-ICD in approximately 90% of the cases, 
whereas device upgrade was responsible for the unsuitability in approximately 10% of 
the cases. 
Monogenetic congenital heart disease
A monogenetic congenital heart disease (e.g. Brugada syndrome, hypertrophic 
cardiomyopathy) was present in 136 (8%) of the patients included in the current study. 
(Table 1) Eighty-four patients had a primary prevention indication and of these, 16 (19%) 
patients received appropriate ATP, 2 (2%) patients underwent a CRT-D upgrade, and 8 
(10%) patients developed the necessity for cardiac pacing. This resulted in a cumulative 
incidence for the combined endpoint of 9.9% (95% CI 2.6% to 15.2%) at 1 year follow-up 
and 24.6% (95% CI 14.2% to 35.0%) at 5 year follow-up. For secondary prevention patients 
with a monogenetic heart disease (n = 52), ATP occurred in 14 (27%) patients, a CRT-D 
upgrade was performed in 1 (2%) patient, and 12 (23%) patients required cardiac pacing. 
This resulted in a cumulative incidence for the combined endpoint of 18.8% (95% CI 7.6% 
to 30.0%) at 1 year follow-up and 47.4% (95% CI 31.9% to 62.9%) at 5 year follow-up for 
secondary prevention patients with a monogenetic congenital heart disease.
Predictors of the unsuitability for an s-ICD 
A Fine-Gray regression analysis was performed in order to establish determinants of the 
unsuitability for an S-ICD. Multivariate analysis controlling for factors with a univariate 
p value < 0.2 indicated that secondary prevention (HR 1.54; 95% CI 1.29 - 1.85, p <0.01), 
NYHA class III/IV (HR 1.68; 95% CI 1.36 - 2.07, p<0.01), history of atrial fibrillation (HR 1.31; 
95% CI 1.04  1.65, p<0.05), and QRS duration (HR 1.24 per 30ms increase; 95% CI 1.13 - 1.36, 
p<0.01) were independent determinants of the unsuitability for an S-ICD. (Table 2)
Figure 3. Kaplan-Meier curve showing the cumulative suitability for an S-ICD.
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In the assessment of the suitability for an S-ICD, findings can be summarized as follows: 
1) a  considerable proportion (60.2%) of the patients, currently having a transvenously 
implanted ICD without a preexistent indication for pacing, could have been considered 
suitable for an S-ICD implantation, retrospectively, after 5 years of follow-up; 2) a sub-
analysis in patients with a structural or monogenetic congenital heart disease demonstrated 
that after 5 years of follow-up, approximately 75% of primary prevention ICD recipients 
with a monogenetic heart disease would have been suitable for an S-ICD implantation; 
3) important predictors for the unsuitability of an S-ICD are: secondary prevention, severe 
heart failure, atrial fibrillation, and prolonged QRS duration.
Unsuitability for the s-ICD
In the current analysis, 3 variables excluding the suitability for an S-ICD implantation were 
defined and merged as a combined endpoint. Firstly, those who developed an indication 
for atrial and/or right ventricular pacing during follow-up were considered unsuitable for 
an S-ICD.8, 9 It is conceivable that these patients would be better off with a transvenously 
implanted device system, which would only require changes in device settings, when the 
patient develops a pacing indication. Based on the results of the current study, atrial and/
or right ventricular pacing during follow-up was indicated approximately in 12% of the 
patients. The significant proportion of patients who developed an indication for atrial and/
or right ventricular pacing during follow-up, underlines the importance of an adequate 
selection of patients suitable for an S-ICD implantation. Hence, implantation of an S-ICD in 
these patients would otherwise result in unnecessary additional procedures (i.e. pacemaker 
implantation or conventional ICD implantation).
The second distinguishing difference between the subcutaneous and conventional ICD 
is the ability for the delivery of ATP. ATP has proven to effectively and safely terminate life 
threatening ventricular tachycardias and thereby avoiding the consequences of painful 
shocks.16, 17 Therefore, ATP is currently programmed as the initial therapy for life threatening 
ventricular tachyarrhythmias in conventional devices followed by device shocks if conversion 
to a normal rhythm is unsuccessful. Although S-ICDs have the ability to successfully 
terminate life threatening ventricular arrhythmias (i.e. ventricular tachyarrhythmias and 
ventricular fibrillation) with shocks, they are unable to deliver ATP. This might be considered 
an important drawback since it has been reported that ICD patients who receive shocks 
might exhibit a decline in the quality of life.18 Therefore, for this study, the first date of 
successful appropriate ATP (i.e. without subsequent appropriate shock) was registered as 
an endpoint. According to the results of the present study, 27% of the patients implanted 
with a conventional ICD would be considered unsuitable for an S-ICD implantation because 
of the delivery of successful appropriate ATP. 
It is however important to realize that due to a short detection time or low number of 
intervals, a number of these appropriate ATPs are treating potentially self-limiting VTs and 




























The third and last variable included in the combined endpoint is the upgrade to a CRT-D 
device. During follow-up, ICD patients may require an upgrade to a CRT-D system due 
to a deterioration of heart failure.11, 12 In these patients, conventional ICD upgrade would 
require pulse generator replacement and implantation of a left ventricular pacing lead. 
However, if those patients were implanted with an S-ICD, upgrading to a CRT-D device 
would often require total explantation of the S-ICD and corresponding lead, followed by the 
implantation of the CRT-D in the pectoral region with corresponding transvenous leads. This 
strategy would most likely be more cumbersome and inefficient for the health care system. 
Therefore, upgrading from a conventional ICD is preferable and makes patients in whom 
during follow-up an upgrade becomes necessary unsuitable for an S-ICD implantation. 
Based on the results of the current study, approximately 7% of the patients underwent 
CRT upgrade and would consequently be considered unsuitable for an S-ICD implantation. 
However, with expanding indications for CRT-D, a higher proportion of patients will be 
eligible for initial CRT-D implantation or CRT-D upgrade and becomes unsuitable for an 
S-ICD implantation.21, 22
ICD or s-ICD
Conventional ICDs are associated with specific complications that might be overcome with 
an S-ICD. For instance, several complications associated with transvenous leads, such as 
not reaching vascular access, pneumothorax, and lead dislodgement can be avoided with 
the implantation of an S-ICD . Although it should be noted  that these complications do 
not occur frequently and that S-ICDs might have their own unrevealed implantation related 
complications.23 Another suggested advantage of S-ICDs over conventional ICDs is the 
preservation of venous access for other uses (i.e. central line, etc.). It has been reported 
that  transvenous system implantation is frequently associated with venous lesions and 
accordingly with total venous obstruction in approximately 3.6% of the patients.24 Finally, 
it is suggested that the removal of failed leads is more difficult and dangerous in patients 
with a transvenous system. On the other hand, recent reports indicate that transvenous 
leads can be removed with high success rates and low concomitant adverse events.25 It 
should however be noted that the risk for adverse events during the removal of an S-ICD 
lead compared with the removal of conventional ICD leads is currently lacking. 
Even though there might be certain advantages for an S-ICD compared to a conventional 
ICD in patients that can be considered suitable for such a device, it should be kept in mind 
that current data regarding S-ICDs are scarce and true comparisons regarding efficacy, 
safety and cost-effectiveness with conventional ICDs cannot (yet) be made. Consequently, 
conclusions regarding the potential benefits of an S-ICD would currently be preliminary and 
therefore should be carefully drawn.
Who are suitable for an s-ICD
Patients who remain free from the combined endpoint of ATP, development of an atrial and/
or right ventricular pacing indication or the necessity for an upgrade to a CRT device, are 
patients who are most likely to benefit of the suggested advantages of an S-ICD. Based on 




























S-ICD are in sinus rhythm, have a primary prevention indication, and have a relative good 
condition and no evidence of electrical dyssynchrony. Moreover, it should be noted that 
also primary prevention ICD recipients with a monogenetic congenital heart disease are 
likely to benefit from an S-ICD implantation.
study limitations
There are several limitations to this analysis assessing the suitability for an entirely 
subcutaneous ICD system. Since this is a retrospective single center study, ascertainment 
bias could have influenced the results. Also, ICD tachycardia therapy programming was 
not homogeneous, since in the minority of the patients, ICD settings were adapted when 
clinically indicated. Moreover, it should be emphasized that a pace burden > 20%,  in 
the current study considered as the development of a pacing indication, is an arbitrarily 
chosen cut-off value which may influence the results. Furthermore, besides the combined 
endpoint (i.e. pacing indication, appropriate ATP without subsequent shock and/or device 
upgrade) other parameters such as posture or vascular anatomy potentially influencing the 
feasibility of a device implantation were not assessed. Another limitation of this study is 
that all patients were considered suitable for defibrillation with an S-ICD. Although current 
data does not indicate that there is a proportion of patients not suitable for defibrillation 
using this new device, it should be acknowledged that this issue should be explored in 
more detail in future studies.6, 26 Furthermore, in the current study, CRT-D implantation 
was done according to the then existing guidelines, therefore changes in these guidelines 
could not be accounted for.11, 12 Finally, the preference of the patient for the implantation 
of a conventional ICD or an S-ICD system, an important factor in decision making, was also 
not included in the present analysis. 
ConCluSIon
At 5 years after ICD implantation, approximately 60% of the patients do not reach the 
combined endpoint of ATP, development of an atrial or right ventricular pacing indication 
or the necessity to undergo an upgrade to CRT-D. Based on those results, these patients 
would have been suitable for implantation of an S-ICD instead of a conventional ICD that 
depends on transvenous leads. Additionally, baseline clinical factors have been identified 
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Although randomized trials have shown the beneficial effect on survival of an implantable 
cardioverter defibrillator (ICD) as primary prevention therapy in selected patients, data 
concerning the cost-effectiveness in routine clinical practice remain scarce. Accordingly, 
the purpose of the current study was to assess the cost-effectiveness of primary prevention 
ICD implantation in the real world.
Methods
Patients receiving primary prevention single-chamber or dual-chamber ICD implantation 
at the Leiden University Medical Center were included in the study. Using a Markov model, 
lifetime cost, life years (LY), and gained quality-adjusted life years (QALY) were estimated 
for device recipients and control patients. Data on mortality, complication rates, and 
device longevity were retrieved from our center and entered into the Markov model. To 
account for model assumptions, one-way deterministic and probabilistic sensitivity analyses 
were performed. 
Results
Primary prevention ICD implantation adds an estimated mean of 2.07 LYs and 1.73 QALYs. 
Increased lifetime cost for single-chamber and dual-chamber ICD recipients were estimated 
at €60,788 and €64,216 respectively. This resulted for single-chamber ICD recipients, in an 
estimated incremental cost-effectiveness rate (ICER) of €35,154 per QALY gained. In dual-
chamber ICD recipients, an estimated ICER of €37,111 per QALY gained was calculated. 
According to the probabilistic sensitivity analysis, estimated cost per QALY gained are 
€35,837 (95% CI: €28,368 - €44,460) for single-chamber and €37,756 (95% CI: €29,055-
€46,050) for dual-chamber ICDs. 
Conclusion
Based on data and detailed costs, derived from routine clinical practice, ICD therapy in 

































Multiple randomized studies have demonstrated a survival benefit in selected groups of 
patients with ischemic and non-ischemic heart disease following implantable cardioverter 
defibrillator (ICD) implantation.1-7 
With the recommendation of ICD therapy as prophylaxis for sudden cardiac death in 
patients with a depressed left ventricular ejection fraction (LVEF), worldwide implantation 
rates have increased significantly.8, 9 Concomitantly, the costs associated with ICD treatment 
increased as well, putting a heavy cost burden on health care systems, making it essential 
to assess the cost-effectiveness of ICDs.10, 11 Previously, several studies have assessed the 
cost-effectiveness of the primary prevention use of ICDs and demonstrated that ICDs may 
be cost-effective if current guidelines are followed.12-18 However, it is difficult to extrapolate 
these results to routine clinical practice since these studies mainly used experts’ opinions 
for complication rates, device longevity, and costs. 
Since 1996, all patients receiving an ICD at the Leiden University Medical Center have 
been assessed and followed-up. This thoroughly screened cohort provided a unique 
opportunity to assess cost-effectiveness of primary prevention ICD implantation based on 
clinical data and detailed costs derived from routine clinical practice. 
meThoDS
Design of the study
The estimated lifetime cost and effects of primary prevention implantable cardioverter 
defibrillator (ICD) implantation were compared with conventional pharmacological therapy 
in patients with a reduced left ventricular ejection fraction (LVEF) using a Markov model. 
For the current analysis, a model initially developed by Sanders et al. and thereafter further 
adapted by Cowie et al was used.13, 15 In this model, a hypothetical cohort of patients receiving 
ICD therapy or conventional pharmacological therapy were tracked using a 1-month cycle 
length. In each model cycle, patients from both cohorts were at risk for sudden cardiac death 
(SCD), heart failure death (HFD), other cardiac death (OCD), and non cardiac death (NCD). 
Also, patients receiving ICD therapy were at risk for ICD treatment related complications 
such as: operative death, implant associated complications, device associated complications 
and discontinuation of ICD therapy. Furthermore, associated medical costs were included in 
the model and therewith provide the opportunity to estimate the lifetime costs and effects 
of patients receiving ICD therapy or conventional pharmacological therapy.
In the previous model however, trial data were based on expert opinion and manufacturer 
data, while in the current study these inputs (i.e. complication rates, device longevity, and 
costs) were based upon actual data of routine clinical practice at the Leiden University 
Medical Center, the Netherlands. 
Cost-effectiveness was calculated for both single-chamber and dual-chamber ICD 
devices. Data entered in the model was derived from 483 consecutive patients with a 
reduced LVEF (≤35%) who received a primary prevention single-chamber (n=45, 9%) or 
































2009. Eligibility for ICD implantation was based on international guidelines for primary 
prevention.8, 9 Baseline characteristics for the complete group are summarized in Table 1. 
During a mean follow-up of 31.7±26.9 months, 22 single-chamber and 86 dual-chamber 
replacement devices were implanted. Eleven (2%) patients without data for the most recent 
6 months prior to the end of the study were considered lost to follow-up, however included 
in the analysis as far as data was acquired. 
Life years and quality-adjusted life years (QALY) gained were discounted at 1.5% per 
annum and costs were discounted at 4% per annum.19-21
Death probabilities
The overall mortality rate in patients with reduced LVEF who received primary prevention 
ICD implantation was founded on data from routine clinical practice. Since specific causes 
of death were unavailable in our center, modeling into different categories of death was 
predicated upon the meta-analysis of mortality rates from six primary prevention trials 
conducted by Cowie et al.13 The overall mortality rate in ICD recipients from routine clinical 
practice was distributed over four different categories of death (SCD, HFD, OCD and NCD) 
in the same proportion as found in the pooled estimate derived from the meta-analysis. Non 
cardiac mortality was adjusted to age by incorporating the Dutch lifetable (statline.cbs.nl).




     Age (years) 61±11
     Male (%) 409 (85)
     Left ventricular ejection fraction (%) 27±7
     QRS, mean (SD), ms 111±26
     Renal clearance, mean (SD), ml/min 85±35
     Ischemic heart disease (%) 399 (83)
     History of atrial fibrillation/flutter (%) 96 (20)
Medication
     ACE inhibitors/AT II antagonist (%) 423 (88)
     Aspirin (%) 239 (49)
     Beta-blocker (%) 331 (69)
     Diuretics (%) 328 (68)
     Statins (%) 359 (74)
antiarrhythmic medication *
     Amiodarone (%) 45 (9)
     Sotalol (%) 57 (12)
ACE = angiotensin-converting enzyme; AT = angiotensin; SD = standard deviation. * Patients could be 
































The efficacy of ICD therapy was defined as the relative risk of death for each type of 
mortality outcome in the ICD therapy group when compared with the control group. Given 
that mortality data of a reliable control group (i.e. without ICD therapy) from routine clinical 
practice was not available, the mortality rates of the control group were assessed by using 
the mortality rates of the ICD therapy group and the relative risks provided by the meta-
analysis of Cowie et al.13 
In our cohort 62 patients died during a mean follow-up of 31.7 months, resulting in a 
monthly death probability of 0.0043 for ICD patients in the current analysis. In the meta-
analysis of Cowie et al., the monthly death probability for ICD patients was 0.0072 and for 
patients receiving conventional pharmacological therapy was 0.0105.13 This resulted in an 
adjusted death probability for the hypothetical cohort of patients receiving conventional 
pharmacological therapy in the current analysis of 0.0063. According to the pooled 
estimate derived from the meta-analysis, these overall monthly death probabilities were 
then proportionally distributed over the four different categories of death (SCD, HFD, 
OCD and NCD) (Table 2). It was assumed that the benefit of ICD therapy was constant 
over time. 
Complications of ICD therapy
Patients with reduced LVEF who received primary prevention ICD implantation were at 
risk for device associated complications. The following complications were included in 
the model: operative death, device infection, lead dislodgement, inappropriate shocks, 
discontinuing ICD therapy following inappropriate shock, and lead failures requiring 
replacement. The probability of experiencing such complications was based on data from 
routine clinical practice in our center and is presented in Table 3. Complication rates were 
calculated for the complete group of devices (i.e. all single-chamber and dual-chamber 
devices). The effect of different complication rates was tested in the sensitivity analysis. 
Mean device longevity was based on data from our center, and was 4.6 years in single-
chamber and 4.7 years in dual-chamber ICD devices. 
Table 2. Estimated mortality rates for different categories of death based on data from a meta-analysis 











sudden cardiac death 0.0015 0.0042 0.0009* 0.0025*
Heart failure death 0.0029 0.0029 0.0017* 0.0018*
Other cardiac death 0.0004 0.0002 0.0002* 0.0001*
non-cardiac death 0.0024 0.0031 0.0014* 0.0019*
all-cause 0.0072 0.0105 0.0043 0.0063*
* Estimated values; †Meta-analysis of mortality rates from the following primary prevention trials: AMIOVIRT, 




































ICD therapy  
dual-chamber Conventional therapy Data sources
One month death probability single-chamber ICD cohort
     Sudden cardiac death 0.000916 0.000916 0.002538 Clinical data /Cowie et al.13
     Heart failure death 0.001743 0.001743 0.001752 Clinical data /Cowie et al.13
     Other cardiac death 0.000224 0.000224 0.000102 Clinical data /Cowie et al.13
     Non-cardiac death 0.001439 0.001439 0.001890 Clinical data /Cowie et al.13
     All cause 0.004322 0.004322 0.006283 Clinical data /Cowie et al.13
Initial implant operative death probability 0.00207 0.00207 Not applicable Clinical data
Mean follow-up (months) 31.7 31.7 28 Clinical data/Cowie et al.13
Mean age (years) 60.8 60.8 61.1 Clinical data/Cowie et al.13
Gender (% male) 84.7 84.7 79.5 Clinical data/Cowie et al.13
One-month probability of inappropriate shocks 0.00538 0.00538 Not applicable Clinical data
One-month probability of discontinuing ICD after inappropriate shocks 0.00000 0.00000 Not applicable Clinical data
Monthly probability of a  right atrial lead replacement due to failure following initial implant Not applicable 0.00017 Not applicable Clinical data
Monthly probability of a  right ventricular lead replacement due to failure following initial implant 0.00127 0.00127 Not applicable Clinical data
Monthly probability of a right atrial lead replacement due to failure following replacement implant Not applicable 0.00083 Not applicable Clinical data
Monthly probability of a right ventricular lead replacement due to failure following replacement implant 0.00234 0.00234 Not applicable Clinical data
Probability of a lead infection at initial implant 0.02277 0.02277 Not applicable Clinical data
Probability of a lead infection at replacement ICD implant 0.03704 0.03704 Not applicable Clinical data
Probability of a lead dislodgement at initial implant 0.00828 0.00828 Not applicable Clinical data
Probability of a lead dislodgement at replacement ICD implant 0.00000 0.00000 Not applicable Clinical data
Initial device + leads cost(€) (2010) 19,600 22,150 Not applicable Clinical data
Replacement device cost (€) (2010) 17,000 19,000 Not applicable Clinical data
atrial lead replacement cost per event (lead failure) (€) (2010) Not applicable 2,845 Not applicable Clinical data/Hakkaart et al.23
Right ventricular lead replacement cost per event (lead failure) (€) (2010) 4,895 4,895 Not applicable Clinical data/ Hakkaart et al.23
lead infection cost (€) (2010) 29,561 32,111 Not applicable Clinical data/ Hakkaart et al.23
lead dislodgement cost (€) (2010) 4,895 4,895 Not applicable Clinical data/ Hakkaart et al.23
Inappropriate shocks cost (€) (2010) 132 132 Not applicable Clinical data/ Hakkaart et al.23
Monthly long term inpatient and outpatient cost (€) (2010) 197 197 197 RIVM 2008
ICD additional monthly follow-up cost (€) (2010) 43 43 Not applicable Clinical data/ Hakkaart et al.23
Mean device longevity (years) 4.6 4.7 Not applicable Clinical data
Duration of ICD benefit Lifetime Lifetime Not applicable Assumption
Utility of heart failure patient annual 0.85 0.85 0.85 Mark et al.14
Utility of ICD complications state (annual) 0.75 0.75 Not applicable Sanders et al.15
Discount rate outcomes (%) 1.5 1.5 1.5 CVZ 200619




































ICD therapy  
dual-chamber Conventional therapy Data sources
One month death probability single-chamber ICD cohort
     Sudden cardiac death 0.000916 0.000916 0.002538 Clinical data /Cowie et al.13
     Heart failure death 0.001743 0.001743 0.001752 Clinical data /Cowie et al.13
     Other cardiac death 0.000224 0.000224 0.000102 Clinical data /Cowie et al.13
     Non-cardiac death 0.001439 0.001439 0.001890 Clinical data /Cowie et al.13
     All cause 0.004322 0.004322 0.006283 Clinical data /Cowie et al.13
Initial implant operative death probability 0.00207 0.00207 Not applicable Clinical data
Mean follow-up (months) 31.7 31.7 28 Clinical data/Cowie et al.13
Mean age (years) 60.8 60.8 61.1 Clinical data/Cowie et al.13
Gender (% male) 84.7 84.7 79.5 Clinical data/Cowie et al.13
One-month probability of inappropriate shocks 0.00538 0.00538 Not applicable Clinical data
One-month probability of discontinuing ICD after inappropriate shocks 0.00000 0.00000 Not applicable Clinical data
Monthly probability of a  right atrial lead replacement due to failure following initial implant Not applicable 0.00017 Not applicable Clinical data
Monthly probability of a  right ventricular lead replacement due to failure following initial implant 0.00127 0.00127 Not applicable Clinical data
Monthly probability of a right atrial lead replacement due to failure following replacement implant Not applicable 0.00083 Not applicable Clinical data
Monthly probability of a right ventricular lead replacement due to failure following replacement implant 0.00234 0.00234 Not applicable Clinical data
Probability of a lead infection at initial implant 0.02277 0.02277 Not applicable Clinical data
Probability of a lead infection at replacement ICD implant 0.03704 0.03704 Not applicable Clinical data
Probability of a lead dislodgement at initial implant 0.00828 0.00828 Not applicable Clinical data
Probability of a lead dislodgement at replacement ICD implant 0.00000 0.00000 Not applicable Clinical data
Initial device + leads cost(€) (2010) 19,600 22,150 Not applicable Clinical data
Replacement device cost (€) (2010) 17,000 19,000 Not applicable Clinical data
atrial lead replacement cost per event (lead failure) (€) (2010) Not applicable 2,845 Not applicable Clinical data/Hakkaart et al.23
Right ventricular lead replacement cost per event (lead failure) (€) (2010) 4,895 4,895 Not applicable Clinical data/ Hakkaart et al.23
lead infection cost (€) (2010) 29,561 32,111 Not applicable Clinical data/ Hakkaart et al.23
lead dislodgement cost (€) (2010) 4,895 4,895 Not applicable Clinical data/ Hakkaart et al.23
Inappropriate shocks cost (€) (2010) 132 132 Not applicable Clinical data/ Hakkaart et al.23
Monthly long term inpatient and outpatient cost (€) (2010) 197 197 197 RIVM 2008
ICD additional monthly follow-up cost (€) (2010) 43 43 Not applicable Clinical data/ Hakkaart et al.23
Mean device longevity (years) 4.6 4.7 Not applicable Clinical data
Duration of ICD benefit Lifetime Lifetime Not applicable Assumption
Utility of heart failure patient annual 0.85 0.85 0.85 Mark et al.14
Utility of ICD complications state (annual) 0.75 0.75 Not applicable Sanders et al.15
Discount rate outcomes (%) 1.5 1.5 1.5 CVZ 200619

































Based on the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), an utility score 
of 0.85 for both the ICD and the conventional therapy group was applied in the current 
model.14 Furthermore, it was assumed that ICD implantation had no effect on the quality 
of life.14, 22 If patients were exposed to ICD-related complications (e.g. device infection, 
inappropriate shocks, and lead replacement) a utility score of 0.75 during a period of one 
month was assumed.15
Costs
Cost analyses were performed from the health care perspective. Costs of health care 
associated with inpatient and outpatient treatment were included. Device and lead costs 
were based on average contractual price agreements between the Dutch hospitals and 
manufacturers (expert’s opinion). For all routine procedures and ICD treatment related 
complications requiring hospital admission, the exact average duration of hospital stay, 
based on the clinical data available, was calculated and then multiplied with the standard 
cost per hospital day.23 Procedural costs of device system implantation, device replacement, 
and lead replacement were derived in a micro cost analysis including personnel costs, 
diagnostic test, costs of consumables used during the procedure, depreciation of the 
radiology equipment and catheterization laboratory, and overhead costs.23 For routine 
ICD and unexpected ICD check-up (i.e. following an appropriate or inappropriate shock), 
cost of an outpatient visit were applied.23 All prices were converted to the price level of 
2011 according to the general Dutch consumer price index (statline.cbs.nl, accessed January 
2011). Results of other studies, reported in US dollars, were also converted to euros using 
the purchasing power parity index with a ratio of $1 = €0.8382 (stats.oecd.org, accessed 
December 2011).
In the current analysis, a cost-effectiveness ratio below €40,000 per gained QALY was 
assumed to be acceptable according to the current Dutch economic threshold.24, 25 
sensitivity analyses
To account for important model assumptions, one-way deterministic sensitivity analyses 
were performed. Ranges of the variables were established on current literature or on 
expert’s opinion if literature was lacking. 
Probabilistic sensitivity analysis (PSA) was performed to evaluate the combined 
uncertainty of individual input variables on the model’s outcome of cost and effects. 
To achieve this, probability distributions for death and complication rates as well as the 




Following primary prevention ICD implantation, all-cause mortality decreased resulting 
































conventional therapy. With an estimated utility score of 0.85 per life-year saved and 0.75 
if patients were exposed to ICD-related complications, incremental QALYs were 1.73 years 
for ICD recipients. 
With respect to single-chamber ICDs, implantation is associated with an average 
additional lifetime cost of €60,788 per patient when compared with conventional therapy. 
Consequently, both the lifetime costs and the effectiveness (i.e. life expectancy) were 
higher in single-chamber ICD recipients as compared with patients receiving conventional 
therapy. Accordingly, this resulted in an estimated cost-effectiveness of €29,369 per 
life year gained and €35,154 per QALY gained for patients with a mean age of 61 years 
receiving single-chamber ICD therapy as compared with patients receiving conventional 
therapy (Table 4).
Regarding primary prevention dual-chamber ICD implantation, average additional 
lifetime cost of €64,216 per patient were calculated. With an increased life-expectancy of 
2.07 and a incremental QALY of 1.73, estimated cost-effectiveness of €31,025 per life year 
gained and €37,111 per QALY gained for patients with a mean age of 61 years receiving dual-
chamber ICD therapy compared to patients receiving conventional therapy was assessed 
(Table 4). 
Table 4. Costs, life years, quality-adjusted life years, and incremental cost-effectiveness ratios for 
implantable cardioverter defibrillator compared with control therapy.
Cost (€) lY QalY ICeR (€/lY) ICeR (€/QalY)
single-chamber
     Discounted
          ICD therapy 79,914 11.62 9.84 29,369 35,154
          Control therapy 19,126 9.55 8.11
          Difference 60,788 2.07 1.73
     Undiscounted
          ICD therapy 104,428 13.24 11.21 31,282 37,641
          Control therapy 25,299 10.70 9.09
          Difference 79,642 2.55 2.12
Dual-chamber
     Discounted
          ICD therapy 83,342 11.62 9.84 31,025 37,111
          Control therapy 19,126 9.55 8.11
          Difference 64,216 2.07 1.73
     Undiscounted
          ICD therapy 109,132 13.24 11.21 32,928 39,583
          Control therapy 25,299 10.70 9.09
          Difference 83,833 2.55 2.12
ICD = implantable cardioverter defibrillator; ICER = incremental cost-effectiveness ratio; LY = life years; 

































With all model variables included in the sensitivity analysis, incremental cost-effectiveness 
of ICD therapy compared with conventional therapy demonstrated to be most sensitive to 
variation in the following five factors: device longevity, device and lead costs, quality of life, 
discount rates, and mortality rates (Figure 1). 
Device longevity in the current analyses (i.e. a mean of 4.6 years for single-chamber and 
4.7 years for dual-chamber ICDs) was based on data from our own center. However, it is 
conceivable that device longevity varies according to the device settings and the generation 
of devices used per center. Accordingly, adaptation of the mean device longevity to 4 years 
resulted in an incremental cost-effectiveness of €38,123 and €40,746 per QALY for single-
chamber and dual-chamber devices respectively. When the mean device longevity was 
increased to 10 years, incremental cost-effectiveness improves to €23,744 and €25,273 per 
QALY for single-chamber and dual-chamber devices respectively. As a result, the factor 
device longevity demonstrated to have the largest effect on the total costs and cost-
effectiveness of all factors in the deterministic model.
With respect to device and lead costs, a 25% lowering in prices would affect incremental 
cost-effectiveness by 19%. Outcomes ranged from €26,392 to €38,817 per QALY for single-
chamber devices and from €28,638 to €42,487 per QALY for dual-chamber devices. 
Variation in the patients’ quality of life to 0.75 in both therapy groups (i.e. ICD and 
conventional therapy) resulted in an incremental cost-effectiveness of €36,376 per QALY for 
single-chamber and of €39,675 per QALY for dual-chamber ICD therapy. Consequently, if 
it was assumed that the patients’ quality of life was 0.75 in the conventional therapy group 
and 0.80 in the ICD therapy group, incremental cost-effectiveness improved to €26,644 per 
QALY and €29,060 per QALY for single and dual-chamber ICDs respectively. 
  




   
  

    
Figure 1. Tornado diagram of the deterministic sensitivity analysis representing the five most sensitive 
factors with regard to the incremental cost per QALY of ICD therapy compared with conventional 
therapy. The estimated cost per QALY based on the base case analyses are demonstrated for both 
































A less favorable incremental cost-effectiveness ratio will result if discount rates for 
both outcomes and cost are assumed to be equal. The effect of the variation of discount 
rates between 0% (i.e. undiscounted) and the more internationally accepted 3% for both 
outcomes and costs on the incremental cost-effectiveness of primary prevention ICD 
therapy is illustrated in Figure 1. 
Another important factor determining the incremental cost-effectiveness of ICD therapy 
is the mortality rate of patients applicable for primary prevention ICD implantation. Based 
on the outcomes of the deterministic sensitivity analysis, the incremental cost-effectiveness 
tended to be more favorable in patients with an increased annual mortality. This outcome 
could be explained by the fact that in the current model a higher mortality is associated with 
an increased number of sudden cardiac deaths and therewith an improved beneficial effect 
of ICD therapy. This results in a higher number of incremental life years added for the ICD 
cohort as compared with the conventional pharmacological therapy cohort. 
Probabilistic sensitivity analysis
Based on the PSA, the incremental cost-effectiveness of single-chamber ICDs compared 
with conventional therapy resulted in a mean estimate of €35,837 per QALY (95% CI: €28,368 
- €44,460 per QALY). For dual-chamber ICDs, the PSA resulted in a mean estimate of the 
incremental cost-effectiveness of €37,756 per QALY (95% CI: €29,055-€46,050 per QALY) 
when compared with conventional therapy. The cost-effectiveness acceptability curve in 
Figure 2 shows the probability that single-chamber and dual-chamber ICDs are cost-effective 
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Figure 2. Cost-effectiveness acceptability curve for single chamber (blue line) and dual chamber (red 
































to the Dutch threshold of €40,000 per QALY, the probability that ICD therapy is cost-effective 
was estimated at respectively 81% for single-chamber ICDs and 67% for dual-chamber ICDs.
DISCuSSIon
In the current analysis, primary prevention ICD implantation in addition to optimal 
pharmacologic therapy (i.e. conventional therapy) in patients with an increased risk for 
sudden cardiac death as a result of a reduced LVEF was assessed with the use of a Markov 
model. Based on the deterministic analysis, both single- and dual-chamber ICD implantation 
had an incremental cost-effectiveness ratio below the accepted threshold of €40,000 per 
QALY gained.24, 25 The probabilistic sensitivity analyses confirms these results, as both single 
and dual chamber ICD therapy have a high probability of being cost-effective.
However, variation in specific model factors demonstrated to have major impact on 
the cost-effectiveness of ICD therapy. For example, an increased device longevity due 
to improved device batteries would have a considerable beneficial effect on the cost-
effectiveness and should therefore be one of the main incentives of device manufacturers 
in the development of new generation ICDs. Furthermore, significant higher prices for ICD 
and leads, with respect to base case prices currently used, could easily result in less favorable 
or even unfavorable cost-effectiveness. Another important model factor with major impact 
on the cost-effectiveness is the quality of life. In the current study, the quality of life is based 
on data derived from the SCD-HeFT trial in which all patient received devices unable to 
deliver ATP.14 However, nowadays almost all patients receive ICDs capable of ATP and as 
demonstrated by the PainFREE trial may experience a higher quality of life then reported 
in the SCD-HeFT trial.26 Although exact data hereof remains unclear, the deterministic 
sensitivity analysis demonstrated that an improved quality of life in ICD recipients could have 
a large, namely beneficial, impact on the actual cost-effectiveness reported in the current 
study. Although exact data hereof remains unclear, the deterministic sensitivity analysis 
demonstrated that an improved quality of life in ICD recipients could have a large, namely 
beneficial, impact on the actual cost-effectiveness reported in the current study. Other 
factors with noteworthy effects on the cost-effectiveness were discount rates, mortality 
rates, and ICD efficacy. 
Furthermore, worth mentioning is the relatively minor effect that most device related 
complications had on the cost-effectiveness. Although complications such as lead infections 
requiring complete replacement of the device and leads are associated with extremely high 
costs, the relatively low incidence significantly reduces the effect on total cost-effectiveness.
Comparison with different ICD cost-effectiveness analyses
Currently, cost-effectiveness analyses of primary prevention ICD therapy in patients with a 
reduced LVEF using data from real clinical practice are scarce. However, based on analysis and 
meta-analysis of the major primary prevention trials of ICD therapy several cost-effectiveness 
analyses have been published. Results from the SCD-HeFT trial demonstrated a comparable 
cost-utility ratio (discounted at 3%) of $41,530 (€34,810) per QALY for single-chamber ICDs as 
compared with medical therapy alone.14 Of note is that, likewise the current analysis, Mark et 
































economically attractive if benefits persist for at least 8 years, which was beyond the empirical 
5-year trial data of the SCD-HeFT. Sanders et al. projected the cost-effectiveness of eight 
randomized trials in which primary prevention ICD implantation among patients who are at 
risk for sudden cardiac death due to a reduced LVEF was evaluated.15 In two of those trials, 
primary prevention ICD implantation did not reduce the risk of death, and thus was both more 
expensive and less effective than control therapy. Since in these two trials primary prevention 
ICD implantation occurred in selected patients who are not included in the current analysis, 
comparison with these outcomes is less appropriate. Regarding the six other trials included 
by Sanders et al., primary prevention single-chamber ICD implantation was projected to 
add between 1.01 and 2.99 QALYs and the incremental cost-effectiveness (discounted at 
3%) ranged from $34,000 (€28,500) to $70,200 (€58,842) per QALY gained. Results of the 
current study regarding the added life years and incremental costs per QALY are for both 
single-chamber and dual-chamber ICDs amidst these outcomes of Sanders et al (Table 5). 
In the meta-analysis by Cowie et al., consisting out of 6 primary prevention trials with 
inclusion criteria matching ACC/AHA/ESC Class I or IIa recommendations, direct medical 
costs were estimated using Belgian national references and complications rates were based 
on experts opinion.13 In this analysis, primary prevention single-chamber ICD implantation 
was projected to add 1.88 LY and the estimated mean lifetime costs per QALY gained were 
€29,530 and €31,717 according to the deterministic and probabilistic sensitivity analysis 
respectively. These outcomes are comparable with outcomes of the current analyses, 
indicating that single-chamber and dual-chamber ICDs are, based on clinical data and 
detailed costs derived from routine clinical practice, cost-effective as primary prevention 
therapy in patients with a reduced LVEF (≤35%). 
Van Brabandt et al. criticized the fact that Cowie et al. based their results on a meta-
analysis of 6 primary prevention trials rather than using data from the SCD-HeFT alone.27 
Table 5. Results of increased costs, increased life years, increased quality-adjusted life years, and 
incremental cost-effectiveness ratios for implantable cardioverter defibrillators compared with control 












MaDIT I 6, 15 77,200 3.64 2.64 21,207 29,254
MUsTT 3, 15 85,080 4.14 2.99 20,536 28,500
MaDIT II 7, 15, 18 66,555 2.03 1.47 32,690 45,348
DefInITe 15, 29 84,241 2.73 1.96 30,847 43,001
COMPanIOn 15, 30 57,251 1.87 1.36 30,595 42,163
sCD-HefT 2, 15 59,514 1.40 1.01 42,498 58,842
study single-chamber† 60,788 2.07 1.73 29,369 35,154
study dual-chamber† 64,216 2.07 1.73 31,025 37,111
† Converted to euros using the purchasing power parity index with a ratio of  $1 = €0.8382 (stats.oecd.org, 
accessed December 2011). 
































According to the results from the deterministic sensitivity analyses of the current study 
were ICD effectiveness was based on results from the SCD-HeFT alone, the incremental 
cost-effectiveness per QALY was €41,837 for single-chamber devices and €44,182 for dual-
chamber devices. Consequently, it can be concluded that ICDs would be approximately 
borderline cost-effective if effectiveness is based on results from the SCD-HeFT trial alone.
limitations
In the current study, mortality rates of the control group were assessed by using mortality 
rates of the ICD therapy group and the relative risks provided by the meta-analysis of 
randomized clinical trials by Cowie et al.13 This was based on the assumption that the efficacy 
of ICD therapy in clinical practice is similar to the efficacy of ICD therapy demonstrated in the 
randomized clinical trials. In addition, the overall mortality rate of the ICD group and control 
group over the four different categories of death were distributed in a similar proportion 
as the pooled estimate derived from the meta-analysis. Furthermore, although clinical 
follow-up data was limited to a mean of 31.7 months, cost and benefits were projected to 
a lifetime horizon. Also, the current analysis was performed in a relatively small cohort of 
483 patients with a low proportion of single chamber ICDs. Finally, the long enrolment time 
may has resulted in heterogeneity regarding clinical management and device technology 
within the study cohort. Importantly, all the above study limitations could have resulted in 
an over- or underestimation of the beneficial effects of ICD therapy, consequently over- or 
underrating the cost-effectiveness of ICD therapy in clinical practice.
Implications for society
In the current analyses, primary prevention ICD implantation has demonstrated to have a 
favorable effectiveness versus acceptable costs in patients with a reduced LVEF in the long 
term. However, despite existing guidelines supporting primary prevention implantation 
of ICDs in these patients, implementation hereof is currently far from complete as is 
demonstrated with the widely varying implantation rates across Europe.9, 28 This might be the 
result of the high upfront cost of ICD therapy following implantation and the large patient 
population in which it may be applied.11 Consequently, wide penetration of ICD therapy 
in selected patients forms an absolute challenge to health policymakers, since healthcare 
expenditure for ICDs in Europe could easily exceed several billion Euros per year. On the 
other hand, a saving effect might be expected due to an increased addition (i.e. work, 
consumption) to the general economy. 
Furthermore it is worth mentioning that the current analysis reflected only the cost-
effectiveness of primary prevention ICD therapy without resynchronization therapy in heart 
failure patients. Since patients, eligible for combined defibrillator and resynchronization 
therapy, are characterized by a more deteriorated form of heart failure, results of the current 
analysis do not apply for these patients. 
ConCluSIon
Based on data from routine clinical practice, primary prevention single-chamber and dual-
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One of the major drawbacks of implantable cardioverter defibrillator (ICD) treatment 
is the limited device service life. Thus far, data concerning ICD longevity under clinical 
circumstances are scarce. In this study, the ICD service life was assessed in a large cohort 
of ICD recipients.
Methods
All patients receiving an ICD in the Leiden University Medical Center were included in the 
analysis. During prospectively recorded follow-up visits, reasons for ICD replacement were 
assessed and categorized as battery depletion and non-battery depletion. Device longevity 
and battery longevity were calculated. The impact of device type, generation, manufacturer, 
percentage of pacing, pacing output, and the number of shocks on the battery longevity 
was assessed. 
Results
Since 1996, 4,673 ICDs were implanted of which 1,479 ICDs (33%) were replaced. Mean 
device longevity was 5.0±0.1 years. A total of 1,072 (72%) ICDs were replaced because of 
battery depletion. Mean battery longevity of an ICD was 5.5±0.1 years. When divided into 
different types, mean battery longevity was 5.5±0.2 years for single-chamber ICDs, 5.8±0.1 
for dual-chamber ICDs and 4.7±0.1 years for cardiac resynchronization therapy-defibrillators 
(CRT-Ds) (p<0.001). Devices implanted after 2002 had a significantly better battery longevity 
as compared to devices implanted before 2002 (5.6±0.1 vs. 4.9±0.2 years, p<0.001). In 
addition, large differences in battery longevity between manufacturers were noted (overall 
log rank test p<0.001).
Conclusion
The majority of ICDs were replaced because of battery depletion. Large differences in 
















Large randomized trials have shown a beneficial effect of implantable cardioverter-
defibrillator (ICD) treatment on mortality in selected groups of patients at risk for a life-
threatening ventricular arrhythmia.1-9 With the rapid expansion of indications for ICD therapy, 
worldwide implantation rates increased greatly in the last decade.10-12 However, despite 
the improved survival in selected patients with an ICD, some limitations of ICD therapy 
should not be overseen. One of these limitations is the finite lifespan of ICD devices and, 
consequently, 70% of all ICD recipients will need an ICD replacement because of battery 
depletion at a certain point in time.10 Since ICD replacement is associated with major 
drawbacks, such as infectious and non-infectious complications, reduced patient comfort, 
and reduced cost-effectiveness, assessment of improvement and potential differences in 
battery longevity is essential for the evaluation of ICD performance.13-15 
However, most data considering device longevity are provided by manufacturers and are 
based on intensive testing under standardized and conditioned laboratory measurements. 
Although this manufacturer provided data might be different from device longevity in 
clinical practice, data concerning ICD longevity under clinical circumstances are scarce. 
The aim of the current study was to assess the longevity of ICDs in routine clinical 
practice in a large cohort of patients. This assessment was performed over a 15-year period 
in a large university hospital in the Netherlands. Additionally, the current dataset provides 
an opportunity to assess potential differences in longevity between different types of ICDs, 
manufacturers and to evaluate improvements throughout time.
meThoDS
Patients
Since 1996, all consecutive patients who received an ICD system in the Leiden University 
Medical Center were collected in the departmental Cardiology Information System (EPD-
Vision®, Leiden University Medical Center). Baseline characteristics of the patient, data of 
the implant procedure, and all follow-up visits (until April 2011) were recorded prospectively. 
Collected data of follow-up visits included the pacing percentage, the pacing threshold, the 
pacing output, and the number of delivered shocks (appropriate and inappropriate) delivered 
by each single ICD. Data regarding the implanted defibrillator as manufacturer, device 
model, and the type of ICD (single-chamber, dual-chamber or cardiac resynchronization 
therapy-defibrillator (CRT-D)) were noted. 
Eligibility for ICD implantation was based on international guidelines and included 
secondary prevention and primary prevention of sudden cardiac death. Due to the evolution 
of these guidelines, indications have changed over time.12, 16  
Device implantation and follow-up
All defibrillator systems used were implanted transvenously and without thoracotomy. 
During the implant procedure, sensing and pacing thresholds were determined. Used 














USA, formerly CPI, Guidant (St Paul, MN, USA)], Medtronic (Minneapolis, MN, USA), and 
St Jude Medical/Ventritex (St Paul, MN, USA). 
As a training facility, different physicians were involved with ICD implantation throughout 
the years and to guarantee uniformity, devices were programmed according to a strict 
protocol. In general, in single-chamber ICD recipients, cardiac stimulation parameters were 
set to VVI 40. If patients were dependent on stimulation or rate responsive pacing, a pacing 
mode of VVIR 40-140 was programmed. To avoid unnecessary right ventricular pacing, dual-
chamber ICDs were programmed in the nontracking backup mode DDI in the majority of 
patients with sufficiently long AV delay to secure intrinsic conduction at the lower rate. For 
those patients with an indication for stimulation or rate responsive pacing, devices were 
programmed in a mode of DDDR 40-140 with sufficiently long AV delay to secure intrinsic 
conduction. CRT-D devices were programmed in a biventricular pacing mode, with the lower 
rate programmed in favor of the patient’s natural sinus rhythm resulting in a minimization 
of atrial stimulation. During follow-up visits, the pacing output was programmed to a value 
that was twice as high as the recorded pacing threshold with a minimum pacing output of 
2.5 V (e.g., threshold 0.5V, output 2.5V; threshold 2.0V, output 4.0V). The average pacing 
percentage and pacing outputs recorded during subsequent ICD follow-up visits were used 
for the current analysis. For dual-chamber and CRT-D devices, the percentage of atrial and 
(bi)ventricular pacing was added resulting in a maximal pacing percentage of 100% for 
single-chamber ICDs, 200% for dual-chamber ICDs and 300% for CRT-Ds.
The antitachycardia modes in all devices were programmed with three consecutive 
zones with limits slightly varying per manufacturer: a monitor zone (lower limit between 
150-155 bpm; upper limit between 185-190 bpm), an antitachycardia pacing (ATP) shock 
zone (lower limit between 185-190 bpm; upper limit between 205-210 bpm), and an initial 
shock zone (≥205-210 bpm). In the monitor zone, no therapy was programmed unless a 
ventricular arrhythmia was detected during follow-up. In the ATP-shock zone, arrhythmias 
were initially attempted to be terminated by two bursts of ATP and, if arrhythmia continued, 
defibrillator shocks were used. In case of a ventricular arrhythmia faster than the ATP shock 
zone, device shocks were the initial therapy. Furthermore, atrial arrhythmia detection was 
set to >170 bpm with supraventricular tachycardia discriminators enabled. Therapy settings 
were adapted, only when clinically indicated. 
Device interrogation was scheduled every 3-6 months after implantation. Data of 
these ICDs were included until the last date of ICD check-up. ICDs of patients referred to 
another center were tracked (i.e. last date of ICD check-up in referred center) and if device 
replacement had occurred, its indication was verified.  
Indications for replacement
During follow-up, all ICD replacement procedures were assessed and the indication for 
device replacement was registered. Replacements were categorized as battery depletion 
(Elective Replacement Indicator [ERI]) and non-battery related causes resulting in device 
replacement. Non-battery related causes were further categorized as follows: 1) device 
upgrade, 2) device infection, 3) device advisory or recall, 4) system malfunction, or 5) heart 














for a dual-chamber ICD or CRT-D or when a dual-chamber ICD was replaced for a CRT-D 
without the necessity for replacement because of battery depletion. Device infection was 
defined as infective symptoms at the generator pocket site with or without verified invasion 
of pathogenic microorganisms within the ICD pocket.13 In addition, patients presenting 
with fever or recurrent bacteremia without an apparent focus, subsequently causing device 
replacement, were also classified as device infection. Device advisory or recall consisted 
of a manufacturer initiated advisory to replace an ICD because of technical problems. 
System malfunction was defined as malfunction of the device, the leads, the header or 
insufficient energy capacity for successful defibrillation resulting in device replacement.17 
Finally, analyses were performed for all causes of device replacement (i.e. device longevity) 
and for device replacements because of battery depletion (i.e. battery longevity). 
statistical analysis
Continuous data are expressed as mean and standard deviation (SD) or median with 25th 
and 75th percentile where appropriate; dichotomous data are presented as numbers and 
percentages. Mean longevity was defined in years and was calculated as the time from ICD 
implantation to the time of replacement and expressed with a two-sided 95% confidence 
interval (95% CI). As described previously, separate analyses were performed for device 
longevity, taking into account all causes of device replacement and for battery longevity, 
taking into account only device replacement because of battery depletion.  Additional 
longevity analyses were performed for the type (i.e. single-chamber, dual-chamber, 
and CRT-D), time of implant (i.e. implanted before or since 2002) and the manufacturer 
(i.e. Biotronik, Boston Scientific/Guidant, Medtronic and St Jude Medical/Ventritex). Event-
free rates from a device replacement were analyzed with the method of Kaplan-Meier and 
the log-rank test. A p-value < 0.05 was considered statistically significant. Univariate and 
multivariate Cox proportional-hazards models were constructed to identify independent 
determinants of battery longevity. Only variables with a p-value<0.25 in univariate analysis 
were retained in the multivariate model. All statistical analyses were performed with SPSS 
software (version 18.0, SPSS Inc., Chicago, Illinois).
reSulTS
Patients and ICD Characteristics
Since 1996, 4,673 consecutive ICDs were implanted in 3,194 patients (78% men, mean age 
62 [SD 13] years), which were included in the analysis. The majority of these patients had 
ischaemic heart disease (64%) and a poor LVEF (mean LVEF 34% [SD 15%]) (Table 1). During 
mean follow-up of 4.1±3.2 years, 708 (22%) patients died and 128 (4%) patients were lost 
to follow-up. 
Of the 4,673 implanted devices, 3,194 (68%) were initial implantations and 1,479 (32%) 
were replacement ICDs. The types (single-chamber, dual-chamber, and CRT-D) and 
manufacturers (Biotronik, Guidant, Medtronic and St Jude Medical/Ventritex) included in 


















     Age, mean (SD), years 62 (13)
     Male sex (%) 2507 (78)
     Primary prevention indication (%) 1979 (62)
     Ejection fraction (%) 34 (15)
     QRS, mean (SD), ms 125 (35)
     Renal clearance, mean (SD), ml/min




     Beta-blocker (%) 1760 (55)
     Sotalol (%) 437 (14)
     ACE inhibitors/AT II antagonist (%) 2411 (75)
     Calcium antagonist (%) 284 (9)
     Diuretics (%) 1984 (62)
     Statins (%) 1846 (58)
     Nitrates (%) 572 (18)
     Amiodarone (%) 539 (17)
     Aspirin (%) 1295 (41)
     Oral anticoagulants (%) 1586 (50)
ACE = angiotensin-converting enzyme; AT = angiotensin; SD = standard deviation.
Table 2. ICDs included for longevity analysis
single-chamber Dual-chamber CRT-D Total
biotronik 23 (3%) 323 (16%) 194 (11%) 540 (12%)
boston scientific/Guidant 450 (62%) 835 (40%) 1005 (54%) 2290 (49%)
Medtronic 200 (27%) 717 (34%) 634 (34%) 1551 (33%)
st. Jude Medical/Ventritex 57 (8%) 215 (10%) 20 (1%) 292 (6%)
Total 730 2090 1853 4673
CRT-D = cardiac resynchronization therapy-defibrillator.
As is shown in Figure 1, the implanted number of single-chamber devices, dual-
chamber devices, and CRT-D devices is unequally distributed over time. In 1996, all 
defibrillators implanted were single-chamber devices. In 2002 the distribution was as 
follows: 21% single-chamber devices, 53% dual chamber devices, 26% CRT-D devices. 
In 2010, of the implanted devices, 6% were single-chambers, 41% were dual-chambers, 















A total of 1113 (35%) patients experienced device replacement, of whom 229 (21%) patients 
underwent 2 replacement procedures, 52 (5%) patients underwent 3 replacement procedures 
and 11 (1%) patients underwent 4 replacement procedures. 
The majority of ICD replacements were performed because of an ERI (n = 1072, 72%). 
Other indications for replacement were device upgrades (n = 145, 10%), device infection 
(n = 118, 8%), device advisory or recall (n = 49, 3%), system malfunction (n = 83, 6%) and 
heart transplantation (n = 12, 1%) (Table 3).
Figure 1. Annual proportion of diverse ICD types out of all implanted ICDs.









end of service, n (%) 1072 (72) 279 (74) 420 (65) 373 (82)
Device upgrade, n (%) 145 (10) 49 (13) 96 (15) 0 (0)
Device infection, n (%) 118 (8) 20 (5) 53 (8) 45 (10)
Device advisory or recall, n (%) 49 (3) 8 (2) 34 (5) 7 (2)
system malfunction, n (%) 83 (6) 23 (6) 38 (6) 22 (5)
Heart transplantation, n (%) 12 (1) 0 (0) 4 (1) 8 (2)














battery and non-battery related longevity
Considering all replacement indications, mean device longevity of ICDs (n=4,673) was 5.0 ± 
0.1 years. Event-free rates for a replacement were 94.4% (95% CI 93.6%-95.2%) after 2 years, 
73.2% (95% CI 71.4%-75.0%) after 4 years and 25.7 % (95% CI 23.3%-28.1%) after 6 years 
(Figure 2). Exclusion of the 407 non-battery related replacements, results in a mean battery 
longevity of 5.5 ± 0.1 years. Event-free rates for replacement because of battery depletion 
were 99.6 % (95% CI 99.4%-99.8%) after 2 years, 83.7 % (95% CI 81.9%-85.5%) after 4 years 
and 31.9 % (95% CI 29.2%-34.6%) after 6 years (Figure 2).  
battery longevity per device type and generation
Battery longevity (i.e. only device replacement because of battery depletion) differed 
significantly between the 3 different types of ICDs and was the longest in dual-chamber 
ICDs, followed by single chamber ICDs and thereafter by the CRT-D devices (5.8 ± 0.1 years, 
5.5 ± 0.2 years and 4.7 ± 0.1 years, respectively, p<0.001; Figure 3). 
Five hundred and eighty devices (12%) were implanted before 2002 and 4,093 (88%) 
after 2002. 
When analyzed per type of ICD, mean battery longevity (i.e. only device replacement 
because of battery depletion) was significantly longer in single-chamber ICDs implanted 
since 2002 as compared with single-chamber ICDs implanted before 2002 (6.7 ± 0.3 vs. 
5.0 ± 0.2 years, p<0.001). Similarly, a significantly improved longevity in dual-chamber 
ICDs (6.0 ± 0.1 vs. 5.0 ± 0.2 years, p<0.001) as well as in CRT-D devices (4.7 ± 0.1 vs. 3.7 ± 
0.4 years, p<0.001) was found if devices implanted since 2002 were compared with devices 
implanted before 2002.
Figure 2. Kaplan-Meier curve for event-free rate for a replacement because of all causes (red line) or 
because of battery depletion alone (green line). Regarding the curve for battery depletion, ICDs were 














battery longevity per device manufacturer
The 4,673 implanted devices in this analysis were produced by four different manufacturers 
(Table 2). Kaplan-Meier curves for device survival, specifically because of an ERI, demonstrate 
considerable differences in battery longevity (overall log rank test p<0.001; Figure 4). Mean 
battery longevity was 4.7 ± 0.1 years for Biotronik, 5.3 ± 0.1 years for Boston Scientific, 5.8 ± 
0.2 years for Medtronic and 5.0 ± 0.2 years for St Jude Medical devices. All manufacturers 
demonstrated an improvement in battery longevity since 2002 (p < 0.05).
Predictors of battery longevity
Multivariate Cox regression analysis demonstrated that device type, device manufacturer, 
device generation (i.e. implanted before or since 2002), the percentage of pacing and 
the pacing output were all highly significant independent predictors of battery longevity 
(Table 4). Noteworthy, the number of shocks (i.e. appropriate and inappropriate) did not 
influence the battery longevity. 
DISCuSSIon
In the present study on the longevity of ICD devices, findings can be summarized as follows: (i) 
although the majority of devices is replaced because of battery depletion, approximately 30% 
of devices is explanted because of a non-battery related indication; (ii) CRT-D devices had a 
significantly shorter battery longevity when compared with single-chamber and dual-chamber 
devices; (iii) modern ICD generations of all three types of ICDs demonstrated significantly 
improved mean battery longevity when compared with early generations; (iv) large differences 
Figure 3. Kaplan-Meier curve for event-free survival of ICDs, replaced because of battery depletion in 














Figure 4. Kaplan-Meier curve for event-free survival of ICDs replaced because of battery depletion for 
the manufacturers (Biotronik (=BIO, blue line), Boston Scientific/Guidant (=BSC, green line), Medtronic 
(=MDT, red line), St. Jude Medical/Ventritex (=SJM, yellow line).
exist between manufacturers; (v) variables such as device type, device manufacturer, device 
generation (i.e. implanted before or since 2002), the percentage of pacing and the pacing 
output were all highly significant independent predictors of battery longevity.
non-battery related indications for replacement
Approximately 30% of all implanted devices in the current analysis were replaced prior 
to battery depletion. Due to this considerable part of early replacements, mean device 
longevity is heavily reduced and many patients are confronted with a premature replacement 
procedure. Important is that 61% of reasons other than battery depletion consist out of 
preventable technical issues or device infection resulting in such an early replacement. In 
addition, other studies demonstrate similar results. For example in a study of Knops et al., 
24% of implanted devices had a non-battery related replacement indication. 17 Although 
there are some remarkable differences between both studies, they clearly demonstrate the 
necessity of reducing non-battery related indications for replacement in order to improve 
device longevity. Even if it is not realistic to completely eliminate these causes, major efforts 
should be made to minimize these occurrences.
battery related ICD longevity
Another notable outcome from the current analysis is that dual-chamber ICDs have a 














chamber ICDs (5.5 ± 0.2 years). This is in contrast with previous reports of Hauser et al., 
in which the service life of pulse generators was 4.7 year for single-chamber devices and 
4.0 year for dual-chamber devices.10, 18 
However, this difference can be explained by the fact that the distribution of device 
types (i.e. single-chamber, dual-chamber and CRT-D) implanted in our center was unequally 
distributed over time (Figure 1). As a result, a relatively older compilation of single-chamber 
devices with a less advanced battery technology was compared with a relatively newer 
compilation of dual-chamber devices. This ‘bias’ is resolved when longevity of dual-chamber 
devices is corrected, among others, for device generation: in univariate analysis having a 
dual-chamber decreases the risk for battery depletion as compared with single-chamber 
devices while in multivariate analysis this effect is reversed (HR 1.29 (95% CI 1.08-1.54, 
p<0.001).
Moreover, in CRT-D devices, battery longevity was remarkably shortened as compared 
with single-chamber and dual-chamber devices. This is most likely due to their inherent 
higher percentage of pacing, which diminishes battery longevity significantly.19, 20    
Given the battery longevity among different manufacturers, devices manufactured by 
Medtronic provided the longest service time. Since devices were implanted in a prespecified 
sequence per device type and independently of their manufacturer over the cohort of 
patients, it can be assumed that no specific bias favoring one certain manufacturer exists. 
Furthermore, these results were similar to other studies, in which it was considered to be 
the effect of a more stable and better battery performance and minimization of intracardiac 
electrogram collection in Medtronic devices.17, 19, 21 
Table 4. Cox proportional hazard ratio model to predict ICD battery depletion
Univariate Multivariate
HR 95%CI p-value HR 95%CI p-value
Device type 
     Single-chamber Reference <0.001† Reference <0.001
     Dual-chamber 0.80 0.69-0.94   0.005† 1.29 1.08-1.54 0.01
     CRT-D 2.25 1.91-2.66 <0.001† 2.51 1.94-3.26 <0.001
Manufacturer* 
     Medtronic Reference <0.001† Reference <0.001
     Boston Scientific/Guidant 1.52 1.33-1.73 <0.001† 1.35 1.18-1.55 <0.001
     St. Jude Medical/Ventritex 1.75 1.42-2.16 <0.001† 3.00 2.41-3.74 <0.001
Device generation <2002 vs. ≥2002 0.59 0.52-0.67 <0.001† 0.34 0.29-0.40 <0.001
Pacing percentage (per 10% increase) 1.16 1.14-1.18 <0.001† 1.14 1.10-1.17 <0.001
Pacing output (per V increase) 1.17 1.09-1.25 <0.001† 1.23 1.14-1.32 <0.001
number of shocks 1.00 0.98-1.02 0.89
CI = confidence interval; HR = hazard ratio. *Biotronik was not included in the analyses since limited data 














Implications of ICD longevity on health care
Similar to results of the study of Schaer et al., the latest ICD generations (i.e. implanted since 
2002) in the current analysis demonstrated improved battery longevity when compared 
to older generations (i.e. implanted before 2002).20 However, despite these advances in 
battery longevity, a substantial part of ICD recipients will still outlive their first device.10 
Hauser et al. already estimated that mean battery longevity of devices should at least 
exceed 10 years of service, in order to prevent replacement procedures to occur in the 
majority of ICD recipients. Although technically feasible because of improved battery 
platforms and advanced battery saving device algorithms, such longevity reports in 
clinical practice are, to the best of our knowledge, not published so far. Consequently, an 
enormous number of ICD recipients will be exposed to the additional risk for complications 
when undergoing a device replacement procedure because of battery depletion.13, 22, 23 In 
addition to impending adverse effects for ICD patients, increased device longevity will 
also result in improved cost-effectiveness of ICDs and reduction in the burden of growing 
health care cost worldwide.15 Therefore, all efforts should be made to increase battery 
longevity of ICDs in the near-term. Since upcoming improvements in battery technology 
remain to be proven in real life, the most feasible near-term solution appears to be the 
provision of devices with larger, longer-life batteries. In a study by Wild et al., 90% of the 
patients preferred a larger device that could reduce the number of potential replacement 
procedures instead of a smaller device with the same or reduced longevity.24 However, ICD 
manufacturers and physicians (i.e. depending on the organization of the national health 
care system)  have little incentive to provide long-lived pulse generators since frequent 
replacements increase sales and profits.10 In order to encourage manufacturers to produce 
longer-life devices, manufacturers should be rewarded on the basis of the amount of 
functional service years per ICD implanted. This could result in a substantial reduction 
of replacement surgery, adverse effects for the patient, increased cost-effectiveness and 
appropriate compensation for ICD manufacturers.
limitations
There are several limitations to this study. First of all, battery longevity was only studied 
in four different manufacturers. Furthermore, although the sequence per device type was 
prespecified (i.e. at random) for the different manufacturers, annual price-volume agreements 
resulted in an unequal number of ICDs implanted per different manufacturer. In addition, 
it is important to be aware of the fact that replaced devices in every longevity analysis are 
outdated and therefore ICD longevity results may not apply to current or future devices.
ConCluSIon
Although the majority of devices are replaced because of battery depletion, approximately 
30% of the devices are replaced for other reasons. Furthermore, device type, device 
manufacturer, device generation (i.e. implanted before or since 2002), the percentage of 
pacing and the pacing output had significant influence on battery longevity. Multivariate 
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Little evidence is available regarding restrictions from driving following implantable 
cardioverter defibrillator (ICD) implantation or following first appropriate or inappropriate 
shock. The purpose of the current analysis was to provide evidence for driving restrictions 
based on real-world incidences of shocks (appropriate and inappropriate).
Methods and results
A total of 2786 primary and secondary prevention ICD patients were included. The 
occurrence of shocks was noted during a median follow-up of 996 days (IQR, 428–1833 
days). With the risk of harm formula, using the incidence of sudden cardiac incapacitation 
(SCI), the annual risk of harm to others posed by a driver with an ICD was calculated. Based 
on Canadian data, annual risk of harm to others of 5 in 100 000 (0.005%) was used as a 
cut-off value. In both primary and secondary prevention ICD patients with private driving 
habits, no restrictions to drive directly following implantation or an inappropriate shock are 
warranted. However, following an appropriate shock, these patients are at increased risk to 
cause harm to others road users and therefore should be restricted to drive for a period of 2 
and 4 months, respectively. In addition, all ICD patients with professional driving habits have 
a substantial elevated risk to cause harm to other road users during the complete follow-up 
after both implantation and shock and should therefore be restricted to drive permanently. 
Conclusion
The current analysis provides a clinically applicable tool for guideline committees to 




























It has been recognized that patients treated with an ICD have an ongoing risk of sudden 
incapacitation that might cause harm to others when driving a car. Although numerous 
recommendations exist, thus far evidence is scarce to justify them. As a result, a large 
variation exists between different countries concerning the legislation of driving restriction 
after both primary prevention and secondary prevention ICD implantation.1-3 Since driving 
restrictions are often being perceived as difficult for patients and their families, clear evidence 
on the necessity of these restrictions is vital. Furthermore, these restrictions should take into 
account the indication for ICD implantation (primary or secondary prevention). In the end, 
however, it must be recognized that the goal of a zero percent risk is unobtainable and that 
society has to accept a certain level of risk by allowing patients at risk to resume driving.4-6
With the constant increase in ICD implants worldwide, clear guidelines regarding driving 
restrictions in both primary and secondary ICD patients are warranted. In this analysis we 
determined the risk for ICD therapy following ICD implantation or following previous device 
therapy (appropriate and inappropriate shock) in relation with driving restriction for private 
and professional drivers in a large number of primary and secondary ICD patients. 
meThoDS
Patients 
The study population consisted of patients from the South-western part of the Netherlands 
(comprising 1.500.000 people) who received an ICD for primary prevention or secondary 
prevention in the Leiden University Medical Centre, the Netherlands. Since 1996, all implant 
procedures were registered in the departmental Cardiology Information System (EPD-
Vision®, Leiden University Medical Centre). Characteristics at baseline, data of the implant 
procedure, and all follow-up visits were recorded prospectively. The data collected for the 
current registry ranged from January 1996 up to September 2009. 
Eligibility for ICD implantation in this population was based on international guidelines 
for primary and secondary prevention. Due to evolving guidelines, indications will have 
changed over time.7, 8
Device implantation and programming
All defibrillator system implantations were performed transvenously, without thoracotomy. 
Testing of sensing and pacing thresholds and defibrillation threshold testing was performed 
during the implant procedure. Implanted systems were manufactured by Biotronik (Berlin, 
Germany), Boston Scientific [Natick, MA, USA, formerly CPI, Guidant (St Paul, MN, USA)], 
Medtronic (Minneapolis, MN, USA), and St Jude Medical/Ventritex (St Paul, MN, USA). 
Defibrillators were programmed as follows: a ventricular arrhythmia monitor zone was 
programmed in all patients (150-188 bpm). No therapy was programmed in this zone until 
arrhythmias were detected during follow-up. Ventricular arrhythmias faster than 188 bpm 
were initially attempted to be terminated with two bursts of antitachycardia pacing (ATP) 



























Ventricular arrhythmias faster than 210 bpm were directly attempted to be terminated 
by device shocks. Furthermore, atrial arrhythmia detection was set to >170 bpm with 
supraventricular arrhythmia discriminators enabled. Settings were adapted, only when 
clinically indicated (e.g. hemodynamic well-tolerated ventricular tachycardia (VT) at high 
rate; VT in the monitor zone).
According to Dutch legislation, updated in June 2004, private driving was prohibited for 
the first 2 months after implantation for both primary prevention and secondary prevention 
ICD patients. Furthermore, private drivers are restricted from driving for a period of 2 months 
following an appropriate shock and professional drivers are permanently restricted from 
driving following ICD implantation.9 
Patient follow-up
Patient check-up was scheduled every 3-6 months, which included device interrogation. 
In case of unplanned hospitalization or symptomatic episodes of arrhythmia, additional 
device interrogations were performed. During device interrogation, episodes were 
assessed for appropriate and inappropriate ICD therapy (ATP or shocks) and verified by an 
electrophysiologist. Shocks were classified as appropriate when they occurred in response 
to VT or ventricular fibrillation (VF) and as inappropriate when triggered by sinus tachycardia 
or supraventricular tachycardia (SVT), T-wave oversensing, or electrode dysfunction. After 
delivery of an appropriate shock, efforts were made by a trained electrophysiologist to 
reduce the recurrence rate of arrhythmic events. When clinically indicated, ICD settings 
and/or antiarrhythmic medication were adjusted. 
Since periodical follow-up was performed every 3-6 months, patients without data for 
the most recent 6 months prior to the end of the study were considered as lost to follow-up. 
However, these patients were included in the analysis as far as data was acquired.
end-points
The first shock (appropriate or inappropriate) was considered the primary end-point. For 
the second shock analysis, only those patients who received a first shock were considered 
at risk for a second shock and only subsequent shocks occurring more than 24 hours after 
first shock were considered second shocks. Noteworthy, ATP therapy was discarded from the 
analysis since the number of patients experiencing syncope – and therefore incapacitation 
– during ATP therapy is low. 10, 11 
Risk assessment
Currently, prospective controlled studies in which ICD patients have been randomized to 
permit driving are not available. In 1992, a ‘risk of harm’ formula was developed to quantify 
the level of risk to drivers with ICDs by the Canadian Cardiovascular Society Consensus 
Conference.12, 13 This formula, with the following equation: RH = TD × V × SCI × Ac, calculates 
the yearly risk of harm (RH) to other road users posed by a driver with heart disease and is 
directly proportional to:
•	 proportion of time spent on driving or distance driven in a given time period (TD),



























•	 yearly risk of sudden cardiac incapacitation (SCI),
•	 the probability that such an event will result in a fatal or injury producing accident (Ac).
Based on the literature, it is known that on average a private driver spends ~4% (TD = 
0.04) and a professional driver spends ~25% (TD = 0.25) of his time driving.14, 15 In addition, it 
was shown that more injurious accidents were caused by heavy truck or passenger-carrying 
vehicles when compared to private automobiles. In the Ontario Road Safety Annual Report, 
truckers were involved in ~2% of all road accidents but in ~7.2% of all lethal accidents. Based 
on this data, V = 1 for a professional driver and V = 0.28 for a private driver in the risk of 
harm formula.14, 15 Furthermore, less than 2% of reported incidents of driver sudden death or 
loss of consciousness has resulted in injury or death to other road users or bystanders (Ac = 
0.02).16-18 In this analysis, the yearly risk of sudden cardiac incapacitation was based on the 
cumulative incidence of ICD shocks (appropriate or inappropriate) which were calculated for 
different follow-up periods as described previously. However, the actual influence of an ICD 
shock on the capacity to drive is unknown. According to the literature, 31% of the patients 
experience syncope or near syncope during an appropriate shock.19 Since this proportion of 
patients receiving an appropriate shock will then be incapacitated to drive, it was assumed 
that the SCI is equal to the cumulative incidence of appropriate ICD shocks times 0.31. 
So far, no reports exist which describe the proportion of patients experiencing syncope 
or near syncope during an inappropriate shock. Based on the causes of inappropriate 
shocks (atrial fibrillation, sinus tachycardia, T-wave oversensing and lead failure) it is less 
likely that inappropriate shocks coincide with more hemodynamic consequences then 
appropriate shocks do. With the assumption that 31% of the patients with appropriate 
shocks experience syncope, it was supposed that at most the same proportion of patients 
receiving an inappropriate shock will experience syncope. Therefore, similar to appropriate 
shocks, the SCI is equal to the cumulative incidence of inappropriate ICD shocks times 0.31.
Considering the fact that driving restrictions for ICD patients are implemented as a 
protection for both ICD patients, as well as other road users, the risk of harm formula is an 
easy tool to calculate the potential harm brought to other road users on a yearly basis when 
ICD patients are not restricted to drive.
Unfortunately, data regarding an acceptable level of risk for private and professional 
drivers with an ICD in society are scarce. However, in Canada an annual risk of death or injury 
to others of 5 in 100 000 (0.005%) appeared to be in general acceptable.3 Therefore, this 
generally accepted level of risk will be used as a cut-off value in the current study. 
Private and professional drivers
Criteria to distinguish a private driver from a professional driver were defined on the basis of 
the Canadian Cardiovascular Society Consensus Conference.12, 13 According to these criteria, 
a private driver was defined as follows: 1) driving < 36 000 km per year; 2) spending < 720 h 
per year driving; 3) driving a vehicle weighting < 11 000 kg, and 4) does not earn a living 
by driving. Any licensed driver who does not fulfil one of these criteria was considered to 




























Continuous data are expressed as mean with standard deviation (SD) or median and first 
and third quartile when appropriate; dichotomous data are presented as numbers and 
percentages. Cumulative incidences for first and second appropriate shock were determined 
by the Kaplan-Meier method to take different follow-up times per patient into account. 
Cumulative incidences were determined for several periods of time after implantation and 
presented with a 95% confidence interval (CI) as the estimate plus or minus 1.96 times the 
standard error. 
Standard errors were derived from the binomial distribution, and the confidence 
interval constructed with the normal approximation. The risk of harm formula was used 
to calculate the yearly risk of harm to other road users posed by an ICD treated driver. 
With this formula, various outcomes were calculated on basis of distinct ICD indication 
(i.e. primary and secondary prevention), type of driver (i.e. private and professional driver) 
and type of vehicle driven (i.e. heavy truck and passenger-carrying vehicle or a private 




Since 1996, data of 2786 consecutive patients receiving an ICD for primary (n=1718, 62%) or 
secondary (n=1068, 38%) prevention were prospectively collected. One hundred and ninety 
eight of these patients (n=126 (64%) primary prevention; n=72 (36%) secondary prevention) 
received an ICD for diagnosed congenital heart disease or monogenetic heart disease. 
A total of 196 (7.0%) patients were lost to follow-up, however included in the analysis as far 
as data was acquired. Median follow-up time was 996 days (interquartile range, 428–1833 
days). The majority of patients (79% men, mean age 61 years (SD 13 years) had ischemic 
heart disease. Baseline patient characteristics are summarized in Table 1.
Device therapy in primary prevention patients
In the group of primary prevention patients, median follow-up was 784 days (interquartile 
range, 363–1495 days). During this follow-up, a total of 190 (10%) patients received an 
appropriate shock. Median time to first appropriate shock was 417 days (interquartile 
range, 134 to 960 days). From those 190 patients who received a first appropriate shock, 
65 patients (34%) received a second appropriate shock. Median time between first and 
second appropriate shock was 66 days (interquartile range, 29-379 days). Cumulative 
incidences for first and second appropriate shock are displayed in Figure 1.
Inappropriate shocks occurred in 175 (10%) patients with a median time of 320 days 
(interquartile range, 124 to 711days). From the 175 patients with a first inappropriate shock, 
47 patients (27%) received a second inappropriate shock. Median time between first and 
second inappropriate shock was 224 days (interquartile range, 77 to 580 days). Cumulative 



































     Age (years) 61±13 62±13 61±14
     Male (%) 2192 (79) 1336 (78) 856 (80)
     Left ventricular ejection fraction (%) 33±15 31±14 39±16
     QRS, mean (SD), ms 125±34 129±35 119±32
     Renal clearance, mean (SD), ml/min 81±37 81±36 82±39
     Ischemic heart disease (%) 1800 (65) 1077 (63) 723 (68) 
     History of atrial fibrillation/flutter (%) 683 (25) 447 (26) 236 (22)
Medication
     ACE inhibitors/AT II antagonist (%) 2107 (76) 1407 (82) 700 (66)
     Aspirin (%) 1107 (40) 649 (38) 458 (43)
     Beta-blocker (%) 1513 (54) 1074 (63) 439 (41)
     Diuretics (%) 1738 (62) 1221 (71) 517 (48)
     Statins (%) 1610 (58) 1075 (63) 535 (50)
antiarrhythmic medication *
     Amiodarone (%) 497 (18) 221 (13) 276 (26)
     Sotalol (%) 386 (14) 184 (11) 202 (19)
ACE = angiotensin-converting enzyme; AT = angiotensin; SD = standard deviation. * Patients could be taking 
>1 antiarrhythmic drug. 
Device therapy in secondary prevention patients
In the group of secondary prevention patients, median follow-up time was 1442 days 
(interquartile range, 618–2469 days). During this follow-up, a total of 342 (32%) patients 
received an appropriate shock. Median time to first appropriate shock was 509 days 
(interquartile range, 141 to 1137 days). From those 342 patients with a first appropriate 
shock, 166 (49%) patients received a second appropriate shock. Median time between 
the first and second appropriate shock was 400 days (interquartile range, 107-1072 days). 
Cumulative incidences for first and second appropriate shock are displayed in Figure 1.
Inappropriate shocks occurred in 177 (17%) patients with a median time of 639 days 
(interquartile range, 190 to 1676 days). From the 177 patients with a first inappropriate 
shock, 60 patients (34%) received a second inappropriate shock. Median time between first 
and second inappropriate shock was 243 (interquartile range, 47 to 435 days). Cumulative 
incidences for first and second inappropriate shock are displayed in Figure 2.
Risk assessment in primary prevention ICD patients
In the risk of harm formula (RH = TD × V × Ac × SCI), the annual risk of harm per specific 
time point is calculated with the prespecified variables TD, V, and Ac and with the SCI. 



























Figure 1. Kaplan-Meier curve for first and second appropriate shock in primary (panel A) and secondary 
(panel B) prevention ICD patients. Only patients who received a first appropriate shock were included 
in the analysis for the second appropriate shock. The time to the occurrence of a second appropriate 



























Figure 2. Kaplan-Meier curve for first and second inappropriate shock in primary (panel A) and 
secondary (panel B) prevention ICD patients. Only patients who received a first inappropriate shock 
were included in the analysis for the second inappropriate shock. The time to the occurrence of a second 



























patients experiencing syncope (31%). For instance, for primary prevention ICD patients 
the cumulative incidence for an appropriate shock at one month following implantation 
is 0.9%. Since the formula uses yearly incidences, the monthly incidence is converted to a 
yearly incidence of 10.8% (0.9% × 12) and hereafter multiplied by the proportion of patients 
experiencing syncope or near syncope during an ICD (i.e. 31%) shock. Therefore, SCI in 
this example equals 0.03 (0.009 × 12 × 0.31). Accordingly, the risk of harm to other road 
users per 100 000 ICD patients for primary prevention ICD patients with private driving 
habits one month after implantation is calculated as follows: 0.04 × 0.28 × 0.02 × 0.009 × 
12 × 0.31 = 0.75. After one year, the cumulative incidence for appropriate shocks in these 
patients is 6.0% following implantation. Consequently, the risk of harm to other road users 
for these patients declines to 0.43 (RH = 0.04 × 0.28 × 0.02 × 0.062 × 0.31) per 100 000 
ICD patients per year (Figure 1 and Figure 3). Directly after implantation, the risk of harm 
to other road users in primary and secondary prevention ICD patients with private driving 
habits remains below the acceptable cut-off value of 5 per 100 000 ICD patients. Also after 
experiencing a first inappropriate shock the risk of harm to other road users remains below 
the accepted cut-off value (Figure 4). 
Following an appropriate shock, the annual risk of harm declines from 8.0 (RH = 0.04 × 
0.28 × 0.02 × 0.096 × 12 × 0.31) after one month to 2.1 (RH = 0.04 × 0.28 × 0.02 × 0.302 × 
0.31) per 100 000 ICD patients after one year (Figure 1 and Figure 3). In Figure 3 it is shown 
that the risk of harm declines below the accepted cut-off value after 4 months following an 
appropriate shock in primary prevention ICD patients with private driving habits. However, 
following an inappropriate shock, the risk of harm in these patients is again directly below 
the accepted cut-off value (Figure 4).  
Due to the heavy type of vehicle driven and the hours spent driving, the annual risk of 
harm following both implantation and appropriate shock was found to be 22.3 times higher 
in primary prevention ICD patients with professional driving habits as compared to private 
drivers. Consequently, the risk of harm to other road users following implantation or shock 
remains above the acceptable cut-off value during the complete follow-up. 
Risk assessment in secondary prevention ICD patients
In secondary prevention ICD patients with private driving habits the annual risk of harm 
based on an appropriate shock was found to be 1.8 (RH=0.04*0.28*0.02*0.022*12*0.31) 
per 100 000 ICD patients 1 month following implantation (Figure 1 and Figure 2). Similar to 
primary prevention ICD patients with private driving habits, the risk of harm to other road 
users of these patients remained below the cut-off value of 5 per 100 000 ICD patients 
during follow-up. Also if the risk of harm to other road users after implantation was based 
on the cumulative incidence of inappropriate shocks, outcomes were directly following 
implantation below the accepted cut-off value (Figure 4).
However, after an appropriate shock, the risk of harm to other road users declined from 
6.9 (RH=0.04*0.28*0.02*0.083*12*0.31) to 2.2 (RH=0.04*0.28*0.02*0.315*0.31) casualties 
on an annual basis per 100 000 ICD patients 1 month and 12 months following appropriate 
shock respectively. This risk following appropriate shock declined below the accepted 



























Figure 3. The annual Risk of Harm to other road users (Y-axis) in primary (panel A) and secondary (panel 
B) prevention ICD patients based on the cumulative incidence of appropriate shocks is illustrated.  
Risk of harm (solid lines) is calculated in the months (X-axis) following implantation or appropriate shock. 
The horizontal dotted line represents the cut-off value for the accepted level of risk of harm (5 per 
100 000). Blue and red dotted lines represent the range of the risk of harm, based on the confidence 
interval of the cumulative incidence for appropriate shocks. In primary prevention ICD patients (panel 
A), driving is acceptable directly following implantation (blue line) and should be restricted for 4 months 
following appropriate shock (red line). In secondary prevention ICD patients (panel B), driving is 
acceptable directly following implantation (blue line) and should be restricted for 2 months following 



























Figure 4. The annual Risk of Harm to other road users (Y-axis) in primary (panel A) and secondary (panel 
B) prevention ICD patients based on the cumulative incidence of inappropriate shocks is illustrated.  
Risk of harm (solid lines) is calculated in the months (X-axis) following implantation or inappropriate 
shock. The horizontal dotted line represents the cut-off value for the accepted level of risk of harm 
(5 per 100 000). Blue and red dotted lines represent the range of the risk of harm, based on the 
confidence interval of the cumulative incidence for inappropriate shocks. In primary prevention ICD 
patients (panel A), driving is acceptable directly following implantation (blue line) as well as directly 
following inappropriate shock (red line). Similar results were found in secondary prevention ICD patients 
(panel B), were driving is again acceptable directly following implantation (blue line) as well as directly 



























driving habits (Figure 1 and Figure 2). Following an inappropriate shock, the risk of harm in 
these patients is again directly below the accepted cut-off value (Figure 4).  
Professional driving in secondary prevention ICD patients was above the cut-off value 
following both implantation and shock during the complete follow-up. 
DISCuSSIon
In this evidence based assessment of driving restrictions using the risk of harm formula, 
the findings can be summarized as follows: 1) following device implantation, primary and 
secondary prevention ICD patients with private driving habits have an acceptable risk of 
harm and therefore can be directly permitted to drive; 2) after an inappropriate shock, the 
level of risk remains below the accepted cut-off value and therefore no restrictions should 
be applied in all ICD patients with private driving habits; 3) in the case of an appropriate 
shock, primary and secondary preventions ICD patients with private driving habits should 
be restricted to drive for 4 and 2 months respectively; 4)  ICD patients with professional 
driving habits do not reach an acceptable level of risk during follow-up and therefore should 
be permanently restricted to drive.
Risk of driving in primary prevention ICD patients
With increasing rates of primary prevention ICD implantations worldwide, clear guidelines 
regarding driving restrictions are essential. Although the risk for sudden incapacitation 
while driving is considered lower in this group of ICD patients than in secondary prevention 
ICD patients, no distinction is made in driving restrictions following ICD treatment. These 
differences in event rates are based on mortality data, rates of sudden cardiac death, and rate 
of ICD discharges reported from primary prevention trials.20-27 With the lack of randomized 
controlled trials concerning ICD patients and the risk of driving, recommendations of the 
European Society of Cardiology (ESC) and American Heart Association (AHA) on driving 
restrictions in the group of primary prevention ICD patients are based on data from 
these trials.1, 3 
The current study shows a cumulative incidence of 6.0% appropriate shocks after 1 year. 
Furthermore, ICD discharges were highest in the first period following implantation and 
showed a slight decline in the years thereafter (Figure 1). These data are not comparable 
with the MADIT I trial which described a shock rate of 30.0% on an annual basis during 
two years follow-up or with the MADIT II trial which described a shock rate of 11.7% on an 
annual basis during three years follow-up. However the appropriateness of the defibrillator 
discharges could not be assessed reliably in the MADIT I trial.26, 28 Furthermore, with regard 
to the MADIT II trial, devices were unable to deliver ATP therapy which could lead to a 
higher shock rate. In the SCD-HeFT trial, the annual rate of appropriate ICD discharge 
during 5 years of follow-up was 7.5% per year.20 In the DEFINITE trial, a shock rate of 7.4% 
occurred on an annual basis, however only 44.9% of discharges were appropriate.25 Data 
of the SCD-HeFT and DEFINITE trials are comparable with data from the current study. 
In the current analysis 10% of the primary prevention ICD patients received an 



























Currently, ESC and AHA recommend primary prevention ICD patients with private 
driving habits not to drive for 1 month and 1 week respectively. It should be noted that 
this is not because of an increased risk of SCI, but to improve recovery from implantation 
of the defibrillator.1-3 The current study demonstrates that the risk of harm for private 
drivers remains well below the acceptable cut-off level after implantation and therefore is 
in agreement with these recommendations (Figures 3 and 4). In addition, for professional 
drivers the outcomes of the risk of harm formula in the current analysis are unfavourable 
during the entire period of ICD implantation. As a result, based on the outcomes of this 
study, these drivers should be permanently restricted from driving which is in line with the 
current recommendations of the ESC and AHA.1-3
Risk of driving in secondary prevention ICD patients
Secondary prevention ICD patients have already experienced a life-threatening arrhythmia (e.g. 
VT or VF). The probability that patients will experience a recurrent arrhythmia is therefore an 
important factor determining the risk of harm, both with respect to themselves as well as others 
in car accidents. With regard to inappropriate shocks, only 17% of the secondary prevention 
ICD patients in the current analysis received such a shock. This proportion is more or less 
comparable with the 15% found in secondary prevention ICD patients included in the PainFREE 
Rx II trial.30 However, the 5 year cumulative incidence of appropriate shock ranged between 
55% and 70% in various trials, compared with a 36% cumulative incidence of appropriate shock 
in the current analysis.19, 31-34 This difference is at least in part explained by the ATP therapy which 
was less frequently applied in the older secondary prevention studies which could prevent 
degeneration of VT in VF resulting in a lower cumulative incidence of appropriate shock therapy 
in the present study. Almost similar to Lubinski et al., the probability of arrhythmic episodes 
resulting in appropriate shocks in the current analysis was 2.2% in the first month, 2.9% in 
the second month, and remained below 2% per month in the months thereafter.35 However, 
it was assumed that the risk for road accidents is just a fraction of the monthly probability of 
appropriate shocks, as described previously. Therefore, in patients with defibrillators implanted 
for secondary prevention, the risk of symptoms that may lead to incapacity while driving is 
low. Consequently in the current analysis, the risk of harm to other road users, based on 
both the cumulative incidence of appropriate and inappropriate shocks, remains below the 
acceptable risk. Therefore, no driving restrictions for secondary prevention ICD patients with 
private driving habits following implantation should be implemented. However, this outcome 
is in contrast with the current guidelines for secondary ICD patients with private driving habits, 
where the ESC and AHA recommend a 3 and 6 months driving restriction respectively.1-3
With respect to professional drivers, outcomes of the risk of harm formula are 
unfavourable during the entire period. Therefore, similar to primary prevention patients, 
secondary ICD patients should be restricted from professional driving.  
Risk of driving following appropriate or inappropriate shock
A particularly difficult issue for patients and physicians is the consideration of driving 
restrictions in an ICD patient who has received an appropriate ICD shock. Following 



























period of driving restriction in ICD patients respectively.1, 3, 36 When patients experience 
an appropriate shock for a spontaneous ventricular arrhythmia during follow-up, the 
risk of driving is determined by the probability of a subsequent arrhythmic event and by 
the likelihood of symptoms of impaired consciousness. However, symptoms of impaired 
consciousness during the first appropriate ICD therapy are not unambiguously predictive for 
future syncope during subsequent shocks.31, 37 In a study of 125 ICD patients by Freedberg 
et al., the median freedom from ICD therapy for the second shock was only 22 days, with a 
one year cumulative incidence of a second appropriate shock being 79%.19 These were all 
secondary prevention ICD patients and the cumulative incidence for a second appropriate 
shock shows large dissimilarity when compared with the one year cumulative incidence of 
32% observed in the secondary prevention group in the present study. However, since these 
are all older devices without the option of ATP, shock rates in the study by Freedberg et al. 
are probably comparable with cumulative incidence of all ICD therapy in the current analysis. 
Finally, substituting these cumulative incidences for appropriate shock in the risk of harm 
formula results in a significant increase in the risk of harm to other road users when ICD 
patients are allowed to drive in the period following this shock. This risk of harm to others 
is above the cut-off value of 5 per 100 000 on an annual basis for a period of 4 months and 
2 months following appropriate shock in primary and secondary ICD patients respectively 
(Figure 3). These outcomes are more or less in line with the guidelines of the ESC and AHA.1-3 
Since, to our knowledge, the incidence of syncope following an inappropriate shock is 
unknown, calculating the corresponding risk of harm is problematic. Therefore, it was assumed 
that the incidence of syncope or near syncope during an inappropriate shock is equal to the 
incidence of syncope or near syncope during an appropriate shock. Even with this apparent 
defensive approach in which the potential risk of harm could be overestimated, the actual 
risk of harm following an inappropriate shock remained below the acceptable cut-off value 
for both primary and secondary ICD patients. Therefore, in line with the current guidelines of 
the ESC and AHA, no driving restrictions following an inappropriate shock should be applied 
in these patients. 1-3 However, it is needless to say that all efforts should be made to prevent 
subsequent inappropriate shock before those patients should be permitted to drive again.
Private and professional drivers
It is however important to recognize the difference between the Canadian and European 
classification of private and commercial drivers. In Canada a private driver is defined as one 
who drives less than 36000 km per year or spends less than 720 h driving per year, drives 
a vehicle weighing < 11 000 kg, and does not earn a living by driving. A commercial driver 
is defined as any licensed driver who does not fulfill the definition of a private driver. In 
Europe, two groups of drivers are defined: Group 1 comprises drivers of motor cycles, cars, 
and other small vehicles with or without a trailer. Group 2 includes drivers of vehicles over 
3.5 metric tons or passenger-carrying vehicles exceeding eight seats excluding.3
As the risk of harm estimations are based on the Canadian data it may be necessary 
to reevaluate the strict European rules. For example a private driver with a motor-home 
exceeding the 3.5 metric ton limit automatically is a group 2 driver and restricted from 




























Recently, EHRA and AHA provided consensus documents on driving restriction for ICD 
patients. Since no data from routine clinical practice was available at that time, restrictions 
were based on data from randomized clinical trials, which to a certain extent differ from 
routine clinical practice. This study is the first to provide accurate data on the incidences of 
appropriate and inappropriate shocks during follow-up in routine clinical practice and based 
on this, established driving restrictions. However, it is of course up to the guideline committees 
and national regulatory authorities to determine final driving restrictions for ICD patients. It 
should be emphasized that for the current study, an acceptable risk of harm of 5 per 100 000 
ICD patients was used based on Canadian consensus. Increasing or decreasing this cut-off 
value may hold significant consequences for the recommendations. Moreover, in the current 
formula, Ac was considered 2% (i.e. 2% of reported incidents of driver sudden death or loss 
of consciousness has resulted in injury or death to other road users or bystanders). This data is 
derived from the Ontario Road Safety Annual Report since exact data usable for the formula 
are scarce. It should be noted that differences in these data will exist between different 
countries or areas affected by population density, driving habits, and type of vehicle driven. 
This could affect the risk of harm to other road users. However, if available, data from other 
countries can be implemented in the formula.2 Finally, guidelines committees and national 
regulatory authorities must taken into account the serious impact of driving restrictions on 
patient’s life and the fact that ICD patients will ignore (too rigorous) driving restrictions.38-40 
limitations
This was a prospective observational study assessing the incidence of SCI in ICD patients. 
Since patients received ICDs in a single center over a long period of time, evolving guidelines 
could have created a heterogeneous population. Moreover, median follow-up time was 
2.1 years in primary prevention and 4.0 years in secondary prevention ICD patients which 
resulted in relatively broad confidence intervals of the cumulative incidences at long-term 
follow-up. In addition, ATP was discarded from the analysis since, according to the literature, 
minority of patients receiving ATP experience syncope.10, 11 As a result, calculated risk of harm 
to others might be underestimated. Moreover, ICD programming was not homogeneous 
since ICD settings were adapted when clinically indicated. Finally, only the first and second 
shock (appropriate or inappropriate) of the ICD patients were taken into account. Although 
patients sometime received more than two shocks, the number of patients receiving three or 
more shocks was small and had limited follow-up making assessment of the SCI unreliable. 
ConCluSIon
The current study provides reports on the cumulative incidences of SCI in ICD patients 
following ICD implantation and following first appropriate or inappropriate shock. The risk of 
harm to others was assessed using this SCI multiplied by the estimated risk of syncope, which 
resulted in specific outcomes for the risk of harm to other road users per different scenario 
(Figure 5). This study may serve as a basis and founding of driving recommendations which 

































































































































































































































































































1. Epstein AE, Baessler CA, Curtis AB et al. 
Addendum to “Personal and public safety 
issues related to arrhythmias that may affect 
consciousness: implications for regulation 
and physician recommendations: a medical/
scientific statement from the American Heart 
Association and the North American Society 
of Pacing and Electrophysiology”: public 
safety issues in patients with implantable 
defibrillators: a scientific statement from the 
American Heart Association and the Heart 
Rhythm Society. Circulation 2007;115:1170-6.
2. Katritsis DG, Webb-Peploe MM. Occupational 
and Regulatory Aspects of Heart Disease. In: 
Camm AJ, Lüscher TF, Serruys PW, editors. 
The ESC Textbook of Cardiovascular Medicine. 
Second ed.  2009. p. 1359-69.
3. Vijgen J, Botto G, Camm J et al. Consensus 
statement of the European Heart Rhythm 
Association: updated recommendations 
for driving by patients with implantable 
cardiover ter def ibr i l lators. Europace 
2009;11:1097-107.
4. Anderson M, Camm AJ. Implantable 
cardioverter defibrillators and fitness to drive. 
Lancet 1994;343:358.
5. Anderson MH, Camm AJ. Legal and ethical 
aspects of driving and working in patients 
with an implantable cardioverter defibrillator. 
Am Heart J 1994;127:1185-93.
6. Petch MC. Implantable cardiover ter 
defibrillators and fitness to drive. Lancet 
1994;343:674.
7. Epstein AE, DiMarco JP, Ellenbogen KA 
et al. ACC/AHA/HRS 2008 Guidelines for 
Device-Based Therapy of Cardiac Rhythm 
Abnormalities: a report of the American 
College of Cardiology/American Heart 
Association Task Force on Practice Guidelines 
(Writing Committee to Revise the ACC/
AHA/NASPE 2002 Guideline Update for 
Implantation of Cardiac Pacemakers and 
Antiarrhythmia Devices): developed in 
collaboration with the American Association 
for Thoracic Surgery and Society of Thoracic 
Surgeons. Circulation 2008;117:e350-e408.
8. Zipes DP, Camm AJ, Borggrefe M et al. ACC/
AHA/ESC 2006 Guidelines for Management of 
Patients With Ventricular Arrhythmias and the 
Prevention of Sudden Cardiac Death: a report of 
the American College of Cardiology/American 
Heart Association Task Force and the European 
Society of Cardiology Committee for Practice 
Guidelines (writing committee to develop 
Guidelines for Management of Patients With 
Ventricular Arrhythmias and the Prevention 
of Sudden Cardiac Death): developed in 
collaboration with the European Heart Rhythm 
Association and the Heart Rhythm Society. 
Circulation 2006;114:e385-e484.
9. ht tp://w w w.cbr.nl /brochure/2000%20
Rijgeschiktheid%20bij%20ICD.pdf.  2010. 
10. Leitch JW, Gillis AM, Wyse DG et al. Reduction in 
defibrillator shocks with an implantable device 
combining antitachycardia pacing and shock 
therapy. J Am Coll Cardiol 1991;18:145-51.
11. Wathen MS, DeGroot PJ, Sweeney MO et 
al. Prospective randomized multicenter trial 
of empirical antitachycardia pacing versus 
shocks for spontaneous rapid ventricular 
tachycardia in patients with implantable 
cardiover ter-defibrillators: Pacing Fast 
Ventricular Tachycardia Reduces Shock 
Therapies (PainFREE Rx II) trial results. 
Circulation 2004;110:2591-6.
12. Assessment of the cardiac patient for fitness 
to drive. Can J Cardiol 1992;8:406-19.
13. Assessment of the cardiac patient for 
fitness to drive: 1996 update. Can J Cardiol 
1996;12:1164-82.
14. Ontario Ministry of Transportation. Ontario 
Road Safety Annual Report. Toronto: Ontario 
Ministry of Transportation, 1987. 
15. Fuel consumption survey annual report: 
October 1981 to September 1982 and 
October 1982 to September 1983 [Catalogue 
53-226]. Ottawa: Statistics Canada, 1987. 
16. Hossack DW. Death at the wheel. A 
consideration of cardiovascular disease as a 
contributory factor to road accidents. Med J 
Aust 1974;1:164-6.
17. Ostrom M, Eriksson A. Natural death while 
driving. J Forensic Sci 1987;32:988-98.
18. Parsons M. Fits and other causes of loss 
of consciousness while driving. Q J Med 
1986;58:295-303.
19. Freedberg NA, Hill JN, Fogel RI, Prystowsky 
EN. Recurrence of symptomatic ventricular 
arrhythmias in patients with implantable 
cardioverter defibrillator after the first device 
therapy: implications for antiarrhythmic 
therapy and driving restrictions. CARE Group. 



























20. Bardy GH, Lee KL, Mark DB et al. Amiodarone 
or an implantable cardioverter-defibrillator 
for congestive heart failure. N Engl J Med 
2005;352:225-37.
21. Bigger JT, Jr. Prophylactic use of implanted 
cardiac defibrillators in patients at high risk 
for ventricular arrhythmias after coronary-
artery bypass graft surgery. Coronary Artery 
Bypass Graft (CABG) Patch Trial Investigators. 
N Engl J Med 1997;337:1569-75.
22. Bristow MR, Saxon LA, Boehmer J et al. Cardiac-
resynchronization therapy with or without an 
implantable defibrillator in advanced chronic 
heart failure. N Engl J Med 2004;350:2140-50.
23. Buxton AE, Lee KL, Fisher JD, Josephson ME, 
Prystowsky EN, Hafley G. A randomized study 
of the prevention of sudden death in patients 
with coronary artery disease. Multicenter 
Unsustained Tachycardia Trial Investigators. 
N Engl J Med 1999;341:1882-90.
24. Hohnloser SH, Kuck KH, Dorian P et al. 
Prophylactic use of an implantable cardioverter-
defibrillator after acute myocardial infarction. 
N Engl J Med 2004;351:2481-8.
25. Kadish A, Dyer A, Daubert JP et al. Prophylactic 
defibrillator implantation in patients with 
nonischemic dilated cardiomyopathy. N Engl 
J Med 2004;350:2151-8.
26. Moss AJ, Hall WJ, Cannom DS et al. Improved 
survival with an implanted defibrillator in 
patients with coronary disease at high risk for 
ventricular arrhythmia. Multicenter Automatic 
Defibrillator Implantation Trial Investigators. 
N Engl J Med 1996;335:1933-40.
27. Moss AJ, Zareba W, Hall WJ et al. Prophylactic 
implantation of a defibrillator in patients with 
myocardial infarction and reduced ejection 
fraction. N Engl J Med 2002;346:877-83.
28. Moss AJ, Greenberg H, Case RB et al. 
Long-term clinical course of patients after 
termination of ventricular tachyarrhythmia 
by an implanted defibrillator. Circulation 
2004;110:3760-5.
29. Daubert JP, Zareba W, Cannom DS et al. 
Inappropriate implantable cardioverter-
defibrillator shocks in MADIT II: frequency, 
mechanisms, predictors, and survival impact. 
J Am Coll Cardiol 2008;51:1357-65.
30. Sweeney MO, Wathen MS, Volosin K et al. 
Appropriate and inappropriate ventricular 
therapies, quality of life, and mortality 
among primary and secondary prevention 
implantable cardiover ter defibrillator 
patients: results from the Pacing Fast VT 
REduces Shock ThErapies (PainFREE Rx II) 
trial. Circulation 2005;111:2898-905.
31. Bansch D, Brunn J, Castrucci M et al. Syncope 
in patients with an implantable cardioverter-
defibrillator: incidence, prediction and 
implications for driving restrictions. J Am Coll 
Cardiol 1998;31:608-15.
32. Curtis JJ, Walls JT, Boley TM et al. Time 
to first pulse after automatic implantable 
cardioverter defibrillator implantation. Ann 
Thorac Surg 1992;53:984-7.
33. Grimm W, Flores BF, Marchlinski FE. Symptoms 
and electrocardiographically documented 
rhythm preceding spontaneous shocks in 
patients with implantable cardioverter-
defibrillator. Am J Cardiol 1993;71:1415-8.
34. Levine JH, Mellits ED, Baumgardner RA et al. 
Predictors of first discharge and subsequent 
sur vival in patients with automatic 
implantable cardiover ter-defibrillators. 
Circulation 1991;84:558-66.
35. Lubinski A, Bissinger A, Truszcz-Gluza M, 
Filipecki A, Kargul W, Zajac T, Aarons D. 
Potentially syncopal arrhythmias in ICD 
secondary prevention patients. Europace 
10, 233. 2008. 
36. Epstein AE, Miles WM, Benditt DG et al. 
Personal and public safety issues related to 
arrhythmias that may affect consciousness: 
implications for regulation and physician 
recommendations. A medical/scientific 
statement from the American Hear t 
Association and the North American Society 
of Pacing and Electrophysiology. Circulation 
1996;94:1147-66.
37. Kou WH, Calkins H, Lewis RR et al. Incidence 
of loss of consciousness during automatic 
implantable cardiover ter-defibr il lator 
shocks. Ann Intern Med 1991;115:942-5.
38. Akiyama T, Powell JL, Mitchell LB, Ehlert FA, 
Baessler C. Resumption of driving after life-
threatening ventricular tachyarrhythmia. N 
Engl J Med 2001;345:391-7.
39. Albert CM, Rosenthal L, Calkins H et al. Driving 
and implantable cardioverter-defibrillator 
shocks for ventricular arrhythmias: results 
from the TOVA study. J Am Coll Cardiol 
2007;50:2233-40.
40. Maas R, Ventura R, Kretzschmar C, 
Aydin A, Schuchert A. Syncope, driving 
recommendations, and clinical reality: survey 
of patients. BMJ 2003;326:21.
9
Primary Prevention Implantable 
Cardioverter Defibrillator Treatment: 
how to Identify Patients most Likely 
to Benefit?
Joep Thijssen, MD; Johannes B. van Rees, MD;  
Martin J. Schalij, MD, PhD, C. Jan Willem Borleffs, MD, PhD;
From the Dept. of Cardiology, Leiden University Medical Center, 
Leiden, the  Netherlands.






























Sudden cardiac death (SCD) is defined as death from an unexpected circulatory arrest, 
mostly due to a cardiac arrhythmia in patients with coronary artery disease, occurring 
within an hour of the onset of symptoms.1 Approximately 50% of all deaths in patients 
with ischemic heart disease are unexpected, occurring shortly after onset of symptoms. 
Concomitantly with the rising number of patients with ischemic heart disease - especially in 
the Western world - annual worldwide mortality rates due to SCD has risen to an estimated 
7 million patients.2-4 
An effective treatment to prevent arrhythmic death is implantation of an implantable 
cardioverter defibrillator (ICD). Large randomized trials have proven the beneficial effect 
of ICD therapy in patients at high risk for SCD. The first trials demonstrated benefit in 
patients who survived a life-threatening ventricular arrhythmia (secondary prevention).5-7 
However, since the chance of surviving such an event is low (estimated at 6%), focus shifted 
to the identification of patients at high risk, prior to a first life-threatening event (primary 
prevention).8 A clear example hereof is the MADIT II trial, which demonstrated that post 
infarct patients with a left ventricular ejection fraction (LVEF) of less than 30% had a 
significant better survival if they underwent  ICD implantation compared with conventional 
medical therapy only.9 In addition, the SCD-HeFT trial demonstrated that both ischemic 
and non-ischemic symptomatic heart failure patients with an LVEF ≤ 35% had an improved 
survival if treated with a defibrillator.10 
Following the inclusion of primary prevention ICD treatment in the international 
guidelines, the implanted population changed from survivors of ventricular arrhythmias 
to patients with a low LVEF due to prior myocardial infarction.11, 12 As a consequence , the 
total number of worldwide ICD  implantations significantly increased to 275 000 in 2008.13 
Clinical trials: identification of primary prevention ICD patients most likely to 
benefit 
Although the large randomized trials clearly demonstrated the positive effect of ICD 
treatment on total mortality, these positive results are not observed in all patients 
currently indicated. A clear example is the analysis of mortality data from the MADIT-II trial, 
including patients with ischemic heart disease and a reduced  LVEF without prior ventricular 
arrhythmias.14 Benefit from ICD treatment was not observed in patients (5%) with severe renal 
failure (defined as blood urea nitrogen (BUN) ≥50 mg/dl or serum creatinine ≥2.5 mg/dl). 
After exclusion of these patients, 17 pre-specified potential risk factors were assessed for 
their predictive value for all-cause mortality in the non-ICD arm of the trial. This resulted in 
the following 5 risk factors: age > 70 years, New York Heart Association (NYHA) functional 
class > II, BUN > 26mg/dL, atrial fibrillation, and QRS duration > 120ms. All patients were 
grouped by the number of risk factors (0, 1, 2 or ≥3) and the effect of ICD treatment was 
assessed per group. The results showed a beneficial effect in patients with 1 or 2 risk factors 
(52% of patients) but no effect in patients without risk factors or with three or more risk 
factors (43% of patients). This implies that the patient who  benefit most from ICD treatment 



























risk for mortality from other causes (e.g. three or more risk factors). Additionally, the results 
show that in 48% of MADIT II patients, no benefit could be observed! An analysis of the 
SCD-HeFT trial showed similar results in a population with poor LVEF and symptomatic heart 
failure (NYHA functional class II or III) due to ischemic or non-ischemic heart disease.15 A 
total of 2483 patients were included and stratified into 5 different risk-groups according to 
their predicted mortality calculated from their baseline variables. In the highest-risk patients 
(20% of patients included) a four-years mortality of 50% was observed and ICD implantation 
had no beneficial effect on survival. These outcomes again suggest that patients with a high 
risk for mortality do not benefit from primary prevention ICD treatment.
Routine clinical practice: identification of primary prevention ICD patients 
most likely to benefit
More recently, efforts have been made to construct a risk model on an ICD treated 
population in a real world population outside the setting of a clinical trial. Initially, risk 
models were constructed to identify patients at high risk for all-cause mortality, implying 
that these patients may have less ICD benefit. The analysis was performed with data from 
a 1036 (68% ischaemic) primary prevention patients registry with a mean follow-up of 873 
± 677 days. The risk score consisted of simple baseline variables such as age, LVEF and 
renal clearance which could stratify ischemic and non-ischemic patients in low (6 years 
mortality of <5%), intermediate, and high risk (6 years mortality of >45%) for mortality and 
therewith create an individual patient-tailored estimation on mortality risk which could aid 
clinicians in daily practice.16 Although, according to the large studies mentioned above, 
high mortality risk can be expected to point out patients at low benefit, one could take 
it to a higher analytical level and by trying identify death prior to ICD discharge as the 
ideal end-point for non-benefit. At our center, we developed a tool to identify patients 
with ischemic heart disease who, although currently indicated for ICD treatment, will have 
a high risk of dying prior to actually receiving a potentially life-saving ICD shock.17 In this 
study, a total of 900 primary prevention ICD patients with ischemic heart disease were 
followed for 669 days (IQR 363 – 1322 days). During follow-up 150 (17%) patients died of 
whom 114 (76%) patients did not receive appropriate device therapy and therewith had 
no clear benefit from ICD treatment. Accordingly, the following 5 independent predictors 
of death without appropriate ICD therapy were selected: NYHA ≥III, age ≥75, diabetes 
mellitus, LVEF ≤25%, and a history of smoking and included in a risk score model for death 
without appropriate ICD therapy (non benefit). The score was named the FADES score 
(acronym for Functional class, Age, Diabetes, Ejection fraction, Smoking) and after the 
determination of the individual patient risk scores cut-offs were determined for a population 
at low, intermediate and high risk of death without prior appropriate ICD therapy. Five-year 
cumulative incidence for death without prior appropriate therapy (non benefit) was 10% 
in low risk patients, 17% in intermediate risk patients and 41% in high risk patients. These 
results demonstrate that especially in the high risk patient group, which comprises 23% 
of the total primary prevention ICD population, a significant number of patients had no 
benefit of ICD therapy. However, it is important to realize that patients classified as high 



























ICD therapy at all. Paradoxically, factors as advanced age, depressed ejection fraction, 
and smoking are also identified as predictors of sudden cardiac death or appropriate ICD 
therapy.14, 15, 18 Nevertheless, following potentially life-saving ICD therapy, life expectancy 
in those high-risk patients remains short: within 5 years following ICD  therapy 61% of the 
high risk patients died. Consequently, the FADES score may offer additional inputs to 
improve patient care.
The potential of ICD treatment
A meta-analysis of all randomized clinical trials on primary prevention ICD treatment 
reported a number needed to treat of 13 (e.g. 13 ICD’s to prevent one death).19 Taking into 
consideration that within the currently indicated population, it may be relatively easy to 
identify patients who do not benefit from ICD therapy, one can imagine the high potential 
of ICD’s, if better allocated than currently according to the guidelines directed clinical 
practice. Consequently, this will improve the cost-effectiveness of ICD therapy even more 
and optimize the utilization of limited financial resources and trained personnel which is so 
evidently needed.20
ConCluSIon
ICD therapy  in primary prevention patients is effective en may save many patients from 
dying suddenly. However the challenge will be to develop and implement criteria allowing 
better identification of high risk patients and to limit the number of implants in patients 
who will not benefit. This is important not only from a cost perspective but also because 
ICD therapy is not harmless. In other words inappropriate shocks, infections and device or 
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The general introduction of this thesis (Chapter 1) gives an overview of epidemiology and 
impact of sudden cardiac death (SCD) and describes its most important risk factors.  The 
chapter further focusses on the development of the implantable cardioverter defibrillator 
(ICD) and major studies establishing the beneficial effect of ICD therapy as primary and 
secondary prevention strategy for SCD are specified. Additionally, the chapter shows 
the combination of an ICD with cardiac resynchronization therapy  (CRT-D) as a frequent 
treatment in heart failure patients and, finally, shortly indicates potential complications and 
the socio-economic impact of device treatment.  Although the beneficial effects of ICD 
therapy and CRT are extensively proven in clinical trials, much still remains unclear about 
the wide optimal allocation of these therapies in routine clinical practice.  Therefore the aim 
of this thesis was to examine several important and unresolved issues regarding ICD and 
CRT treatment in daily clinical care by studying a large cohort of ICD and CRT-D recipients 
outside the setting of a clinical trial. The first part (Part I) of this thesis was focused on the 
clinical characteristics and outcomes of the population indicated for defibrillator treatment. 
In the second part (Part II), the social and economic implications of ICD and CRT-D therapy 
were examined.
Part I: Clinical aspects of implantable defibrillator treatment 
In Chapter 2 the mode of death of 2,859 ICD and CRT-D patients in routine clinical practice 
were assessed. For patients who died during follow-up, the mode of death was retrieved from 
hospital and general practitioner records and categorized according to a predetermined 
classification: heart failure death, other cardiac death, sudden death, non-cardiac death, 
and unknown death. During a median follow-up of 3.4 years, 107 (14%) primary prevention 
ICD, 253 (28%) secondary prevention ICD, and 302 (25%) CRT-D recipients died. The 8-year 
cumulative incidence of all-cause mortality was 39.9%. Heart failure death and non-cardiac 
death were the most common modes of death for all groups. Sudden death accounted for 
approximately 7-8% of all deaths. 
This study demonstrated that heart failure and non-cardiac death are the most common 
modes of death in ICD and CRT-D patients and that the proportion of patients who died 
suddenly was low and comparable for all groups.
In Chapter 3 the requirement for pocket related surgical re-interventions following 3,161 ICD 
implantations was evaluated and the effect of device replacement on the occurrence of re-
interventions was assessed. In total, 145 surgical re-interventions were required in 122 (3.9%) 
patients, with a median time to first re-intervention of 75 days. The three years cumulative 
incidence of first re-intervention was 4.7% and the incidence of re-intervention was 1.9 per 
100 ICD-years. Event rate comparison of replacement ICDs versus first implanted ICDs 
showed a more than doubled need for re-interventions in replacement ICDs (rate ratio 2.2). 
Further sub-division by the consecutive number of ICD replacements, shows an increase in 
the annual need for surgical re-intervention, ranging from 1.5% in the first implanted ICD, 































This study showed the effect of ICD replacement on the requirement of pocket related 
surgical re-interventions.
In Chapter 4 we assessed the impact of upgrading ICD therapy to CRT-D, in 115 heart 
failure patients, on the occurrence of ventricular arrhythmias (VAs) and appropriate ICD 
therapies. Episodes of VA, triggering device therapy (anti-tachycardia pacing and shocks) 
were recorded before and after upgrade for the overall population. In addition, these 
outcomes were compared between CRT responders and non-responders during the 
follow-up period after CRT response, defined as a LV end-systolic volume reduction of ≥15%, 
was assessed. It was found that in CRT responders (n=70), the frequency of VAs requiring 
appropriate device therapy demonstrated a trend toward a decrease from 0.51±0.79 to 
0.30±0.59 per patient per year after CRT-D upgrade (p=0.052). In CRT non-responders 
(n=45), the frequency of VAs requiring appropriate device therapy significantly increased 
from 0.40±0.69 to 1.21±2.53 per patient per year after CRT-D upgrade (p=0.014).
This study clearly demonstrated that after an upgrade from ICD to CRT-D, non-
responders to CRT showed a significant increase in VAs burden, requiring appropriate 
device therapy.
Chapter 5 assessed what proportion of 1,742 transvenously implanted ICD recipients would 
have been suitable for an ICD with a subcutaneous lead (S-ICD) and what the characteristics 
of these patients were. Patients without a preexistent indication for pacing  were defined 
suitable for an S-ICD if they did not require atrial and/or right ventricular pacing, received 
successful antitachycardia pacing without a subsequent shock or an upgrade to a CRT-D 
device. During a median follow-up of 3.3 years, 627 (36%) patients reached an endpoint. 
The cumulative incidence of ICD recipients, suitable for an initial S-ICD implantation was 
60% after 5 years. Significant predictors for the unsuitability of an S-ICD were: older age, 
secondary prevention, severe heart failure, atrial fibrillation, and a wide QRS. 
This study shows that after 5 years of follow-up, more than half of the ICD recipients would 
have been suitable for S-ICD implantation and that several baseline clinical characteristics 
could be useful in the selection of those patients.
Part II: socio-economic implications of implantable defibrillator treatment
The purpose of Chapter 6 was to assess the cost-effectiveness of prophylactic ICD 
implantation in the real world. Using a Markov model, lifetime cost, life years (LYs), and 
gained quality-adjusted life years (QALYs) were estimated for device recipients and control 
patients. Based on data retrieved from our own center, prophylactic ICD implantation adds 
an estimated mean of 2.07 LYs and 1.73 QALYs. Increased lifetime cost for single-chamber 
and dual-chamber ICD recipients were estimated at €60,788 and €64,216 respectively. This 
resulted in an estimated incremental cost-effectiveness rate of €35,154 per QALY gained 
for single-chamber ICD recipients and an estimated incremental cost-effectiveness rate of 































This study demonstrated that, based on data and detailed costs derived from routine 
clinical practice, ICD therapy in selected patients with a reduced LVEF appears to be cost-
effective.
In Chapter 7 the ICD service life was studied in a cohort of 3,194 device recipients, and 
reasons for ICD replacement were assessed and categorized as battery depletion and 
non-battery depletion. During follow-up, 4,673 ICDs were implanted of which 1,479 ICDs 
(33%) were replaced. Mean device longevity was 5.0±0.1 years. A total of 1,072 (72%) 
ICDs were replaced because of battery depletion. Mean battery longevity of an ICD was 
5.5±0.1 years. When divided into different types, mean battery longevity was 5.5±0.2 years 
for single-chamber ICDs, 5.8±0.1 for dual-chamber ICDs and 4.7±0.1 years for cardiac 
resynchronization therapy-defibrillators (CRT-Ds) (p<0.001). Devices implanted after 2002 
had a significantly better battery longevity as compared to devices implanted before 2002 
(5.6±0.1 vs. 4.9±0.2 years, p<0.001). In addition, large differences in battery longevity 
between manufacturers were noted (overall log rank test p<0.001).
This study showed that the majority of ICDs were replaced because of battery depletion 
and that large differences in device longevity exist between different ICD types, generation, 
and manufacturers.
Chapter 8 provides evidence for driving restrictions in primary and secondary ICD recipients 
with private or professional driving habits using real-world incidences of appropriate and 
inappropriate shocks. A total of 2,786 ICD patients were included and the occurrence of 
shocks was noted during a median follow-up of 996 days. In both primary and secondary 
prevention ICD patients with private driving habits, no restrictions to drive directly following 
implantation or an inappropriate shock are warranted. However, following an appropriate 
shock, these patients are at increased risk to cause harm to others road users and therefore 
should be restricted to drive for a period of 2 and 4 months, respectively. In addition, all 
ICD patients with professional driving habits have a substantial elevated risk to cause harm 
to other road users during the complete follow-up after both implantation and shock and 
should therefore be restricted to drive permanently.
This study provides a clinically applicable tool for guideline committees to establish 
evidence-based driving restrictions.
Chapter 9 is an editorial describing the challenge to develop and implement criteria 
allowing better identification of high risk patients for sudden cardiac death and to 
limit the number of implants in patients who will not benefit from primary prevention 
ICD therapy. This is important not only from a cost perspective but also because ICD 
therapy is not harmless. In other words, inappropriate shocks, infections, and device or 
lead malfunction are serious issues and well-defined criteria are needed to warrant that 













Although both ICD and CRT have proven to be an effective treatment strategy for selected 
patients in large clinical trials, many issues of the effects of defibrillator treatment in routine 
clinical practice remain unclear. In the current thesis, some of these unresolved questions 
are clarified based on data from a large cohort of ICD and CRT-D patients with long-term 
follow-up in routine clinical practice. 
The first part of the thesis focusses on the clinical aspects of patients treated with a 
defibrillator. Even though the mode of death of defibrillator patients is extensively reported 
in randomized control trials, data outside the setting of a clinical trial is lacking. Based on a 
large number of patients from routine clinical practice the mode of death in ICD and CRT-D 
recipients was assessed and the most common modes of death turned out to be heart 
failure and non-cardiac death in primary prevention ICD, secondary prevention ICD,  and 
CRT-D recipients. Furthermore, in defibrillator replacement patients, it was demonstrated 
that device replacement is associated with a doubled risk for pocket related surgical re-
interventions and that every consecutive replacement increases the risk for re-intervention. 
Additionally, in the subpopulation who underwent upgrade from ICD to CRT-D, due to 
progression of heart failure, the incidence of ventricular arrhythmias was analyzed. Most 
strikingly was the difference in the burden of ventricular arrhythmias following an upgrade 
in both CRT-responders (decrease of ventricular arrhythmias) and CRT non-responders 
(increase of ventricular arrhythmias). In the last fragment of the first part, the suitability for 
the recently developed subcutaneous ICD was studied in our cohort and showed that more 
than half of the current ICD recipients are eligible for this type of device with potentially 
less associated device related-complications.  
The second part of the thesis comprised the implications of large scale defibrillator 
treatment for both patients and society. First of all, the cost-effectiveness of primary 
prevention ICD implantation in the real world was assessed. Although ICD therapy in these 
selected patients appears to be cost-effective, improvement in device longevity and a 
reduction in the cost of the defibrillator system could have a large beneficial impact on 
the actual cost-effectiveness. However, in a subsequent analysis, modern ICD generations 
demonstrated only moderate improvement of longevity and more efforts should be made 
to prolong the battery life of defibrillator devices. Importantly, this could result in a decrease 
of pocket related complications, reduced mortality and improved cost-effectiveness 
ratios. Another important aspect for ICD recipients and society are the restrictions to drive 
following ICD implantation and therapy. While little evidence is available, legislation in 
many countries prohibits patients to drive following defibrillator implantation consequently 
limiting for instance severe heart failure patients in their daily movement. In the last fragment 
of the second part different approaches for the identification of primary prevention patients 

















Following the inclusion of primary prevention defibrillator treatment in the international 
guidelines of cardiology, an enormous increase in the number of implanted defibrillator 
devices occurred in the last decade. As a result, the implanted population changed 
from survivors of ventricular arrhythmias to patients with a reduced LVEF with or without 
symptomatic drug refractory heart failure. Noteworthy is that a significant proportion of 
these defibrillator patients do not receive potentially life-saving therapy during follow-up 
and therewith have no benefit from defibrillator implantation. On the other hand, patients at 
high risk for sudden cardiac death, without an indication for defibrillator therapy according 
to the current guidelines, will have to be identified. Given the serious drawbacks, such as 
inappropriate shock, lead failure, and cardiac device infections associated with this therapy, 
better patient selection prior to defibrillator implantation is required. In addition, the 
population eligible for primary prevention defibrillator treatment is of such magnitude that 
treatment of every patient will strain financial resources and the pool of trained personnel. 
This once more stresses the necessity of optimal allocation of defibrillator treatment. 
Accordingly, future research for defibrillator devices in routine clinical practice should 
focus on both diminishing the adverse events of this treatment by enhancing defibrillator 
longevity, improving antitachycardia algorithms, and reducing the proportion of lead failures 
as well as on the development and implementation of criteria that allow better identification 
of high risk patients and to limit the number of defibrillator implants in patients who will 
not benefit.
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De algemene introductie van dit proefschrift (hoofdstuk 1) geeft een overzicht van de 
epidemiologie en de gevolgen van plotse hartdood (SCD, Sudden Cardiac Death) en 
beschrijft de belangrijkste risicofactoren hiervan. Het hoofdstuk richt zich onder meer op 
de ontwikkeling van de Implanteerbare Cardioverter Defibrillator (ICD) en specificeert de 
belangrijke studies die hebben bijgedragen aan het vaststellen van het gunstige effect 
van ICD-therapie als primaire en secundaire preventie voor SCD. Daarnaast wordt de 
combinatie van een ICD met cardiale re-synchronisatie therapie (CRT-D) als een frequente 
behandeling bij patiënten met hartfalen toegelicht en zullen kort de mogelijke complicaties 
en sociaaleconomische effecten van ICD therapie worden aangestipt. Ondanks het feit dat 
de gunstige effecten van ICD therapie en CRT uitvoerig zijn bewezen in klinische studies, 
bestaan er nog veel onduidelijkheden over de optimale allocatie van deze therapieën in 
de dagelijkse klinische praktijk. Dientengevolge, is het doel van dit proefschrift om een 
aantal belangrijke en onopgeloste kwesties met betrekking tot ICD en CRT-behandeling 
in de klinische praktijk te beantwoorden door middel van het onderzoeken van een 
groot cohort van ICD en CRT-D patiënten buiten de setting van een klinische studie. 
Het eerste deel (deel I) van dit proefschrift is gericht op de klinische kenmerken en 
uitkomsten van patiënten die behandeld worden met een ICD. In het tweede deel (deel 
II), worden de sociale en economische gevolgen van de brede toepassing van ICD en 
CRT-D therapie onderzocht.
Deel I: Klinische aspecten van implanteerbare defibrillator behandeling
In hoofdstuk 2 werd de doodsoorzaak van 2859 patiënten met een ICD of CRT-D in de 
klinische setting geanalyseerd. Bij de patiënten die gedurende de follow-up overleden, 
werd de doodsoorzaak via het betreffende ziekenhuis of via de huisarts achterhaald en 
gecategoriseerd aan de hand van de vooraf bepaalde indeling: hartfalen dood, andere 
hartdood, plotse dood, niet-cardiale dood, en onbekende dood. Gedurende een mediane 
follow-up van 3,4 jaar, overleden 107 (14%) primaire preventie ICD patiënten, 253 (28%) 
secundaire preventie ICD patiënten, en 302 (25%) CRT-D patiënten. De 8-jaar cumulatieve 
incidentie van de totale mortaliteit was 39.9%. Hartfalen dood en niet-cardiale dood waren 
de meest voorkomende doodsoorzaken voor alle groepen. Plotse hartdood  was goed voor 
ongeveer 7-8% van alle sterfgevallen. 
Deze studie toonde aan dat hartfalen dood en niet-cardiale dood de meest voorkomende 
vormen van overlijden zijn in ICD en CRT-D patiënten en dat het aandeel van de patiënten 
die plotseling overlijd relatief laag was en vergelijkbaar is voor alle groepen.
In hoofdstuk 3 werd de noodzaak tot pocket gerelateerde chirurgische re-interventie na ICD 
implantatie (n=3161) geëvalueerd en werd onderzocht of er sprake is van een relatie tussen 
het aantal ICD implantaties per patiënt en de frequentie van chirurgische re-interventie. 
In totaal werden er 145 chirurgische re-interventies verricht in 122 (3.9%) patiënten, met 
een mediane tijd tot de eerste re-interventie van 75 dagen. De cumulatieve incidentie drie 
































100 ICD-jaren. Vergelijking tussen de event rates van chirurgische re-interventie in initieel 
geïmplanteerde ICD’s versus vervangen ICD’s toonde een meer dan verdubbelding in de 
noodzaak tot re-interventies aan in vervangen ICD’s (rate ratio 2.2). Verdere onderverdeling 
op basis van het volgnummer van de geïmplanteerde ICD per patiënt, toont een toename 
van de jaarlijkse noodzaak tot chirurgische re-interventie, variërend van 1,5% in de eerste 
geïmplanteerde ICD, tot 8,1% in het vierde geïmplanteerde ICD.
In deze studie werd het effect van ICD vervanging op de noodzaak tot pocket 
gerelateerde chirurgische re-interventies onderzocht.
In hoofdstuk 4 hebben we, bij 115 patiënten met hartfalen, de impact van het upgraden 
van een ICD systeem naar een CRT-D systeem op het optreden van ventriculaire aritmieën 
en terechte ICD therapie onderzocht. Episodes van ventriculaire aritmieën die resulteerde 
in therapie (anti-tachycardia pacing en/of defibrillatie) voor en na het upgraden van de 
geïmplanteerde cardioverter defibrillator werden in de gehele populatie geregistreerd. 
Daarnaast werden deze resultaten vergeleken tussen CRT responders en non-responders 
in de follow-up periode nadat er was vastgesteld of er sprake was van een CRT respons 
welke werd gedefinieerd als een linker ventrikel eind-systolische volume vermindering van 
≥ 15%. Het bleek dat in CRT responders (n=70), de frequentie van ventriculaire aritmieën 
die resulteerde in terechte therapie, een dalende trend van 0,51 ± 0,79 naar 0,30 ± 
0,59 therapieën per patiënt per jaar liet zien na CRT-D upgrade (p = 0.052). In CRT non-
responders (n=45), was de frequentie van ventriculaire aritmieën die resulteerde in terechte 
therapie aanzienlijk toegenomen, van 0,40 ± 0,69 tot 1,21 ± 2,53 per patiënt per jaar na 
CRT-D upgrade (p = 0.014).
Dit onderzoek heeft duidelijk aangetoond dat er, na de upgrade van ICD naar CRT-D, 
in non-responders een significante toename van het aantal ventriculaire aritmieën is die 
resulteerde in terechte therapie.
In hoofdstuk 5 werd onderzocht welk deel van 1742 transveneus geïmplanteerde ICD 
patiënten geschikt zou zijn geweest voor implantatie van een subcutane ICD (S-ICD) 
en welke patiënten karakteristieken deze groep kenmerkte. Patiënten zonder pre-
existente indicatie voor pacing werden geschikt geacht voor een S-ICD indien er: geen 
atriale en/of rechterventrikel pacing nodig was, bij een ventriculaire aritmie succesvolle 
anti-tachycardie pacing zonder defibrillatie plaatsvond en er geen upgrade naar een 
CRT-D geschiedde. Gedurende een mediane follow-up van 3,3 jaar bereikte 627 (36%) 
patiënten een van bovenstaande eindpunten. De cumulatieve incidentie van ICD 
patiënten, geschikt voor S-ICD implantatie was 60% na 5 jaar. Significante voorspellers 
voor de ongeschiktheid van een S-ICD betroffen de volgende patiënten karakteristieken: 
hogere leeftijd, secundaire preventie, ernstig hartfalen, atriumfibrilleren, en een breed 
QRS complex.
Deze analyse toont aan dat, na 5 jaar follow-up, meer dan de helft van de huidige ICD 
patiënten geschikt zou zijn geweest voor S-ICD implantatie en dat verschillende patiënten 
































Deel II: socio-economische gevolgen van een implanteerbare defibrillator 
behandeling
Het doel van hoofdstuk 6 was om de kosteneffectiviteit van profylactische ICD implantatie 
in de klinische praktijk te beoordelen. Met behulp van een Markov-model werden de 
levensduurkosten, gewonnen levensjaren, en behaalde kwaliteits-gewonnen levensjaren 
(QALY’s) voor ICD patiënten en een controle groep geschat. Gebaseerd op gegevens uit 
ons eigen centrum, voegt profylactische ICD implantatie naar schatting een gemiddelde van 
2,07 LYs en 1,73 QALY’s per patiënt toe. De levensduurkosten voor een een-kamersysteem 
en twee-kamersysteem ICD werden geschat op respectievelijk €60.788 en €64.216. Dit 
resulteerde in een geschatte kosteneffectiviteit van €35.154 per gewonnen QALY voor een-
kamersysteem ICD en van €37.111 per gewonnen QALY voor een twee-kamersysteem ICD.
Deze studie toonde aan dat, op basis van data en gedetailleerde kosten verkregen uit de 
klinische praktijk, blijkt dat ICD therapie bij geselecteerde patiënten met een verminderde 
LVEF kosteneffectief is.
In hoofdstuk 7 werd de levensduur van een ICD aan de hand van een cohort van 3194 patiënten 
berekend en werden de oorzaken voor ICD vervanging beoordeeld en gecategoriseerd naar 
batterij gerelateerd en niet batterij gerelateerd. Gedurende de follow-up, werden er 4673 
ICD’s geïmplanteerd waarvan er uiteindelijk 1479 (33%) werden vervangen. De gemiddelde 
levensduur van de ICD was 5,0±0,1 jaar. Een totaal van 1.072 (72%) ICD’s werden vervangen 
als gevolg van uitputting van de ICD batterij. De gemiddelde batterijlevensduur kwam uit 
op 5,5±0,1 jaren. Onderverdeling op basis van de verschillende ICD’s resulteerde in een 
gemiddelde levensduur van 5,5±0,2 jaren voor een een-kamersysteem, 5,8±0,1 jaren voor 
een twee-kamersysteem en 4,7±0,1 jaren voor een biventriculaire ICD (CRT-D) (p <0,001). Er 
was sprake van een significant betere levensduur van ICD’s welke na 2002 zijn geïmplanteerd 
ten opzichte van ICD’s die voor 2002 zijn geïmplanteerd (5,6±0,1 versus 4,9±0,2, p <0,001). 
Verder werden er grote verschillen in de batterijlevensduur van de ICD van verschillende 
fabrikanten opgemerkt (algemeen log rank test p <0,001).
Dit onderzoek toonde aan dat de meerderheid van ICD’s werd vervangen als gevolg 
van batterij uitputting en dat er sprake is van significante verschillen in de levensduur van 
het apparaat tussen de verschillende ICD systemen, generaties en fabrikanten.
Hoofdstuk 8 is een analyse waarin het wel of niet toepassen van rijrestricties voor primaire 
en secundaire ICD patiënten met particulier of professioneel rijgedrag aan de hand 
van incidenties van terechte en onterechte ICD defibrillatie in de klinische praktijk werd 
berekend. Een totaal van 2786 ICD patiënten werden geïncludeerd en het optreden van ICD 
defibrillatie werd gedurende een mediane follow-up van 996 dagen genoteerd. In zowel 
primaire als secundaire preventie ICD patiënten met particulier rijgedrag bleken rijrestricties 
zowel direct na de implantatie als na een onterechte defibrillatie niet gerechtvaardigd. 
Echter, na een terechte defibrillatie, is er sprake van een verhoogd risico op het toebrengen 
van schade aan andere weggebruikers waardoor respectievelijk een rijrestrictie van 2 en 
































ICD implantatie als terechte defibrillatie, bij alle ICD patiënten met professioneel rijgedrag 
sprake van een aanzienlijk verhoogd risico op het toebrengen van schade aan andere 
weggebruikers waardoor een permanente rijrestrictie voor deze groep dient te gelden. 
Deze analyse geeft een klinisch toepasbaar wetenschappelijk onderbouwd model wat 
kan dienen als hulpmiddel voor een richtlijnencommissie bij het vaststellen van rijrestricties 
in ICD patiënten.
Hoofdstuk 9 is een editorial welke de uitdaging beschrijft om criteria voor een betere 
identificatie van patiënten met hoog risico op plotse hartdood te ontwikkelen en te 
implementeren en het aantal implantaties bij patiënten die niet zullen profiteren van 
primaire preventie ICD therapie te beperken. Dit is niet alleen van belang vanuit een 
kostenoogpunt, maar ook omdat ICD therapie nadelig kan zijn voor patiënten. Met 
andere woorden, ongewenste schokken, infecties, en apparaat of lead malfuncties zijn 
ernstige problemen en goed gedefinieerde criteria zijn nodig om te rechtvaardigen dat 
het overlevingsvoordeel van primaire preventie ICD therapie opweegt tegen de nadelen 

































Hoewel zowel ICD als CRT in grote gerandomiseerde studie hebben bewezen een effectieve 
behandelingsstrategie te zijn voor geselecteerde patiënten, blijven er onduidelijkheden 
bestaan over de effecten van defibrillator behandeling in de dagelijkse klinische praktijk. In 
het huidige proefschrift worden een aantal van deze onopgeloste vragen, met behulp van 
gegevens van een groot cohort van ICD en CRT-D patiënten met een lange follow-up in de 
klinische praktijk, opgehelderd.
Het eerste deel van het proefschrift richt zich op de klinische aspecten van de patiënten 
met een implanteerbare defibrillator. Ondanks het feit dat in gerandomiseerde controle studies 
de oorzaak van overlijden van patiënten met een ICD of CRT-D uitgebreid is gerapporteerd, 
ontbreken dergelijke rapportages buiten de setting van een gerandomiseerde trial. Met behulp 
van een groot aantal patiënten uit de klinische praktijk werd de doodsoorzaak van ICD en CRT-D 
patiënten onderzocht en bleken de meest voorkomende oorzaken van overlijden, hartfalen en 
niet cardiale dood te betreffen in zowel primaire preventie ICD, secundaire preventie ICD en 
CRT-D patiënten. Verder werd aangetoond dat er, bij patiënten die een defibrillator vervanging 
ondergingen, sprake is van een dubbel risico op het ondergaan van pocket gerelateerde 
chirurgische re-interventie na defibrillator vervanging en dat iedere volgende defibrillator 
vervanging het risico van re-interventie verhoogd. Daarnaast werd in een subpopulatie, die 
een upgrade van ICD naar CRT-D onderging vanwege progressie van hartfalen, de incidentie 
van ventriculaire aritmieën geanalyseerd. Het meest opvallende was het verschil in de incidentie 
van ventriculaire aritmieën na een upgrade in zowel CRT-responders (afname van het aantal 
ventriculaire aritmieën) en CRT non-responders (toename van het aantal ventriculaire aritmieën). 
In het laatste fragment van het eerste deel, werd de toepasbaarheid voor de recent ontwikkelde 
subcutane ICD in ons cohort bestudeerd en werd aangetoond dat meer dan de helft van de 
huidige ICD patiënten hiervoor in aanmerking zou kunnen komen waardoor er mogelijk minder 
defibrillatorsysteem geassocieerde complicaties zouden hoeven optreden.
Het tweede deel van het proefschrift bestaat uit de gevolgen van het op grote schaal 
toepassen van implanteerbare defibrillator behandeling voor zowel patiënten als voor de 
maatschappij. Allereerst werd de kosteneffectiviteit van primaire preventie ICD implantatie in 
de praktijk onderzocht. Hoewel ICD therapie bij deze geselecteerde patiënten kosteneffectief 
lijkt te zijn, zouden verbetering van de levensduur en een vermindering van de kosten van 
de ICD een gunstig effect op de werkelijke kosteneffectiviteit kunnen hebben. Echter, in een 
latere analyse bleek dat modernere ICD generaties slechts een geringe verbetering van de 
levensduur toonden, waardoor het duidelijk is dat er meer inspanningen nodig zijn om met 
name de levensduur van de ICD batterij te verlengen. Belangrijk is dat dit uiteindelijk kan 
resulteren in een daling van het aantal pocket gerelateerde complicaties, de mortaliteit en een 
verbeterde kosteneffectiviteitsratio. Een ander belangrijk aspect voor zowel ICD patiënten als 
wel voor de maatschappij zijn de rijrestricties die direct na ICD implantatie en na therapie van 
toepassing zijn. Ondanks het beperkte bewijs hiervoor, gelden er in veel landen rijrestricties 
na implantatie van een defibrillator welke als gevolg hebben dat bijvoorbeeld ernstig hartfalen 
patiënten in hun bewegingsvrijheid worden beperkt. In het laatste fragment van het tweede 
deel worden verschillende strategieën voor de identificatie van primaire preventie patiënten 

































Na het toevoegen van primaire preventie defibrillatorbehandeling in de internationale 
richtlijnen van de cardiologie, vond een enorme toename van het aantal geïmplanteerde 
defibrillatorsystemen plaats in het laatste decennium. Dientengevolge veranderde de 
geïmplanteerde patiëntenpopulatie van voornamelijk overlevenden van ventriculaire 
aritmieën naar patiënten met een verminderde LVEF met of zonder symptomatisch hartfalen. 
Opmerkelijk is dat een aanzienlijk deel van deze patiënten met een geïmplanteerde 
defibrillator geen potentieel levensreddende therapie ontvangen gedurende de follow-up 
en daarmee dus geen voordeel hebben van defibrillator implantatie. Anderzijds, is het 
juist weer noodzakelijk om patiënten met een hoog risico op plotse hartdood, zonder 
volgens de huidige richtlijnen in aanmerking te komen voor een behandeling met een 
geïmplanteerde defibrillator, te identificeren. Gezien de ernstige nadelen, zoals onterechte 
shocks, leadproblemen, en defibrillatorsysteeminfecties die geassocieerd zijn met deze 
therapie, is een betere selectie van patiënten voorafgaand aan de defibrillator implantatie 
vereist. Bovendien is de populatie die in aanmerking komt voor primaire preventie 
defibrillator implantatie van een dusdanige omvang dat behandeling van ieder patiënt 
zowel de beschikbare financiële middelen als ook het hiervoor opgeleide personeel 
zal uitputten. Dit benadrukt des te meer de noodzaak voor optimale allocatie voor de 
behandeling met implanteerbare defibrillatorsystemen. Dientengevolge zal toekomstig 
onderzoek voor implanteerbare defibrillatorsystemen in de klinische praktijk zich moeten 
focussen op zowel het verminderen van de nadelige gevolgen van deze behandeling; door 
het verlengen van de levensduur, het verbeteren van antitachycardie pacing algoritmes, 
en het verminderen van leadproblemen, alsook op de ontwikkeling en implementatie van 
criteria die het mogelijk maken hoog risico patiënten goed te identificeren en het aantal 
implantaties van defibrillatorsystemen bij patiënten die niet zullen profiteren te beperken.

12





































1. Thijssen J, Borleffs CJ, de Bie MK, van Rees JB, van Welsenes GH, van EL, Bax 
JJ, Cannegieter SC, Schalij MJ. Recurrent implantable cardioverter-defibrillator 
replacement is associated with an increasing risk of pocket-related complications. 
Pacing Clin Electrophysiol 2010;33:1013-9.
2. Bertini M, Ng AC, Borleffs CJ, Delgado V, Wijnmaalen AP, Nucifora G, Ewe SH, Shanks M, 
Thijssen J, Zeppenfeld K, Biffi M, Leung DY, Schalij MJ, Bax JJ. Longitudinal mechanics 
of the periinfarct zone and ventricular tachycardia inducibility in patients with chronic 
ischemic cardiomyopathy. Am Heart J 2010;160:729-36.
3. Ng AC, Bertini M, Borleffs CJ, Delgado V, Boersma E, Piers SR, Thijssen J, Nucifora G, 
Shanks M, Ewe SH, Biffi M, van de Veire NR, Leung DY, Schalij MJ, Bax JJ. Predictors 
of death and occurrence of appropriate implantable defibrillator therapies in patients 
with ischemic cardiomyopathy. Am J Cardiol 2010;106:1566-73.
4. van Welsenes GH, Borleffs CJ, van Rees JB, Atary JZ, Thijssen J, van der Wall EE, Schalij 
MJ. Improvements in 25 Years of Implantable Cardioverter Defibrillator Therapy. Neth 
Heart J 2011;19:24-30.
5. Piers SR, Wijnmaalen AP, Borleffs CJ, van Huls van Taxis CF, Thijssen J, van Rees JB, 
Cannegieter SC, Bax JJ, Schalij MJ, Zeppenfeld K. Early reperfusion therapy affects 
inducibility, cycle length, and occurrence of ventricular tachycardia late after myocardial 
infarction. Circ Arrhythm Electrophysiol 2011;4:195-201.
6. van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van EL. Implantation-related 
complications of implantable cardioverter-defibrillators and cardiac resynchronization 
therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol 
2011;58:995-1000.
7. Mooyaart EA, Marsan NA, van Bommel RJ, Thijssen J, Borleffs CJ, Delgado V, van der 
Wall EE, Schalij MJ, Bax JJ. Comparison of long-term survival of men versus women with 
heart failure treated with cardiac resynchronization therapy. Am J Cardiol 2011;108:63-8.
8. Man S, De Winter PV, Maan AC, Thijssen J, Borleffs CJ, van Meerwijk WP, Bootsma 
M, van EL, van der Wall EE, Schalij MJ, Burattini L, Burattini R, Swenne CA. Predictive 
power of T-wave alternans and of ventricular gradient hysteresis for the occurrence 
of ventricular arrhythmias in primary prevention cardioverter-defibrillator patients. J 
Electrocardiol 2011;44:453-9.
9. Thijssen J, Borleffs CJ, van Rees JB, de Bie MK, van der Velde ET, van EL, Bax JJ, 
Cannegieter SC, Schalij MJ. Driving restrictions after implantable cardioverter 
defibrillator implantation: an evidence-based approach. Eur Heart J 2011;32:2678-87.
10. Auger D, Bertini M, Marsan NA, Hoke U, Ewe SH, Thijssen J, Witkowski TG, Yiu KH, Ng 
AC, van der Wall EE, Schalij MJ, Bax JJ, Delgado V. Prediction of response to cardiac 
resynchronization therapy combining two different three-dimensional analyses of left 

































11. Thijssen J, Borleffs CJ, Delgado V, van Rees JB, Mooyaart EA, van Bommel RJ, van 
EL, Boersma E, Bax JJ, Schalij MJ. Implantable cardioverter-defibrillator patients who 
are upgraded and respond to cardiac resynchronization therapy have less ventricular 
arrhythmias compared with nonresponders. J Am Coll Cardiol 2011;58:2282-9.
12. van Welsenes GH, van Rees JB, Thijssen J, Trines SA, van EL, Schalij MJ, Borleffs 
CJ. Primary prevention implantable cardioverter defibrillator recipients: the need 
for defibrillator back-up after an event-free first battery service-life. J Cardiovasc 
Electrophysiol 2011;22:1346-50.
13. van Rees JB, Borleffs CJ, Thijssen J, de Bie MK, van EL, Cannegieter SC, Bax JJ, Schalij 
MJ. Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, 
adverse events, and survival gain. Europace 2012;14:66-73.
14. de Bie MK, Fouad DA, Borleffs CJ, van Rees JB, Thijssen J, Trines SA, Bootsma M, 
Schalij MJ, van EL. Trans-venous lead removal without the use of extraction sheaths, 
results of >250 removal procedures. Europace 2012;14:112-6.
15. de Bie MK, van Rees JB, Thijssen J, Borleffs CJ, Trines SA, Cannegieter SC, Schalij MJ, 
van EL. Cardiac device infections are associated with a significant mortality risk. Heart 
Rhythm 2012;9:494-8.
16. Thijssen J, Borleffs CJ, van Rees JB, Man S, de Bie MK, Venlet J, van der Velde ET, 
van EL, Schalij MJ. Implantable cardioverter-defibrillator longevity under clinical 
circumstances: an analysis according to device type, generation, and manufacturer. 
Heart Rhythm 2012;9:513-9.
17. van Rees JB, van Welsenes GH, Borleffs CJ, Thijssen J, van der Velde ET, van der Wall 
EE, van EL, Schalij MJ. Update on small-diameter implantable cardioverter-defibrillator 
leads performance. Pacing Clin Electrophysiol 2012;35:652-8.
18. Thijssen J, van Rees JB, Venlet J, Borleffs CJ, Hoke U, Putter H, van der Velde ET, 
van EL, Schalij MJ. The mode of death in implantable cardioverter-defibrillator and 
cardiac resynchronization therapy with defibrillator patients: results from routine clinical 
practice. Heart Rhythm 2012;9:1605-12.
19. Leong DP, Hoke U, Delgado V, Auger D, Thijssen J, van EL, Bax JJ, Schalij MJ, Marsan 
NA. Predictors of long-term benefit of cardiac resynchronization therapy in patients 
with right bundle branch block. Eur Heart J 2012;33:1934-41.
20. Thijssen J, van Rees JB, Schalij MJ, Borleffs CJ. Primary prevention implantable 
cardioverter-defibrillator treatment: how to identify patients most likely to benefit? 
Expert Rev Cardiovasc Ther 2012;10:1197-9.
21. Leong DP, Hoke U, Delgado V, Auger D, Witkowski T, Thijssen J, van EL, Bax JJ, Schalij MJ, 
Marsan NA. Right ventricular function and survival following cardiac resynchronisation 
therapy. Heart 2013;99:722-8.
22. Hoke U, Thijssen J, van Bommel RJ, van EL, van der Velde ET, Holman ER, Schalij MJ, 

































diastolic function and on long-term outcome after cardiac resynchronization therapy. 
Diabetes Care 2013;36:985-91.
23. Thijssen J, de Bie MK, van Rees JB, Putter H, van der Velde ET, Schalij MJ, van EL. 
Suitability for subcutaneous defibrillator implantation: results based on data from 
routine clinical practice. Heart 2013;99:1018-23.
24. van der Heijden AC, Thijssen J, Borleffs CJ, van Rees JB, Hoke U, van der Velde ET, van 
EL, Schalij MJ. Gender-specific differences in clinical outcome of primary prevention 
implantable cardioverter defibrillator recipients. Heart 2013;99:1244-9.
25. Thijssen J, van den Akker ME, Borleffs CJW, van Rees JB, de Bie MK, van der Velde 
ET, van Erven L, Schalij MJ. Cost-effectiveness of primary prevention ICDs in routine 
clinical practice. Pacing Clin Electrophysiol 2013;37:25-34.
26. Hoogslag GE, Hoke U, Thijssen J, Auger D, Marsan NA, Wolterbeek R, Holman ER, Schalij 
MJ, Bax JJ, Verwey HF, Delgado V. Clinical, Echocardiographic, and Neurohormonal 
Response to Cardiac Resynchronization Therapy: Are They Interchangeable? Pacing 
Clin Electrophysiol 2013;36:1391-401.
27. Auger D, Hoke U, Thijssen J, Abate E, Yiu KH, Ewe SH, Witkowski TG, Leong DP, Holman 
ER, Ajmone Marsan N, Schalij MJ, Bax JJ, Delgado V. Effect of cardiac resynchronisation 
therapy on the sequence of mechanical activation assessed by two-dimensional radial 
strain imaging. Am J Cardiol 2014;113:982-7
28. Höke U, Auger D, Thijssen J, Wolterbeek R, van der Velde ET, Holman ER, Schalij MJ, Bax 
JJ, Delgado V, Marsan NA. Significant lead-induced tricuspid regurgitation is associated 
with poor prognosis at long term follow-up. Heart 2014;100:960-8.
29. Debonnaire P, Thijssen J, Leong DP, Joyce E, Katsanos S, Hoogslag GE, Schalij MJ, Atsma 
DE, Bax JJ, Delgado V, Marsan NA. Global longitudinal strain and left atrial volume 
index improve prediction of appropriate implantable cardioverter defibrillator therapy 
in hypertrophic cardiomyopathy patients. Int J Cardiovasc Imaging 2014;30:549-58.
30. Hoogslag GE, Thijssen J, Höke U, Boden H, Antoni ML, Debonnaire P, Haeck MLA, 
Holman ER, Bax JJ, Ajmone Marsan N, Schalij MJ, Delgado V. Prognostic implications 
of left ventricular regional function heterogeneity assessed with 2-dimensional speckle 
tracking in patients with ST-segment elevation myocardial infarction and depressed left 
ventricular ejection fraction. Heart Vessels 2013; in press. 
31. Man SM, Meerwijk WPM, Maan AC, Thijssen J, Borleffs CJW, de Winter PV, Bootsma M, 
van Erven L, van der Wall EE, Schalij MJ, Burattini L, Burattini R, Swenne CA. Association 
of Exercise ECG/VCG Variables and Occurrence of Ventricular Arrhythmias in Primary 
Prevention ICD Patients. Submitted. 
32. Höke U, Thijssen J, van der Velde ET, Schalij MJ,  Bax JJ, Delgado V, Marsan NA. Cardiac 



































De afgelopen jaren heb ik met veel plezier onderzoek gedaan op de afdeling Hartziekten 
van het Leids Universitair Medisch Centrum. Mijn dank gaat uit naar diegenen met wie ik in 
deze periode heb mogen samenwerken bij de totstandkoming van dit proefschrift. In het 
bijzonder wil ik mijn dank uitspreken aan:
Jan Willem, vanaf het moment dat ik als student de “tuin” binnenkwam was er tussen ons 
een klik. Jij bent voor mij de grondlegger van mijn promotietraject en hebt mij gedurende de 
rit altijd gesteund. Mijn dank hiervoor is enorm, fantastisch dat je mijn co-promotor wilt zijn!
De verpleging, de echolaboranten, het personeel van de catheterisatiekamers, Renée, de 
research verpleegkundigen (Ellen, Josien en Marian) en de pacemakertechnici (Annette, 
Janneke, Gerben en Ronald), om patiënten te screenen en onderzoeken uit te voeren. De 
ondersteuning van het stafcentrum (Talitha, Bea, Cora, Kariene en Anne) om vrijwel altijd 
mijn verzoeken in te willigen en alles in goede banen te leiden. Enno voor de gigantische 
databases waar alles in stond en zeker 3 jaar promotietijd hebben bespaard.
Alle “tuin” en “achtertuin” collega’s: Hadrian, Jaap, Jan, Rutger, Roderick, Ellen, Jaël, 
Joëlla, Fleur, Dennis, Mark, Louisa, Guido, Sum-Che, Mihály, Carine, Eline, Caroline, Jeffrey, 
Sander, Eleanore, Helèn, Dominique, Darryl, Marlieke, Thijs, Georgette, Philippe, Marieke, 
Sebastiaan, Michiel, Emer, Spyros, Gijs, Aafke en Jeroen. Veel dank voor jullie stimulatie 
en adviezen op de werkvloer en de gezelligheid bij de borrels en congressen. Ulas, dank 
voor de goede samenwerking als “CRT-buddy’s. Verder wil ik in het bijzonder Hans, Mihály 
en Kees bedanken voor de mooie vriendschap van de afgelopen jaren. Hans, dank voor je 
oneindige support en altijd verfrissende blik, mooi dat jij mijn paranimf wilt zijn!
Victoria and Nina for the never ending support to measure echo's of potential EchoCRT 
study patients within a very limited time frame.
Het Challenge-organisatie team: Els, Greetje en Niek. Ik weet nog steeds niet of de uitdaging 
nu een heel weekend al navigerend in eenzelfde auto betrof of toch de marathon afstand 
rennen. Hoe dan ook was het een fantastische ervaring met jullie, veel dank hiervoor.
Daphne, super dat ik gebruik mocht maken van jouw creatieve geest en vakkundigheid om 
dit promotieboek zo mooi vorm te geven.
Xerxianen, Aguilas, Klaas, Maarten en aanverwanten, jullie vormen voor mij het zo belangrijke 
leven buiten de medische wereld. Veel dank voor alle geweldige ervaringen met jullie bij 
skireizen,  themaborrels, kerstavonden, beleggingsvergaderingen, gewone afspraken en 
sportieve uitdagingen. Wat mij betreft gaan we hier nog lang mee door. In het bijzonder 

































Daan, ook jou wil ik bedanken voor onze bijzonder mooie vriendschap. Jij kent mij als geen 
ander en staat altijd aan mijn zijde. Mooi dat je ditmaal als paranimf aan mijn zijde wilt staan!
Lieve zus (Geertje) en lief broertje (Stef), we zijn alle drie heel divers maar passen toch altijd 
samen door dezelfde deur. Dit vind ik heel bijzonder, ik waardeer jullie enorm. Veel dank 
voor onze goede broeder-zuster relatie.
Lieve mamma, mijn dank aan jou is het allergrootst. Jouw onvoorwaardelijke steun en liefde 
zijn voor mij van onschatbare waarde. Ik kan simpelweg niet verwoorden hoe blij ik ben 
met de manier hoe je mij, vrijwel geheel zelfstandig, hebt opgevoed en soms nog opvoed. 
Lieve Claudia, ook al is onze liefde relatief nog pril, het voelt heel goed zo samen. Je liefde 



































De auteur van dit proefschrift werd geboren op 2 januari 1983 in Katwijk. In 2001 behaalde 
hij het eindexamen VWO aan het Da Vinci College te Leiden. In 2002 startte hij met de 
studie Geneeskunde aan de Universiteit van Leiden. Tijdens zijn studie was hij onder meer 
actief als bestuurslid binnen de Medische Faculteit der Leidse Studenten (M.F.L.S.) en volgde 
hij een Summer class Fysische Antropologie aan de faculteit Geneeskunde Leiden. Direct 
na het behalen van zijn artsexamen in 2009, startte hij  in het Leids Universitair Medisch 
Centrum zijn promotieonderzoek onder leiding van Prof. dr. M.J. Schalij. Een selectie van 
de resultaten hiervan staan beschreven in dit proefschrift. 
Per 1 september 2012 is hij in opleiding tot cardioloog in het Leids Universitair Medisch 
Centrum (opleider: Prof. dr. M.J. Schalij). Recent heeft hij zijn vooropleiding Interne 
Geneeskunde in het Rijnland ziekenhuis in Leiderdorp (opleider: dr. M.J.M.F. Janssen) 
afgerond en is hij momenteel bezig met het B-jaar cardiologie in het Rijnland ziekenhuis in 
Leiderdorp (opleider: C.J.H.J. Kirchhof). 

